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ABSTRACT 
 
Many human traits and diseases have a polygenic architecture, where phenotype is 
partially determined by variation in many genes. These complex traits or diseases can be highly 
heritable and genome-wide association studies (GWAS) have been relatively successful in the 
identification of associated variants. However, these variants typically do not account for most of 
the heritability and thus, the genetic architecture remains uncertain. 
This dissertation describes analytical approaches to look for evidence of models of 
genetic architecture that could explain the remaining heritability.  We develop methods to make 
predictions under various models, and compare the expected results from these predictions 
against the observed data for several traits and diseases. First, in studies of height (a classical 
polygenic trait), we modeled the expected cumulative effect of common variants identified from 
GWAS and compared the model with empirical data in individuals from the tails of the height 
distribution. We found that these common variants are predictive of stature, but have less than 
expected effects specifically at the short end of the height distribution. This result is consistent 
with models where rare variants with moderate effect, influence stature only in the shortest 
individuals. Second, we showed that under genetic models where low frequency variants make 
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polygenic contributions to disease, there will be an excess of low frequency risk-increasing 
variants detected in GWAS. As such, by comparing the number of detected risk-increasing to 
risk-decreasing variants, one can detect a signal of the contribution to polygenic inheritance from 
low frequency variants. Finally, we examine the genetic architecture of sitting height ratio 
(SHR), a measure of body proportion that varies dramatically between individuals of African and 
European ancestry. We find that the SHR difference between populations is largely due to 
polygenic architecture; there is no evidence for any major locus accounting for most of this 
difference. 
These results show that, with the appropriate computational and genetic models, one can 
use empirical results of genetics studies to make inferences regarding genetic architecture of 
human traits and diseases. Doing so can help investigators prioritize strategies for uncovering the 
remaining unexplained heritability.  
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A PREAMBLE 
Mendelian inheritance 
It has long been recognized that physical traits are more likely to be shared by parents and 
their offspring, between siblings or close relatives as well as between individuals of similar 
ethnic ancestry [1]. Such a phenomenon is known as heritability and the modern explanation of 
heritability was first broadly described by Gregor Mendel more than two centuries ago, where he 
showed that some traits of pea plants follow a specific pattern of inheritance [2]. Mendel 
theorized that each individual possesses a pair of alleles for each trait and will randomly pass on 
one of the alleles to its offspring. The offspring would then inherit two alleles, one from its father 
and one from its mother and the pair of alleles would determine the trait of the offspring. Such a 
pattern is now popularly known as Mendelian inheritance. 
Polygenic inheritance 
In the beginning of the 20
th
 century, there were anthropologists and biologists who argued 
that since Mendelian inheritance predicts that traits would be discrete in nature, it cannot account 
for the number of continuous or quantitative traits (e.g. height) observed in humans and thus the 
theory cannot be applied to humans. However, in 1918, R. A. Fisher demonstrated that if there 
were multiple allele pairs, that each pair is responsible for only a fraction of the trait and each of 
these pairs observed the same pattern of Mendelian inheritance, it could account for most of the 
continuous or quantitative traits observed in humans [3]. This proposed model of Fisher is what 
we now call polygenic inheritance. 
Disease mapping 
Today, we know that the source of heritability is largely from within the variants contained 
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in the DNA of genes of our diploid chromosomes although there is some indication that 
epigenetics, molecular factors that attach to DNA, can have a role as well [4]. With the invention 
of methods like molecular cloning and the subsequent typing of genetic markers, it became 
possible to map heritable diseases to their respective genetic locus. Doing so allowed researchers 
to pinpoint the exact genetic variants that are responsible for causing the disease. Studying the 
genes underlying these variants can potentially inform us about the disease etiology and thereby 
be informative for developing therapeutics. Therefore to map a disease to a genetic locus, one 
must be able to determine if a genetic marker is associated with disease status. 
Linkage analysis 
There many types of genetic markers that can be used for this purpose. One of the earliest 
markers that were used for this purpose were microsatellite markers or short tandem repeats 
(STRs) [5]. These STR alleles can be genotyped in a variety of ways, from performing gel-
electrophoresis to parallel sequencing [6]. However, more recently, since the completion of the 
human genome project [7] and the international hapmap project [8], single nucleotide 
polymorphisms (SNPs) have become the dominant marker of choice as it is more abundant and 
covers more of the human genome than any of the other known markers [9]. Having determined 
the marker, determining if the genetic marker is associated with disease status is the next 
problem. One of the first methodology used for determining this is linkage analysis [10,11]. 
Linkage analysis is a process by which researcher use genetic markers to determine if disease 
status co-segregates with any of these markers more so than by random chance by studying the 
inheritance pattern of these markers in families that have the trait or disease. The degree of co-
segregation is measured by the LOD (logarithm of odds) score and a LOD score of 3.0 or greater 
is usually taken as evidence that the genetic locus represented by the marker harbors the variant 
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that causes the disease. This approach has been very successful at identifying Mendelian 
diseased genes [12] but fall short when trying to identify genes for complex disease [13]. 
 Linkage analysis not amenable for complex diseases 
There are a number of reasons why linkage analysis is not amenable to identifying genes 
associated with complex diseases. First, complex diseases are thought to be genetically 
influenced by multiple genes rather than a single gene. This could mean that an affected 
individual could be genetically predisposed to having the disease because of variants from many 
genes, each of which causes a small increase to the risk of obtaining the disease (polygenic 
inheritance). This could also mean that while for each family, only mutations in a single gene is 
responsible, that gene is different for different families (locus heterogeneity). For example, an 
autosomal recessive disease like Fanconi Anemia has about 16 different genes [14]. If the 
number of genes were to be much more, for example 160 instead of 16, then there would be a 
good chance that every family analyzed for the disease will have a different causal gene and thus 
no overlapping genes. Whichever the case maybe, be it polygenic inheritance of locus 
heterogeneity, linkage analysis will be less powered for complex diseases as the genetic basis for 
each affected child within each family or across families is different. 
Genetic Association Studies 
Polygenic inheritance is a defining feature of most complex traits and one of the major 
reasons why linkage analysis in family pedigrees is not amenable to identifying genes 
responsible for complex traits. The problem is further compounded by the fact that many 
complex traits are influence by non-genetic (environmental) factors as well. To solve this 
problem, researchers suggested that genetic association studies rather than linkage analysis 
would be more effective in identifying the responsible genetic loci under the assumption of 
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polygenic inheritance. Instead of examining chromosome markers that co-segregate with disease 
status in family pedigrees, genetic association studies examine the frequency of the allele in a 
large population cohort to determine if the allele frequency is correlated with the trait or disease 
status. Indeed, researchers have shown that for studies with the same sample sizes, genetic 
association studies significantly outperforms linkage analysis under the assumption of polygenic 
inheritance. The process of performing genetic association studies have now evolved into a 
process known as Genome wide association studies (GWAS), where markers on the entire 
genome are systematically tested at the appropriate threshold of significance such that the 
significant results are robust and reproducible [15]. To date, there are many successful GWAS 
that are published highlighting the overall success of GWAS as a methodology for identifying 
genetic loci associated with complex traits or diseases. 
Missing heritability 
Although genome wide association studies (GWAS) have been largely successful, the 
variants identified typically do not explain most of the trait’s heritability. This result is known as 
the missing heritability problem and there are suggested hypotheses to explain the missing 
heritability [16]. One such hypothesis is that a substantial fraction of the heritability of the 
disease or trait is due to rare genetic variants [17]. As these variants are rare in the population, 
they are not well assayed by many of the genotyping arrays available nor are they amenable to 
imputation [18]. Another hypothesis is that there are more common variants with even smaller 
effect sizes and these studies are not well powered to detect these variants. A solution to answer 
this question would be to perform whole-genome sequencing instead of using genotyping arrays 
on even more number of samples although performing such an experiment can be costly as 
whole-genome sequencing is still significantly more expensive than genotyping arrays. 
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Therefore, perhaps it would be useful to determine if the exercise of performing sequencing 
and/or studying more samples to answer this question would be fruitful from the results from 
existing GWAS. In this dissertation, I present various methods to infer from GWAS results the 
genetic landscape that could explain the remaining trait heritability. Apart from performing 
GWAS, I described two different and independent approaches for making this inference without 
the need for performing additional whole-genome or whole-exome sequencing. 
Approaches to examine genetic architecture 
The first approach is one that explores the possibility of rare genetic variants contributing to 
the trait by examining the effect of the variants identified through GWAS on individuals at the 
tails of the distribution (Chapter 2). Using human height as our model phenotype, we showed 
that common variants identified through GWAS at the short end of the distribution are less 
predictive than expected. This result can be explained by the presence of rare genetic variants 
contributing to short stature. The second approach is one that explores the summary statistics 
obtained from GWAS (Chapter 3). By examining the direction of effect (odds-ratios or effect 
sizes), an excess of risk-increasing variants compared to risk-decreasing one can be indicative of 
polygenic inheritance from low-frequency or rare genetic variants, especially for dichotomous 
traits or diseases. In the subsequent chapter (Chapter 4), I will describe our study to determine 
genetic variants that can explain the heritable complex trait of body proportion using sitting-
height ratio (SHR) as the phenotype. SHR is thought to be heritable and the SHR of European 
Americans is known to be significantly larger than African Americans. I will provide evidence 
that this difference in SHR is largely genetically driven as well as polygenic. Finally, I will 
conclude with a summary of the findings presented and discuss the potential implications and 
possible future research stemming from the discoveries described in this dissertation. 
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THE HERITABILITY OF COMPLEX TRAITS 
A description of heritability 
Complex traits or diseases are broadly defined as phenotypes that do not follow a Mendelian 
pattern of inheritance. Such traits are usually relatively common, i.e. at least 1% of the 
population have the trait or disease in contrast to Mendelian disorders, which are usually much 
rarer [19]. A main question in human biology is whether the expression of a trait of interest is 
due to genetic factors, environmental factors or just a product of stochasticity. To measure the 
contribution of genetic factors to the trait, one can measure the heritability. Heritability is a 
measurement of how much genetics play a role of explaining the difference of the trait between 
individuals of a population [20]. It can be loosely described as how much of the trait that you 
have is due to you inheriting it from your parents. It is also a technical term, defined as the ratio 
of variances, specifically the proportion of total variance in a population for a trait that is 
attributable to genetic variation [20]. This distinction of its varied use in literature is sometimes 
not made which can be a source of confusion [21]. Heritability can also be divided into 2 
categories, the first being broad-sense heritability and the second being narrow-sense heritability. 
Broad-sense heritability (H
2) describes the attribution of total genetic variation to the trait’s 
variability while narrow-sense heritability (h
2
) describes the attribution of only additive genetic 
variation to the trait’s variability. 
Methods for estimating heritability 
 As heritability is not a physical trait that can be directly measured, one can only use 
various methods to provide an estimate. One of the first methods would be to determine if 
average phenotypic value of the parents (mid-parental phenotype) is correlated with the 
offspring’s phenotypic value. This method was first used by Francis Galton over a 100 years ago 
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to show that human height is heritable [22]. The correlation can be measured by linear regression 
and studies have put the estimate of height as high as 80% (h
2
 ~ 0.8) [23]. This method can also 
be adapted to use correlation estimates of full-siblings instead of parent-offspring although some 
other adjustments are required. Another popular way of measuring heritability would be the use 
of Falconer's formula in twin studies [24]. Given that dizygotic (DZ) twins on average are only 
50% identical by descent (IBD) while monozygotic (MZ) twins are 100% IBD, MZ twins are 
therefore expected to be two times more similar than DZ twins. As DZ twins are approximately 
50% IBD, heritability can be estimated by taking twice the difference of the phenotypic 
correlation between MZ twins and DZ twins. More recently, with the introduction of whole-
genome genotyping arrays, heritability can be now be estimated by taking the correlation of 
phenotypic values with IBD estimates from full siblings [25] as well as using the correlation of 
all common SNPs in predicting the phenotype [26]. Heritability is not necessary constant over 
time. Heritability can decrease with increased environmental variability. It has been suggested 
that heritability for morphological traits will decrease in poorer environmental conditions [27], 
e.g. nutrient poor environment. This fits the theory that in a poor environment, competition for 
resources will cause increased environmental variability that will influence the outcome of the 
trait. Nonetheless, heritability estimates provide us with a way to determine which traits are 
mainly genetically influenced and which traits are mainly environmentally influenced. 
Heritability and genetic architecture 
It is known that it is not a single gene but a multitude of genes that are responsible for 
complex traits or diseases. We also find that most of these complex traits or diseases, their 
occurrences are not as rare as most of the Mendelian diseases with prevalence rate very much 
greater than 1 in 1000 individuals. For example, a study of the incidence of Schizophrenia 
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reported an average lifetime morbid risk for schizophrenia to be 7.2 per 1000 persons [28]. A 
study of prevalence of type 2 diabetes in adolescents put the prevalence as high as 110 per 1000 
persons (11%) [29].   Given that the disease can be common in the population, we can ask if the 
genetic variants that are responsible for the disease are common or rare in the population. Asking 
this question would illustrate 2 concepts. The first is what is known as the “common disease, 
common variant hypothesis”. In this scenario, it is thought that the genetic variants that give rise 
to risk of disease is relatively common but that each variant’s contribution to disease risk is 
small. This means that the effect size per allele is small, that is the effect size usually less than 
0.1 standard deviations or has an odds-ratio less than 1.1. In such a mode of inheritance, also 
known as polygenic inheritance, the genetic cause of the disease per individual or family is due 
to all the risk variants collectively. The next concept is what is known as the “common disease, 
rare variant hypothesis”. In this case, the genetic variants that give rise to the risk of disease are 
very rare and each variant’s contribution to disease risk is large. The effect size per allele can be 
large, perhaps more than 0.5 standard deviations or an odds-ratio greater than 1.6. For this mode 
of inheritance, also called locus heterogeneity, the genetic cause of the disease per individual or 
family is due largely to only 1 gene and other individuals or family with the disease have other 
genes responsible for their disease. Although these “hypotheses” are seemingly different, they do 
not have to be mutually exclusive. Effectively, these “hypotheses” can be unified by addressing 
the effect sizes and variant frequencies for the spectrum of genetic variants that give rise to the 
disease. For such traits, the variant cannot be common and have a large effect. If that is true, the 
trait or disease would be monogenic and would be classified as a Mendelian disorder. As such, it 
is not inconceivable that a disease could have both rare large effect alleles as well as common 
small effect alleles. For example, even when GWAS show that most variants that are associated 
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with height have small effects [30], there are very rare alleles that can give rise to short stature, 
e.g. Achondroplasia [31] as well as rare alleles that give rise to tall stature, e.g. Marfan syndrome 
[32]. The same can be said for many other complex traits or disease and it is important to be 
aware of the genetic architecture giving rise to the trait or disease. 
Heritability and polygenic inheritance 
To explain the heritability of non-Mendelian complex traits and diseases, the pattern of 
inheritance is usually assumed to be polygenic, i.e. many variants across multiple genes each 
contribute a small fraction of the heritability. Examples of complex traits include asthma, 
schizophrenia, type 2 diabetes, inflammatory bowel disease and coronary heart disease. These 
traits are highly heritable [33–37] even though they do not follow a Mendelian pattern of 
inheritance. In type 2 diabetes, the first notable gene with variation conferring risk to the disease 
was TCF7L2 [38]. While not completely penetrant, individuals having a single copy of the risk 
allele are 1.45 times more likely to get type 2 diabetes than individuals without the risk allele. 
Since then, studies with much larger sample sizes have yielded about 30 distinct loci that are 
associated with the risk of getting type 2 diabetes [39]. A similar situation exists for 
schizophrenia, where prior to having sufficiently large sample sizes, no single locus or gene was 
determined to be significantly associated with schizophrenia [40]. However, in one of the earlier 
studies of schizophrenia with just over 3,000 cases and 3,000 controls, the authors reported a 
significant signal of polygenic inheritance from common variants [41]. In that study, the authors 
used the common variants that were marginally associated in their samples to model a 
“polygenic score”, a score that represents the overall cumulative predictability of these common 
variants to schizophrenia risk. They found that the polygenic score is significantly predictive of 
schizophrenia in an independent cohort of individuals. This suggest that there are many, perhaps 
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thousands of variants that modulates the risk of acquiring schizophrenia, each of which have 
only a very small effect on the overall risk and they are not discovered to be significant because 
the study is simply underpowered and further studies with many more samples would be 
necessary. Indeed, when larger sample sizes were available for association, we begin to see 
significant loci emerge [42]. Other complex traits have similar stories where multiple loci have 
been discovered, each of which confers only a fraction of the total risk. 
Quantitative traits and polygenic inheritance 
 Quantitative traits that are approximately normally distributed in a population are usually 
complex traits as well. If such a trait is heritable, then it is unlikely for variation only within a 
single gene or locus to influence the trait. Traits like height, body mass index (BMI), lipid levels, 
fasting glucose levels, blood pressure are just some notable examples. There are now well over a 
hundred loci that are associated with human height [30], each locus only has a very small effect 
on the overall height. For example, a variant in the HMGA2 locus (rs1351394), one of the first 
loci discovered to be associated with height, has an allele frequency of 49% and an effect size of 
0.054 standard deviations or approximately 0.3 centimeters. That means every height increasing 
allele of this variant predicts on average an increase of only a 0.3 centimeter increase in overall 
height, which is just a small effect. For other quantitative traits, similar results were reported 
from association studies like BMI [43], LDL cholesterol [44] and blood pressure [45], etc, where 
many common variants have been found to be associated with these traits with each of these 
variants explaining only a small fraction of the overall trait. Because of the highly polygenic 
nature of such complex traits, methods like linkage analysis that were successful in identify loci 
for Mendelian disorders can be suboptimal when applied on complex traits. Therefore, new 
methodologies and paradigms were developed to map the variants in genes that influence 
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complex traits. We will discuss this in more detail in the next section. 
 
METHODS FOR STUDYING GENETICS OF COMPLEX TRAITS 
Single nucleotide polymorphisms (SNPs) 
 The principle for determining if variants in a gene cause or modulate risk for a disease or 
a trait is to be able to determine if they are associated with the disease or trait in a non-random 
way. As whole genome deep coverage sequencing in a large number of individuals is not feasible 
at this point in time (too costly), we rely on genetic markers for mapping a trait or disease to a 
genetic locus. The genetic marker that is currently very widely used for such a purpose is single-
nucleotide polymorphisms (SNPs). SNPs are single base pair differences within the genome that 
is polymorphic in a population. As we are diploid for most of our chromosomes (males are 
largely hemizygous for the X-chromosome), some individuals in the population might have a 
different pair of alleles than other individuals for any particular SNP. These usually bi-allelic 
markers are found in abundance throughout the genome, much more frequently than STRs [46]. 
For each SNP, because of their bi-allelic nature as well as being diploid, each individual would 
largely be of only 3 genotypic states. For example, if the alleles for the SNP are “A” and “C”, 
then the 3 possible genotypic states would be homozygous “AA”, heterozygous “AC” or 
homozygous “CC”. SNPs were discovered and made publically available in a major way from 
the efforts of the International Hapmap Project [47]. In the phase 2 release of the project, they 
reported more than 3 million SNPs from 4 geographically diverse populations [9]. To find and 
characterize even more SNPs, the 1000 genomes project, a project that aims to characterize 
genomic variation from whole genome sequencing, reported their findings of about 15 million 
SNPs [48].  
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SNP genotyping strategies 
While it might not be difficult or tedious to determine the genotypic state of any SNP in 
an individual, genotyping many SNPs for many individuals can be challenging, both from a 
technical as well as a cost perspective. Methods such as Sanger sequencing [49] and PCR-RFLP 
[50] were possible methods for performing SNP genotyping but is too tedious and expensive to 
perform them in high-throughput (many SNPs) over many individuals. As such, there was a need 
for a relatively cheap and fast technology that could genotype thousand of SNPs efficiently in 
many individuals. With success from efforts to characterize SNPs within human populations, that 
knowledge made it possible for the design of high-density SNP genotyping arrays. SNP 
genotyping arrays work in principle by probing for sequence variation of many targets in parallel 
by immobilizing the probe sequences on a surface and determine the genotype by reading out the 
strength to which these probe sequences are bound to their targets. These arrays can easily 
genotype many SNPs across the genome in a cost efficient manner [51]. There are now many 
companies that sell these high-density SNP genotyping arrays that can perform genotyping for 
over a million SNPs per sample. However, high-density SNP genotyping arrays might become 
less and less utilized with the growth and availability of whole-genome sequencing. Whole-
genome sequencing cost have gone down significantly and it may come to a point in the near 
future that whole-genome sequencing will be the major strategy used by researchers to perform 
genotyping of genetic variants on a large scale. 
Genotype imputation 
While it is possible to genotype many SNPs in parallel, it is still not possible to genotype 
all or most of the known SNPs in the human genome from SNP genotyping arrays. This is 
because there are just too many SNPs and it is impossible to fit all or most of them onto a single 
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genotyping array. As such, these SNP genotyping arrays have only a subset of the total possible 
SNPs from the human genome. Another potential problem would be that different companies that 
design and sell these arrays do not use the same subset of SNPs. This problem can be solved by 
performing genotype imputation. Genotype imputation is the process of determining the 
genotypes of unknown markers with some level of certainty using the genotype information of 
neighboring markers. This is possible because linkage disequilibrium, that variants within the 
genome are not independent [52]. This is because the human population is relatively new and 
variants that were introduced into the population tend to travel together. With enough time, 
recombination events between the variants will break the variants’ correlation and bring about 
linkage equilibrium which will make imputation impossible. Genotype imputation can be 
performed computationally with the use of a reference panel. The reference panel is typically a 
more complete catalog of SNP genotypes obtained from a large cohort of individuals. Some 
examples of these panels would be those provided by the International Hapmap Project [47] as 
well as the 1000 genomes project [48] although it is not uncommon to use panels from other 
sources as well. With these panels together with the genotypes of one’s samples, one can 
computationally impute the variants that are present in the panels but not genotyped in the 
samples. Some of the more utilized software for this purpose include BEAGLE [53], MACH 
[54] and IMPUTE2 [55] just to name a few. With imputation, SNPs that were directly genotyped 
in one set of samples that were not directly genotyped in other sets of samples can now be use 
for association studies. 
Performing genome wide association 
  Linkage analysis has been shown to be less successful at identifying loci associated with 
complex traits than with Mendelian traits [13]. An arguably more effective approach would be to 
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perform a Genome wide association study (GWAS). Instead of tracking genetic markers in 
affected familial pedigrees, one can instead design a study and determine if the frequency of the 
genetic markers are significantly different between case individuals and control individuals. In 
such study designs, case individuals (cases) are usually randomly selected unrelated individuals 
that are affected and control individuals (controls) are randomly selected unrelated individuals 
that are unaffected. Assuming a scenario where 2 SNPs are genotyped in 1000 cases and 1000 
controls (Figure 1.1), one can measure the frequency of the alleles in both SNPs to determine if 
the allele frequencies are significantly different by performing a chi-squared test. In this 
example, SNP1 is significantly associated (P = 2.82 x 10
-13
) at a genome wide significance. The 
genome wide significance threshold is taken to be  P < 5x10
-8
 although it has been suggested 
that it could be relaxed just a little [56]. The genome wide significance threshold has to be 
stringent to correct for multiple hypothesis testing given that GWAS test multiple markers at the 
same time [57].  SNP2 on the other hand is only marginally associated (P = 0.001) and does not 
reach genome wide significance. This process can be systematically pursued for all the SNPs that 
were genotyped via the high-density SNP arrays and subsequently imputed from a reference 
panel. The first successful GWAS was performed on a disease called Age-related macular 
degeneration in 2005 [58]. In that study of 96 cases and 50 controls, they reported 2 strongly 
associated SNPs (P < 10
-7
) in the complement factor H gene (CFH). Since then, there are many 
more GWAS performed with more than 10,000 SNPs identified as genome wide significant for 
various different traits and diseases in more than 1000 publications [59]. The large growth of 
GWAS can be attributed to the affordability of high density SNP arrays as well as freely 
available bioinformatics tools like PLINK [60] for data analysis. Besides performing 
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Figure 1.1: An example of GWAS on cases versus controls. SNP1 and SNP2 are genotyped in 
1000 cases and 1000 controls (1 stickman = 100 individuals). SNP1 is significantly associated 
with disease status while SNP2 is only marginally associated and does not reach genome wide 
significance. Genome wide significance is assumed to be P < 5 x 10
-8
. 
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case-control analyses, GWAS can also be performed on quantitative traits like height, BMI, 
blood pressure and lipid levels. Since there are no cases or controls, GWAS on quantitative traits 
seek to determine if the allele dosages for each SNP is significantly trending, either increasing or 
decreasing with the trait. This is usually done by linear regression of the allele dosages against 
the quantitative trait via a simple linear model [61]. For example, we simulated a scenario where 
a SNP with minor allele frequency of 30% have a 0.5 standard deviation effect (β) on the 
phenotype. After performing a linear regression of the allele dosages against the phenotypic 
score, we find a strong correlation between the SNP and the phenotype (Figure 1.2A) resulting in 
an estimated β of 0.47 and a very strong association signal (P=2.97 x 10-22).  On the other hand, 
when we simulated a scenario where the SNP has no effect, then there is no strong correlation 
(Figure 1.2B). This example shows that GWAS can be use not only for dichotomous traits, but 
also for quantitative traits. 
GWAS ineffective if causal variants not linked to SNPs 
Linkage disequilibrium (LD) is a major factor for the success of GWAS. This is because, 
the vast majority of the time, SNP markers tested for association with diseases are not the actual 
genetic variant that has an effect but rather simply a marker that is in linkage disequilibrium with 
the disease variant. The disease variants could be SNPs, copy number polymorphisms (CNVs), 
short tandem repeats, insertion or deletion polymorphisms (indels) and perhaps even inversion 
polymorphisms. In most cases, there should be a SNP that is in LD (tagging) the causal variant. 
For example, many SNPs have been shown to be strong tagging the common inversion 
polymorphism on the human chromosome 17 [62]. It has also been shown that some SNPs from 
GWAS hits are strongly tagging CNVs and that these CNVs are suggested to be the causal 
variants [63]. However, we cannot discount the possibility that the causal variant is not 
18 
 
 
Figure 1.2: An example of GWAS on quantitative trait. Phenotypic score represents the 
quantitative trait. SNP genotype dosage is the number of effect alleles (0, 1 or 2) that each 
individual has. The association of between genotype and phenotype is shown by the least-
squared regression line. (A) The least squared regression line (red) shows a positive correlation 
of genotype dosage with phenotype (β=0.47, P=2.97 x 10-22). (B) The least squared regression 
line (grey) shows no correlation of genotype dosage with phenotype (β=0.06, P=0.21). 
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well-tagged by SNPs. For example, a recent study showed that CNVs in two amylase genes 
(AMY1 and AMY2) are associated with obesity and that these regions are hard to be mapped by 
SNPs [64]. Only by genotyping the copy number did the authors observed the association. 
Therefore, besides performing GWAS using only SNPs as markers, it may be in some cases, 
useful to also genotype other potential markers, especially in genomic regions not well covered 
by SNPs. 
Not straightforward to implicate causal gene from GWAS locus 
While linkage disequilibrium allows one to find loci associated with disease, it is not 
clear which gene within the identified locus is the gene that is causal. Because of linkage 
disequilibrium, the region implicated in GWAS can span many genes and in that respect, linkage 
disequilibrium is more of a problem than a solution. To overcome this, solutions such as systems 
approaches that examines all the loci associated with the disease to determine its molecular 
architecture may be the way forward [65]. Using methods to determine if certain genes within 
various loci identified through GWAS are more biologically connected, those genes are more 
likely to be the causal gene within each of their locus. For example, in one study, the authors 
used a variety of biological functional databases to determine the degree of connectivity between 
genes [66]. In another study, the authors described an approach to form relationships between 
genes by analyzing PubMed abstracts [67]. These approaches have been successfully applied to 
results from GWAS and can prioritize the genes within each locus as to which of them are more 
likely to be the causal gene. 
Population stratification 
Genome wide association studies (GWAS) may also be confounded by population 
stratification. Unlike linkage analysis where studies are perform on familial pedigrees; GWAS on 
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the other hand compares genetic markers between unrelated cases against controls. As such, 
markers that reflect differences in the underlying structure of the population between cases and 
controls may have significant associations when performing GWAS. For example, a SNP in the 
LCT gene locus had significant association with height but the association is largely driven by 
population stratification [68]. Many methods have been developed to try and correct for 
population stratification. One of the more popular methods would be to include principal 
components as covariates when performing the statistical association with linear or logistic 
regression [69]. A study performed to determine the efficacy of the available methods showed 
that most of the methods work comparatively well to address the problem of population 
stratification [70]. Therefore population stratification is now not a major problem and can be 
adequately corrected for. 
Admixture mapping 
Another possible method besides GWAS would be admixture mapping. Admixture 
mapping, also known as “mapping by admixture linkage disequilibrium” (MALD) is a method 
that uses genetically mixed populations to determine if the local ancestry of different ancestral 
populations is correlated with a trait or disease [71]. For example, African Americans have 
genetic ancestry of largely African descent with a proportion being of European origin [72]. If 
one could determine the genomic regions of European ancestry, one could test if having 
European ancestry in these regions is associated with trait differences between individuals. 
Following this idea, methods were developed to accurately determine which regions in an 
individual’s genome are of any particular ancestry. One of the first approach that is used 
extensively for this purpose is to perform the prediction using a hidden markov model (HMM) 
[73]. By systematically walking through each marker consecutively, HMM can be use to predict 
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the most likely ancestral state of the genetic marker given its frequency in each ancestral 
population. The more divergent the frequencies are in different population, the more likely the 
prediction will be accurate. The accuracy can be further improved by incorporating both linked 
markers as well as the use of an explicit population genetic model [74]. Admixture mapping has 
been performed on a multitude of phenotypes, including prostate cancer [75], body mass index 
[76,77], blood lipids [78], just to name a few. One of the reasons why admixture mapping might 
perform better than GWAS is because of admixture linkage disequilibrium. One of the initial 
reasons why GWAS on African populations might yield fewer results than GWAS performed on 
European or non-African populations is because the average linkage disequilibrium (LD) block 
in Africans is much smaller as they are a relatively older population [79,80]. As such, when there 
are relatively few SNPs genotyped for performing GWAS, it might be sufficient for studies in 
non-African populations but inadequate in populations of African ancestry. However, since 
admixture LD, LD of genomic regions due to admixture from a different population, is much 
stronger, this allows association signals to be discovered even with relatively lower marker 
density. However, this also means that if an admixture signal were to be discovered, it would be 
much harder to pinpoint the gene responsible for the association. GWAS on the other hand would 
be more sensitive and better powered if there is high density coverage of the genome, either from 
using high density SNP arrays or whole genome sequencing strategies. Given that high density 
SNP arrays are now widely used, GWAS might now be a better strategy to uncover genetic loci 
associated with disease. 
 
COMPLEX PHENOTYPES 
Human height is a classical complex trait 
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 Human height is probably the best example of a heritable trait that has a polygenic 
architecture [81]. It is the example that Fisher used to reconcile how quantitative traits could also 
adhere to Mendelian inheritance [3]. Instead of having a single gene influencing the outcome of 
one’s height, having many genes do so can explain the distribution of height in the population, 
which is in most cases, normally distributed [82]. However, we do know about diseases that are 
caused by rare mutations that have large effects on one’s stature. These diseases, in most cases, 
have other obvious phenotypes besides the change in stature. For example, Achondroplasia, the 
most common cause of dwarfism is caused by a rare mutation in the FGFR3 gene. Individual 
carrying the mutant allele have on average about a 6 standard deviation decrease in height. The 
prevalence of Achondroplasia is extremely rare, affecting only about 1 in 25,000 individuals 
[83]. Another example would be Marfan syndrome, a genetic disorder caused by mutations in the 
FBN1 gene. Individuals with this Marfan syndrome are unusually tall, on average about 2 
standard deviations taller. The prevalence of Marfan syndrome is rare, affecting only about 1 in 
9802 individuals [84]. In both of these examples, individuals with Achondroplasia or Marfan 
syndrome have other consequential phenotypes as well besides their short or tall stature. 
Achondroplasia individuals usually present with other phenotypes like short fingers and toes 
[85]. Individuals with Marfan syndrome normally present with cardiovascular or vision problems 
too [86]. Nonetheless, rare Mendelian diseases like these do not explain for most of the variation 
of height in the population. 
The alleles of height 
 Most of the variation of height is probably due to common variants that have small effect 
sizes. Indeed, the first such gene implicated in height is HMGA2 [87]. Identified from an initial 
GWAS of just under 5000 individuals, it harbors a common variant that has only an estimated 
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effect size of 0.4 cm per allele. Since then, many more common variants with small effects 
robustly associated with height have been discovered [30]. Among these variants, there are some 
that are associated with human syndromes characterized by abnormal skeletal growth. For 
example, the gene ACAN, of which there is a signal of common variant association with height, 
have been shown to be responsible for syndromes like Osteochondritis dissecans [88] and 
Spondyloepimetaphyseal dysplasia [89]. This suggests that while the common variants might be 
altering the gene activity in a minor way resulting in a small change in overall height, deleterious 
variants in these genes can cause severe reduction in stature. Thus the question remains as to 
what the genetic architecture is for non-syndromic individuals with short or tall stature. Is there a 
contribution of such large effect variants that can explain a person’s tall or short stature in the 
general population? Or is a person’s tall or short stature driven mainly by small effect common 
variants? In chapter 2, we shall discuss a method to infer the genetic architecture of individuals 
at the tails of the height distribution by examining the recently discovered common variants 
associated with height. 
Body proportion is more constrained than height 
While height is a commonly measured anthropometric that varies within a population, 
our heights are not as constrained and individuals can be relatively short or tall without any 
adverse effect on our health. Most of the problems associated with extreme tall or short stature 
are usually because of other adverse phenotypes associated with the tall or short stature. For 
example, individuals with Turner syndrome, a disease cause by monosomy X have short stature 
but commonly have other problems like Lymphedema or cardiovascular related problems. Also, 
given that women are about 2 standard deviations shorter than men shows that short stature itself 
is does not necessary have any health consequences and can vary within the population. On the 
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other hand, our body proportions are more well-defined. Humans have expected ratios of limb 
lengths that are vastly different from other species. For example, unlike humans, chimpanzees 
have arms longer than their legs [90]. 
Sitting height ratio as a measurement of body proportion 
There certain measurements other than our full body height that can be use to judge our 
body proportions. Iliac length, subischial leg length, thigh length, knee height, sitting height are 
just some such measurements [91]. Another such measurement is arm span, which is a good 
proxy for overall height [92]. These measurements can be measured in a clinic but require either 
precise instruments or trained practitioners that they are usually not measured of patients when 
they pay a visit to their doctors even though they may be as informative as knowing our overall 
height and weight. However, one of the measurements that exist in some publically available 
data-sets is measurements of sitting height. Sitting height is the total stature that is comprised by 
the head and trunk. It is usually measured by first having the person sit on a table, then taking the 
measurement of the distance from the surface of the table to the top of the person’s head. If one 
were to divide the sitting height with a person’s height, one can calculate the sitting height ratio 
(SHR) which can then be a measure of body proportion. While short and tall stature is the 
characteristic of many skeletal dysplasia and overgrowth syndromes respectively, many of these 
syndromes can also cause severe deviations of SHR. For example, adult individuals with 
Achondroplasia have average SHR values of 0.66, very much higher than the population 
average, which is around 0.53 [93]. Another type of dysplasia, Spondyloepiphyseal dysplasia, is 
a syndrome characterized by severe short spines and neck. These patient’s hands and feet are of 
normal length suggesting that their SHR values will be lower than average [94]. Next, 
individuals with Marfan syndrome have above average heights and may have lower than average 
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SHR values [95]. However, some individuals with mutations causing severe short stature might 
have SHR within the normal range. For example, a patient with premature pubarche and severe 
short stature has normal SHR [96]. SHR has also been used as a rudimentary predictor of 
phenotypes like body mass index, Age of Menarche and risk of diabetes [97]. Sitting height ratio 
(SHR) is a measurement that changes with age. More of our stature is due to our head and trunk 
as children than as adults, evidenced from the gradual decreasing of SHR till we reach adulthood 
[95]. 
 Sitting height ratio and ancestry 
SHR also differs significantly from individuals with different ancestries. Accordingly, 
individuals of Asian ancestry have higher SHRs than individuals of European ancestry and 
individuals of European ancestry have higher SHRs than individuals of African ancestry [91]. 
The question remains as to whether genetics is the primary driving force for the difference 
between SHR in different populations and whether these SHR differences between populations is 
a polygenic phenomenal or driven by only a single or a few genes. In chapter 4, I shall present 
some recent findings that will reveal more about the genetic architecture of SHR. 
 
ACCUMULATING EVIDENCE FROM MULTIPLE STUDIES 
Being underpowered 
While Genome wide association studies (GWAS) have been very successful at 
elucidating loci that are associated with complex traits and diseases [98], this has not always 
been the case. Studies performed with limited samples are just underpowered for any genome 
wide significant associations to be discovered. The power to detect any SNP to be associated 
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with the trait is directly correlated to the variance of the phenotype explained by the SNP. This 
means that the larger the effect size or the more frequent the SNP is, the more power there is for 
the SNP to be detected as genome wide significant. However, given that for complex traits, the 
effect sizes for any given variant is very small, larger numbers of samples are required for any 
loci to be discovered. 
Combining results by meta-analysis 
 While most studies may be underpowered due to small sample sizes, different studies 
performed on different samples with similar phenotypes could be combined or pooled together in 
an effort to increase the power of the study. Ideally, the genotypes and phenotypes could be 
shared among different research groups such that every group would have access to other group’s 
data to perform the joint study. However, this is usually not feasible due to data sharing 
constraints such as the lack of storage space, privacy issues as well as the unwillingness of 
research groups to share their data prior to publication of their results. As such, for a typical 
GWAS, the association is performed on individual cohorts. Each of these cohorts has whole 
genome SNP data, usually produced by genotyping arrays as well as their corresponding 
phenotypes. The phenotype can be either a quantitative one, e.g. height, body mass index, blood 
pressure, etc, where there is a numerical value attached to each individual or a dichotomous one, 
e.g. type 2 diabetes, schizophrenia, etc, where each individual is either affected with the disease 
(cases) or are unaffected (controls). A dichotomous phenotype can be modeled as a phenotype 
with an underlying quantitative trait distribution, of which individuals whose trait value 
exceeded a threshold are affected and individuals who do not are unaffected [99]. For example, 
in the case of obesity, the underlying phenotype can be body mass index (bmi) and individuals 
whose bmi exceeds 30 can be classified as obese while those whose bmi are below 30 are not 
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[100]. However, in most dichotomous traits or diseases, this underlying trait is usually 
unobservable or unknown. Testing for genetic factors associated with the trait or disease is 
usually done by performing linear regression (quantitative trait), logistic regression 
(dichotomous traits) or some other test of correlation of the SNP dosages with the phenotype. 
Performing the test will produce resulting statistics for each SNP and by combining the statistics 
produced across cohorts through a process known as meta-analysis [101], one would be able to 
obtain the resulting summary statistics for the GWAS. 
GWAS summary statistics 
The resulting summary statistics contains the necessary information to determine which 
SNPs are significantly associated with the trait or disease in question. Typically, the summary 
statistics is reported in the following manner. Each row represents the result of the test for a SNP 
and each column reports a specific result for that SNP. There would a SNP identifier, usually the 
dbSNP rs-number [102], the allele frequency, the odds-ratio or effect size as well as the 
significance of the result, reported as the 2-tailed P-value. For a dichotomous trait, the odds-ratio 
(OR) would tell us the direction of effect of the allele, whether they are associated with increased 
or decreased risk for being affected by the trait or disease. An OR > 1 would indicate increased 
risk while an OR < 1 would indicate decreased risk. For a quantitative trait, the effect size (β) 
would be the equivalent, with a positive β indicating that the allele is associated with increased 
trait values and vice-versa. In either case, the P-value gives us the strength of the association and 
a P-value < 5 x 10
-8
 is suggested to be the genome-wide significant threshold [57]. SNPs that 
have P-values that are less than this threshold are said to have reached genome-wide significance 
and they are usually reported to be significantly associated with the trait or disease in question. 
Genes in the vicinity of such SNPs are then suspected to be involved with the trait or disease 
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etiology and are usually reported as well. 
Independent loci 
Even though by performing the GWAS, the SNPs that achieved genome-wide 
significance are not necessary independent and one must consider the effect of linkage 
disequilibrium (LD). As discussed earlier, there are many variants, SNPs included, in the genome 
that are correlated with one another due to LD. The SNP with the lowest P-value is called the 
“lead SNP” with SNPs in strong LD (usually taken as r2 > 0.5) with it labeled as tagging SNPs. 
Together these SNPs represent only a single locus of association as the signal may well be only 
from a single source of variation within this region in the genome. To determine the total number 
of independent loci that is significantly associated with the trait, one can perform a process 
known as LD-pruning. This process orders the SNPs from most significant to least and 
systematically takes away significant SNPs that are in LD with any of the SNPs prior. On top of 
LD-pruning, one could also perform conditional analysis where SNPs in LD with the lead SNP 
can be tested again with the dosage of the lead SNP as a covariate. If the significant association 
is solely due to LD, the resulting P-value would not be significant. However, if the resulting P-
value is still significant, then that SNP’s significance cannot be explained just by LD and 
therefore could be counted as a separate locus associated with the trait or disease. This process 
could also be done in a high throughput manner taking existing summary statistics and LD 
information [103]. 
Not quite genome wide significant  
While the genome-wide significant signals are said to be robust associations discovered 
with the trait or disease, SNPs that do not reach genome-wide significance could still be 
informative. While these marginally associated SNPs cannot be individually considered as robust 
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associations, they may inform us about the genetic architecture of the trait or disease as a whole. 
For example, in the GWAS of human height, the QQ-plots show a significant deviation of the 
marginally associated SNPs from the null model. This is indicative of the fact that there are more 
marginally associated SNPs than that expected under the null model and thus informs us that 
there are more associations to be discovered. In other cases, the QQ-plot might now show much 
of a deviation. Nonetheless, this suggests that the marginally associated SNPs can be informative 
even if most GWAS publications chose only to report the genome-wide significant ones. In 
chapter 3, I will discuss in depth a new method that can exploit the marginally associated SNPs 
to determine if there is evidence of polygenic inheritance. 
 
SUMMARY 
 It is well known that many human traits and diseases do not follow a Mendelian pattern 
of inheritance; that most of these traits and diseases are influenced by variation in many genes, 
each of which contribute a small effect to the total heritability of the trait. These traits and 
diseases are highly heritable and therefore, mapping these traits and diseases to their genetic 
locus can be useful for understanding the disease etiology thereby informative for the 
development of potential therapeutics. Performing genetic association studies (GWAS), where 
one performs genetic genotyping on many genetic markers to determine if they are associated 
with the trait or disease has become a common technique for identifying such genetic loci. 
However, these loci discovered in most GWAS do not account for most of the heritability and 
thus our genetic understanding of these diseases is far from complete. This dissertation aims to 
leverage on results from GWAS to infer the genetic architecture of various complex human traits 
and diseases which could lead to increasing our understanding of disease etiology. 
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ABSTRACT 
Common genetic variants have been shown to explain a fraction of the inherited variation 
for many common diseases and quantitative traits, including height, a classic polygenic trait. The 
extent to which common variation determines the phenotype of highly heritable traits such as 
height is uncertain, as is the extent to which common variation is relevant to individuals with 
more extreme phenotypes. To address these questions, we studied 1,214 individuals from the top 
and bottom extremes of the height distribution (tallest and shortest ~1.5%), drawn from ~78,000 
individuals from the HUNT and FINRISK cohorts. We found that common variants still 
influence height at the extremes of the distribution: common variants (49/141) were nominally 
associated with height in the expected direction more often than is expected by chance (p <5x10
-
28
) and the odds ratios in the extreme samples were consistent with the effects estimated 
previously in population-based data.  To examine more closely whether the common variants 
have the expected effects, we calculated a weighted allele score (WAS), which is a weighted 
prediction of height for each individual based on the previously estimated effect sizes of the 
common variants in the overall population. The average WAS is consistent with expectation in 
the tall individuals, but was not as extreme as expected in the shortest individuals (p<0.006), 
indicating that some of the short stature is explained by factors other than common genetic 
variation. The discrepancy was more pronounced (p<10
-6
) in the most extreme individuals 
(height <0.25 percentile). The results at the extreme short tails are consistent with a large number 
of models incorporating either rare genetic, non-additive or rare non-genetic factors that decrease 
height. We conclude that common genetic variants are associated with height at the extremes as 
well as across the population, but that additional factors become more prominent at the shorter 
extreme. 
40 
 
AUTHOR SUMMARY 
Although there are many loci in the human genome that have been discovered to be 
significantly associated with height, it is unclear if these loci have similar effects in extremely 
tall and short individuals. Here, we examine hundreds of extremely tall and short individuals in 2 
population-based cohorts to see if these known height determining loci are as predictive as 
expected in these individuals. We found that these loci are generally as predictive of height as 
expected in these individuals but that they begin to be less predictive in the most extremely short 
individuals. We showed that this result is consistent with models that not only include the 
common variants but also multiple low frequency genetic variants that substantially decrease 
height. However, this result is also consistent with non-additive genetic effects or rare non-
genetic factors that substantially decrease height. This finding suggests the possibility of a major 
role of low frequency variants, particularly in individuals with extreme phenotypes and has 
implications on whole-genome or whole-exome sequencing efforts to discover rare genetic 
variation associated with complex traits. 
 
INTRODUCTION 
Height is a highly heritable trait, with estimates of heritability as high as 90% [1]. Recent 
genome-wide association studies of height have discovered over 180 common variants 
associated with height [2]. These variants have small effect sizes and collectively explain 
approximately 10% of the heritability. While these 180 common variants are robustly associated 
with height when studied as a quantitative trait in the general population, it is not known whether 
these variants have similar associations with stature in individuals at the extreme tails of the 
height distribution. If these common variants do not show the expected association with stature 
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at the extremes (based on their continuous distribution effect sizes), then other factors beyond 
common variants must contribute to extreme stature. Although there are multiple possible 
scenarios, one possible explanation is the existence of rare or low frequency variants with larger 
effect sizes, which have been proposed to explain a portion of the heritability not accounted for 
by the known common variants [3–5] and which may provide novel biological insights into 
mechanisms that affects height. Understanding the role of common variants in the tails of the 
height distribution will also provide methodological insight into the utility of extreme tails 
analysis for future genetic studies of quantitative traits. 
In this chapter, we describe our approach to determine whether common alleles known to 
be associated with height in the general population have the expected distribution in individuals 
from the extremes of the height distribution. We used DNA samples from individuals with 
extreme heights from two population-based cohorts of Finnish (FINRISK) and Norwegian 
(HUNT) ancestry and genotyped them for common variants known to be associated with height. 
Under a polygenic model in which there are many variants and each variant additively 
contributes a small effect to the phenotype, we found that for individuals within ~2.81 standard 
deviations of the mean, the common variants have the predicted associations with height, 
consistent with their effect sizes estimated from the previous population study [2]. However, in 
individuals with more extreme short stature (the shortest 0.25% of the distribution), common 
variants play a less prominent role in explaining phenotype, and the data are consistent with 
various models in which rare variants, non-additive effects or rare non-genetic factors contribute 
to short stature in these individuals. 
 
RESULTS 
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Individual common variants are associated with height in the extremes 
 We attempted to genotype SNPs at the 180 loci previously associated with height in 
individuals from the short and tall extremes of the FINRISK and HUNT cohorts and then 
performed association analyses for each SNP with height using the Cochran-Mantel-Haenszel 
test and logistic regression respectively. In FINRISK, SNPs at 158 of the height loci were 
successfully genotyped in 181 short and 192 tall individuals from the 1% tails of the height 
distribution. In the HUNT study, SNPs at 160 of the height loci were successfully genotyped in 
385 short and 456 tall individuals from the ~1.5% tails of height. Here we focus on the 279 short 
and 309 tall individuals from the 1% tails of the HUNT study, so as to provide consistency with 
the FINRISK study. In both cohorts, the majority of SNPs had effect directions consistent with 
the published results [2] (HUNT 137/160, p<0.0001; FINRISK 122/155, p<0.0001) and there 
was a significant enrichment in SNPs reaching nominal significance for association with height 
(Table 2.1; Table 2.2). We then combined the data from both cohorts in a meta-analysis of 141 
overlapping loci (Table 2.3). Ninety-one percent of SNPs (128/141, p<0.0001) had directions of 
effect consistent with previously published results [2] and 49 SNPs had p-values <0.05, as 
opposed to 7 expected by chance (p<5x10
-28
). This result confirms that, as a group, SNPs found 
to be associated with height in the general population are also associated with height at the 
extremes of the phenotypic spectrum. 
 
The effect sizes of individual common variants on height are similar in the extremes and 
the general population 
 We next tested whether the observed odds ratios (OR) are consistent with the expected 
odds ratios, based on the previously estimated effect sizes from the GIANT study [2] and study 
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Table 2.1: Individual SNP analysis for HUNT cohort 
 
Rsid Chr Pos Closest gene Effect allele Effect size Freq Observed OR Expected OR 
rs425277 1 2059032 PRKCZ t 0.0240 0.28 1.19 1.14 
rs6657613 1 17200787 MFAP2 t 0.0328 0.52 1.19 1.19 
rs2903545 1 23413695 HTR1D t 0.0215 0.59 1.16 1.12 
rs4601530 1 24916698 CLIC4 c 0.0238 0.74 1.02 1.14 
rs7532866 1 26614131 LIN28 a 0.0222 0.68 1.16 1.13 
rs11209376 1 41270935 SCMH1 g 0.0319 0.22 1.33 1.19 
rs17391694 1 78396214 GIPC2 t 0.0399 0.13 1.25 1.24 
rs6699417 1 88896031 PKN2 t 0.0217 0.63 1.12 1.12 
rs10874746 1 93096559 RPL5 c 0.0217 0.64 1.12 1.12 
rs12731372 1 118654498 SPAG17 c 0.0379 0.75 1.25 1.22 
rs11205277 1 148159496 SF3B4 g 0.0452 0.44 1.46 1.27 
rs17346473 1 170349716 DNM3 g 0.0365 0.30 0.95 1.21 
rs1014719 1 175069389 PAPPA2 t 0.0253 0.55 1.21 1.14 
rs1046934 1 182290152 TSEN15 c 0.0459 0.35 1.21 1.28 
rs10863936 1 210304421 DTL g 0.0220 0.47 1.13 1.12 
rs6684205 1 216676325 TGFB2 g 0.0328 0.26 1.15 1.19 
rs11118346 1 217810342 LYPLAL1 c 0.0264 0.58 1.12 1.15 
rs1172294 2 25022704 DNAJC27 a 0.0334 0.50 1.42 1.19 
rs1545552 2 33213842 LTBP1 g 0.0246 0.72 1.27 1.14 
rs2341459 2 44621706 C2orf34 t 0.0276 0.28 1.18 1.16 
rs3791675 2 55964813 EFEMP1 c 0.0496 0.75 1.65 1.30 
rs1913671 2 88680998 EIF2AK3 c 0.0268 0.37 1.31 1.15 
rs7567288 2 134151294 NCKAP5 c 0.0309 0.22 1.11 1.18 
rs3770047 2 178393780 PDE11A g 0.0402 0.06 0.99 1.24 
rs12470505 2 219616613 CCDC108/IHH t 0.0483 0.91 0.85 1.29 
rs6756793 2 224737163 SERPINE2 t 0.0248 0.55 1.30 1.14 
rs12694997 2 241911659 SEPT2 g 0.0274 0.77 1.07 1.16 
rs2597513 3 13530836 HDAC11 c 0.0392 0.10 1.73 1.23 
rs13088462 3 51046753 DOCK3 c 0.0543 0.07 1.49 1.34 
rs2336725 3 53093779 RTF1 c 0.0263 0.46 0.96 1.15 
rs9833926 3 56625218 C3orf63 a 0.0216 0.50 1.24 1.12 
rs17806888 3 67499012 SUCLG2 t 0.0399 0.90 1.40 1.24 
rs11128265 3 72538487 RYBP a 0.0304 0.80 1.27 1.18 
rs6765930 3 130503468 C3orf47 g 0.0352 0.79 1.24 1.21 
rs9844666 3 137456906 PCCB g 0.0284 0.76 1.36 1.16 
rs724016 3 142588260 ZBTB38 g 0.0670 0.46 1.52 1.43 
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Table 2.1 (Continued) 
 
Rsid Chr Pos Closest gene Effect allele Effect size Freq Observed OR Expected OR 
rs572169 3 173648421 GHSR t 0.0355 0.33 1.32 1.21 
rs720390 3 187031377 IGF2BP2 a 0.0305 0.36 1.24 1.18 
rs2247341 4 1671115 SLBP/FGFR3 a 0.0251 0.38 1.29 1.14 
rs6449353 4 17642586 LCORL t 0.0714 0.86 1.52 1.46 
rs17081935 4 57518233 POLR2B t 0.0306 0.19 1.01 1.18 
rs7697556 4 73734177 ADAMTS3 t 0.0219 0.48 1.21 1.12 
rs1975474 4 82397961 PRKG2/BMP3 g 0.0376 0.30 1.30 1.22 
rs10010325 4 106325802 TET2 a 0.0214 0.47 1.21 1.12 
rs7689420 4 145787802 HHIP c 0.0687 0.84 1.28 1.44 
rs955748 4 184452669 WWC2 g 0.0243 0.78 1.23 1.14 
rs13154066 5 32867427 NPR3 t 0.0350 0.39 1.12 1.20 
rs6897117 5 55022532 SLC38A9 t 0.0278 0.27 1.28 1.16 
rs6894139 5 88363538 MEF2C t 0.0266 0.56 1.18 1.15 
rs13177718 5 108141243 FER c 0.0412 0.90 1.48 1.25 
rs274546 5 131727766 SLC22A5 g 0.0278 0.59 1.27 1.16 
rs526896 5 134384604 PITX1 t 0.0315 0.72 1.14 1.18 
rs4282339 5 168188818 SLIT3 g 0.0352 0.81 1.08 1.21 
rs12153391 5 171136043 FBXW11 c 0.0329 0.76 1.21 1.19 
rs889014 5 172916720 BOD1 c 0.0290 0.67 1.15 1.17 
rs422421 5 176449932 FGFR4/NSD1 c 0.0332 0.79 1.13 1.19 
rs6879260 5 179663620 GFPT2 c 0.0281 0.60 1.24 1.16 
rs12198986 6 7665058 BMP6 a 0.0359 0.46 1.34 1.21 
rs806794 6 26308656 Histone cluster a 0.0528 0.71 0.98 1.32 
rs3129109 6 29192211 OR2J3 c 0.0257 0.64 0.90 1.15 
rs2596530 6 31495352 MICA g 0.0341 0.53 1.38 1.20 
rs6457617 6 32771829 HLA locus c 0.0238 0.52 1.38 1.14 
rs2780226 6 34307070 HMGA1 c 0.0790 0.08 1.39 1.52 
rs6457821 6 35510783 PPARD/FANCE c 0.1210 0.98 0.98 1.90 
rs12530016 6 44974300 SUPT3H/RUNX2 g 0.0305 0.80 1.55 1.18 
rs310405 6 81857081 FAM46A a 0.0300 0.52 1.08 1.17 
rs7759938 6 105485647 LIN28B c 0.0420 0.35 1.00 1.25 
rs3757235 6 109818534 ZBTB24 c 0.0216 0.58 0.91 1.12 
rs6915129 6 117629512 VGLL2 c 0.0216 0.60 1.13 1.12 
rs1490384 6 126892853 C6orf173 t 0.0370 0.54 1.17 1.22 
rs6569648 6 130390812 L3MBTL3 c 0.0358 0.24 1.26 1.21 
rs7763064 6 142838982 GPR126 g 0.0445 0.72 1.31 1.27 
rs543650 6 152152636 ESR1 g 0.0318 0.59 1.25 1.18 
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Table 2.1 (Continued) 
 
Rsid Chr Pos Closest gene Effect allele Effect size Freq Observed OR Expected OR 
rs12206717 6 158830686 TULP4 g 0.0487 0.95 0.91 1.30 
rs798489 7 2768329 GNA12 c 0.0515 0.75 1.37 1.32 
rs1708299 7 28156471 JAZF1 a 0.0417 0.34 1.43 1.25 
rs6959212 7 38094851 STARD3NL c 0.0229 0.68 1.24 1.13 
rs42235 7 92086012 CDK6 t 0.0548 0.30 1.25 1.34 
rs822552 7 148281567 PDIA4 g 0.0302 0.27 1.20 1.17 
rs17088190 8 24167275 ADAM28 c 0.0278 0.75 0.91 1.16 
rs6473015 8 78341040 PEX2 c 0.0320 0.32 1.25 1.19 
rs6470764 8 130794847 GSDMC c 0.0469 0.83 0.92 1.28 
rs894345 8 135682763 ZFAT c 0.0297 0.59 1.17 1.17 
rs7864648 9 16358732 BNC2 t 0.0246 0.35 0.96 1.14 
rs11144688 9 77732106 PCSK5 g 0.0548 0.87 1.14 1.34 
rs296886 9 85781846 C9orf64 g 0.0250 0.19 1.04 1.14 
rs181338 9 88297981 ZCCHC6 t 0.0234 0.53 1.20 1.13 
rs2814828 9 90001002 SPIN1 t 0.0268 0.24 1.31 1.15 
rs9969804 9 94468941 IPPK a 0.0281 0.45 0.94 1.16 
rs1257763 9 95933766 PTPDC1 a 0.0685 0.06 1.31 1.44 
rs473902 9 97296056 PTCH1/FANCC t 0.0741 0.93 1.01 1.48 
rs7027110 9 108638867 ZNF462 a 0.0337 0.22 0.81 1.20 
rs1468758 9 112846903 LPAR1 c 0.0258 0.76 1.03 1.15 
rs751543 9 118162163 PAPPA t 0.0287 0.69 1.13 1.17 
rs7466269 9 132453905 FUBP3 a 0.0359 0.66 1.39 1.21 
rs12338076 9 138261561 QSOX2 c 0.0304 0.29 0.95 1.18 
rs7909670 10 12958770 CCDC3 c 0.0219 0.55 1.11 1.12 
rs7332 10 80784066 PPIF g 0.0252 0.50 1.30 1.14 
rs11599750 10 101795432 CPN1 c 0.0230 0.66 1.12 1.13 
rs2237886 11 2767307 KCNQ1 t 0.0429 0.11 1.16 1.26 
rs7937898 11 12660137 TEAD1 g 0.0239 0.48 0.90 1.14 
rs1330 11 17272605 NUCB2 t 0.0241 0.38 1.16 1.14 
rs2904315 11 48066524 PTPRJ/SLC39A13 a 0.0311 0.30 1.04 1.18 
rs1814175 11 49515748 FOLH1 t 0.0230 0.44 1.15 1.13 
rs3782089 11 65093395 SSSCA1 c 0.0583 0.93 1.10 1.36 
rs7112925 11 66582736 RHOD c 0.0229 0.64 1.20 1.13 
rs606452 11 74953826 SERPINH1 a 0.0397 0.16 1.12 1.24 
rs494459 11 118079885 TREH t 0.0207 0.43 0.99 1.12 
rs654723 11 128091365 FLI1 a 0.0237 0.61 1.19 1.13 
rs2954980 12 11750815 ETV6 t 0.0295 0.36 1.11 1.17 
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Table 2.1 (Continued) 
 
Rsid Chr Pos Closest gene Effect allele Effect size Freq Observed OR Expected OR 
rs10770705 12 20748734 SLCO1C1 a 0.0314 0.34 1.14 1.18 
rs2638953 12 28425682 CCDC91 c 0.0356 0.69 1.53 1.21 
rs2066807 12 55026949 STAT2 g 0.0520 0.08 1.68 1.32 
rs1351394 12 64638093 HMGA2 t 0.0535 0.55 1.31 1.33 
rs10748128 12 68113925 FRS2 t 0.0347 0.37 1.36 1.20 
rs11107116 12 92502635 SOCS2 t 0.0524 0.21 1.68 1.32 
rs12298826 12 122394981 SBNO1 g 0.0350 0.21 0.85 1.20 
rs7332115 13 32045548 PDS5B/BRCA2 g 0.0250 0.39 1.10 1.14 
rs3118906 13 50004789 DLEU7 g 0.0518 0.75 1.24 1.32 
rs4773624 13 90817730 GPC5 g 0.0286 0.40 1.11 1.16 
rs1950500 14 23900690 NFATC4 t 0.0323 0.24 1.55 1.19 
rs10483727 14 60142628 SIX6 t 0.0322 0.38 1.25 1.19 
rs6573834 14 67878151 RAD51L1 c 0.0253 0.80 1.01 1.14 
rs862031 14 74061608 LTBP2 g 0.0224 0.64 1.42 1.13 
rs10150088 14 91573329 TRIP11 t 0.0270 0.60 1.05 1.15 
rs16964211 15 49317787 CYP19A1 g 0.0511 0.95 1.32 1.31 
rs7178424 15 60167551 C2CD4A c 0.0235 0.51 1.12 1.13 
rs10152591 15 67835211 TLE3 a 0.0447 0.88 1.15 1.27 
rs3759901 15 70298469 MYO9A a 0.0555 0.02 0.94 1.34 
rs5742915 15 72123686 PML c 0.0308 0.47 0.91 1.18 
rs11259936 15 82371586 ADAMTSL3 c 0.0419 0.48 1.30 1.25 
rs16942341 15 87189909 ACAN c 0.1335 0.98 1.26 2.04 
rs4965598 15 98577137 ADAMTS17 c 0.0353 0.30 1.20 1.21 
rs1659127 16 14295806 MKL2 a 0.0240 0.29 1.05 1.14 
rs4640244 17 21224816 KCNJ12 a 0.0279 0.56 1.01 1.16 
rs3110496 17 24941897 ANKRD13B g 0.0229 0.67 0.81 1.13 
rs3764419 17 26188149 ATAD5/RNF135 c 0.0374 0.62 1.12 1.22 
rs17780080 17 27367259 LRRC37B a 0.0344 0.17 1.01 1.20 
rs1043515 17 34175722 PIP4K2B g 0.0219 0.54 1.38 1.12 
rs4986172 17 40571807 ACBD4 c 0.0283 0.68 1.02 1.16 
rs11652146 17 44777362 ZNF652 g 0.0255 0.30 0.96 1.15 
rs227723 17 52133903 NOG t 0.0272 0.28 1.13 1.16 
rs2079795 17 56851431 TBX2 t 0.0395 0.33 1.23 1.23 
rs12325866 17 59109706 CSH1/GH1 a 0.0343 0.28 1.36 1.20 
rs11867479 17 65601802 KCNJ16/KCNJ2 t 0.0240 0.36 1.24 1.14 
rs4800452 18 18981609 CABLES1 t 0.0475 0.80 1.33 1.29 
rs2078286 18 45132860 DYM a 0.0372 0.41 1.20 1.22 
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Table 2.1 (Continued) 
 
Rsid Chr Pos Closest gene Effect allele Effect size Freq Observed OR Expected OR 
rs6567160 18 55980115 MC4R c 0.0245 0.27 1.15 1.14 
rs12980348 19 2132607 DOT1L g 0.0323 0.36 1.30 1.19 
rs891088 19 7135762 INSR g 0.0251 0.23 0.91 1.14 
rs4542783 19 8548160 ADAMTS10 t 0.0313 0.55 1.07 1.18 
rs2279008 19 17144303 MYO9B t 0.0308 0.75 1.04 1.18 
rs17318596 19 46628935 ATP5SL a 0.0290 0.38 1.31 1.17 
rs1741344 20 4049800 SMOX c 0.0263 0.39 1.14 1.15 
rs2145272 20 6574218 BMP2 g 0.0386 0.34 1.25 1.23 
rs7274811 20 31796842 ZNF341 g 0.0402 0.76 1.47 1.24 
rs143384 20 33489170 GDF5 g 0.0639 0.41 1.42 1.41 
rs1567865 20 47315374 ZNFX1 t 0.0337 0.22 1.15 1.20 
rs2834440 21 34612369 KCNE2 a 0.0247 0.62 1.23 1.14 
rs4821083 22 31386341 SYN3 t 0.0332 0.84 1.15 1.19 
 
The table shows the results for the SNPs used in the individual association analysis in the HUNT 
cohort. 
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Table 2.2: Individual SNP analysis for FINRISK cohort 
 
Rsid Chr Pos Closest gene Effect allele Effect size Freq Observed OR Expected OR 
rs425277 1 2069172 PTCH1/FANCC T 0.024 0.30 1.18 1.14 
rs2284746 1 17306675 FAM46A A 0.0354 0.52 1.52 1.21 
rs1738475 1 23536891 NPR3 C 0.0216 0.61 1.14 1.12 
rs4601530 1 24916698 FUBP3 A 0.0238 0.27 1.25 1.14 
rs2154319 1 41745770 OR2J3 T 0.0335 0.74 1.18 1.20 
rs17391694 1 78623626 SLC38A9 T 0.0399 0.12 2.31 1.24 
rs6699417 1 89123443 SBNO1 T 0.0217 0.66 0.75 1.12 
rs10874746 1 93323971 DNM3 T 0.0217 0.36 0.98 1.12 
rs9428104 1 118855587 ADAMTS10 C 0.0375 0.22 1.09 1.22 
rs11205277 1 149892872 TGFB2 G 0.0452 0.62 1.76 1.28 
rs17346452 1 172053287 WWC2 A 0.038 0.77 1.37 1.23 
rs1325598 1 175058872 RTF1 T 0.0256 0.45 1.12 1.15 
rs1046934 1 184023529 SCMH1 C 0.0459 0.63 1.47 1.28 
rs10863936 1 212237798 SF3B4 G 0.022 0.53 1.10 1.13 
rs6684205 1 218609702 CCDC53/GNPTAB A 0.0328 0.67 1.16 1.19 
rs11118346 1 219743719 TSEN15 C 0.0264 0.50 1.30 1.15 
rs10799445 1 227911883 SPAG17 A 0.0306 0.72 1.73 1.18 
rs4665736 2 25187599 PPIF T 0.0335 0.59 1.22 1.20 
rs6714546 2 33361425 LTBP1 C 0.0254 0.28 1.53 1.15 
rs17511102 2 37960613 CEP120 A 0.0601 0.90 2.05 1.38 
rs2341459 2 44768202 ZBTB24 T 0.0276 0.31 1.59 1.16 
rs3791675 2 56111309 BNC2 G 0.0496 0.25 1.25 1.31 
rs11684404 2 88924622 DNAJC27 C 0.027 0.65 0.89 1.16 
rs7567288 2 134151294 IGF1R G 0.0309 0.75 1.05 1.18 
rs1351164 2 217980143 RYBP T 0.0279 0.75 1.62 1.16 
rs12470505 2 219908369 NCKAP5 T 0.0483 0.88 1.37 1.30 
rs2629046 2 225047744 GPR126 T 0.0247 0.55 1.11 1.14 
rs2580816 2 232797966 C6orf173 C 0.0412 0.20 1.65 1.25 
rs12694997 2 241911659 NPPC C 0.0274 0.24 0.88 1.16 
rs2597513 3 13555836 L3MBTL3 C 0.0392 0.88 0.77 1.24 
rs13088462 3 51071713 DOCK3 C 0.0543 0.92 1.02 1.34 
rs2336725 3 53093779 LIN28B C 0.0263 0.55 1.48 1.15 
rs9835332 3 56642722 GDF5 A 0.0217 0.48 1.03 1.12 
rs9863706 3 72437413 KCNE2 A 0.0304 0.21 0.98 1.18 
rs9844666 3 135974216 ZNFX1 G 0.0284 0.23 0.99 1.17 
rs724016 3 142588510 C2CD4A C 0.067 0.58 1.58 1.44 
rs572169 3 172165727 SERPINH1 T 0.0355 0.33 1.06 1.21 
rs720390 3 185548683 CYP19A1 A 0.0305 0.43 1.17 1.18 
rs2247341 4 1671115 HMGA1 A 0.0251 0.40 0.96 1.14 
rs6449353 4 18033488 ETV6 T 0.0714 0.87 1.40 1.47 
rs17081935 4 57823476 TET2 T 0.0306 0.22 1.00 1.18 
rs7697556 4 73515313 CTU2/GALNS T 0.0219 0.49 1.49 1.13 
rs10010325 4 106106353 PRKCZ A 0.0214 0.45 1.12 1.12 
rs7689420 4 145568352 MKL2 G 0.0687 0.19 1.81 1.45 
rs955748 4 184215675 BMP2 A 0.0243 0.24 0.87 1.14 
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Table 2.2 (Continued) 
 
Rsid Chr Pos Closest gene Effect allele Effect size Freq Observed OR Expected OR 
rs1173727 5 32830521 LTBP1 T 0.0356 0.38 1.47 1.21 
rs11958779 5 55001899 EFEMP1 T 0.0282 0.72 0.89 1.16 
rs10037512 5 88354675 MFAP2 T 0.0267 0.58 1.45 1.15 
rs1582931 5 122657199 SLBP/FGFR3 G 0.0254 0.49 0.93 1.15 
rs274546 5 131727766 TULP4 A 0.0278 0.45 1.58 1.16 
rs526896 5 134384604 SSSCA1 T 0.0315 0.72 1.27 1.19 
rs4282339 5 168256240 ZNF462 G 0.0352 0.22 0.90 1.21 
rs12153391 5 171203438 EIF2AK3 T 0.0329 0.28 1.31 1.19 
rs889014 5 172984114 MC4R T 0.029 0.40 1.17 1.17 
rs422421 5 176517326 PTPDC1 G 0.0332 0.22 1.19 1.20 
rs6879260 5 179731014 PDS5B/BRCA2 T 0.0281 0.38 1.38 1.16 
rs3812163 6 7670759 PCSK5 A 0.0366 0.57 1.08 1.22 
rs1047014 6 19949472 PKN2 C 0.0291 0.75 1.19 1.17 
rs806794 6 26200677 KCNJ16/KCNJ2 A 0.0528 0.64 1.21 1.33 
rs3129109 6 29084232 PEX2 A 0.0257 0.37 0.88 1.15 
rs2256183 6 31380529 PPARD/FANCE A 0.0345 0.37 1.29 1.20 
rs2780226 6 34199092 TWISTNB T 0.079 0.92 1.19 1.53 
rs9472414 6 44946506 SMOX T 0.0306 0.22 0.92 1.18 
rs9360921 6 76265642 INSR G 0.0479 0.85 1.83 1.29 
rs310405 6 81800362 CDK6 A 0.03 0.48 1.40 1.18 
rs7759938 6 105378954 KCNJ12 G 0.042 0.71 1.48 1.25 
rs1046943 6 109783941 GIPC2 A 0.0223 0.53 0.96 1.13 
rs961764 6 117522156 ZNF341 G 0.0228 0.41 1.47 1.13 
rs1490384 6 126851160 GHSR T 0.037 0.49 1.11 1.22 
rs6569648 6 130349119 SOCS2 T 0.0358 0.76 1.26 1.21 
rs7763064 6 142797289 ANKRD13B G 0.0445 0.29 1.92 1.27 
rs543650 6 152110943 RHOD C 0.0318 0.47 1.34 1.19 
rs9456307 6 158929442 MYO9B T 0.0499 0.07 1.48 1.31 
rs798489 7 2801803 NOG A 0.0515 0.33 1.19 1.32 
rs4470914 7 19616522 PAPPA T 0.0328 0.17 1.22 1.19 
rs12534093 7 23502974 TNS1 T 0.0298 0.20 1.24 1.17 
rs1708299 7 28189946 HHIP A 0.0417 0.32 0.95 1.25 
rs6959212 7 38128326 DLEU7 G 0.0229 0.30 0.93 1.13 
rs42235 7 92248076 SPIN1 T 0.0548 0.32 1.33 1.34 
rs822552 7 148650634 DYM G 0.0302 0.74 1.22 1.18 
rs7460090 8 57194163 ADAMTSL3 T 0.0546 0.86 1.23 1.34 
rs6473015 8 78178485 STAT2 G 0.032 0.74 1.41 1.19 
rs6470764 8 130725665 CCDC91 C 0.0469 0.19 1.21 1.29 
rs12680655 8 135637337 SERPINE2 C 0.0298 0.55 1.21 1.17 
rs7864648 9 16358732 PIP4K2B T 0.0246 0.35 1.18 1.14 
rs11144688 9 78542286 DTL A 0.0548 0.12 0.91 1.34 
rs7853377 9 86552205 LRRC37B A 0.0256 0.76 1.88 1.15 
rs2778031 9 90835726 GNA12 T 0.0273 0.23 1.25 1.16 
rs1257763 9 96893945 CCDC108/IHH A 0.0685 0.06 1.17 1.45 
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Rsid Chr Pos Closest gene Effect allele Effect size Freq Observed OR Expected OR 
rs473902 9 98256235 CPN1 T 0.0741 0.90 1.08 1.49 
rs7027110 9 108638867 GPC5 A 0.0337 0.23 0.98 1.20 
rs751543 9 119122342 ADAMTS17 T 0.0287 0.73 1.23 1.17 
rs7466269 9 133464084 ACAN A 0.0359 0.60 1.03 1.21 
rs7849585 9 138251691 ATAD5/RNF135 T 0.0324 0.32 1.06 1.19 
rs7909670 10 12918764 ACBD4 C 0.0219 0.46 1.02 1.13 
rs2145998 10 81121696 Histone G 0.0252 0.56 0.98 1.15 
rs11599750 10 101805442 JMJD4 A 0.023 0.34 1.17 1.13 
rs2237886 11 2810731 MICA T 0.0429 0.11 1.58 1.26 
rs7926971 11 12698040 NME2 C 0.0244 0.58 1.16 1.14 
rs1330 11 17316029 C3orf63 T 0.0241 0.33 1.07 1.14 
rs1814175 11 49559172 FBXW11 T 0.023 0.30 1.31 1.13 
rs3782089 11 65336819 ZFAT C 0.0583 0.07 0.84 1.37 
rs7112925 11 66826160 NFATC4 C 0.0229 0.32 1.05 1.13 
rs634552 11 75282052 FLI1 T 0.0412 0.17 1.43 1.25 
rs494459 11 118574675 TEAD1 T 0.0207 0.41 1.13 1.12 
rs654723 11 128586155 HMGA2 A 0.0237 0.64 1.13 1.14 
rs2856321 12 11855773 JAZF1 A 0.0298 0.65 1.22 1.17 
rs10770705 12 20857467 RPL5 A 0.0314 0.30 1.29 1.18 
rs2638953 12 28534415 ESR1 C 0.0356 0.70 0.96 1.21 
rs2066807 12 56740682 FGFR4/NSD1 T 0.052 0.93 1.19 1.32 
rs1351394 12 66351826 PCCB T 0.0535 0.49 1.45 1.33 
rs11107116 12 93978504 PAPPA2 T 0.0524 0.24 1.04 1.33 
rs7971536 12 102373788 ZNF652 G 0.0247 0.41 0.78 1.14 
rs11830103 12 122389499 CDC42EP3 T 0.0351 0.78 1.12 1.21 
rs1809889 12 124801226 SLIT3 T 0.0315 0.31 1.33 1.19 
rs7332115 13 33147548 PML C 0.025 0.58 0.92 1.14 
rs3118905 13 51105334 SDR16C5 T 0.052 0.33 1.31 1.32 
rs7319045 13 92024574 MYO9A A 0.029 0.45 1.49 1.17 
rs1950500 14 24830850 BOD1 T 0.0323 0.30 1.06 1.19 
rs1570106 14 68813115 IGF2BP2 G 0.0256 0.23 1.38 1.15 
rs7155279 14 91555634 RAD51L1 C 0.0285 0.35 0.95 1.17 
rs16964211 15 49317787 ADAMTS3 C 0.0511 0.09 1.39 1.32 
rs7178424 15 62380259 TRIP11 T 0.0235 0.54 1.34 1.14 
rs12902421 15 72161403 SEPT2 A 0.0691 0.95 0.96 1.45 
rs5742915 15 74336633 TREH T 0.0308 0.56 0.98 1.18 
rs11259936 15 84580582 LYPLAL1 T 0.0419 0.47 1.82 1.25 
rs16942341 15 89388905 POLR2B C 0.1335 0.05 1.90 2.06 
rs4965598 15 98577137 NUCB2 T 0.0353 0.68 1.17 1.21 
rs2871865 15 99194896 STARD3NL C 0.0535 0.88 1.45 1.33 
rs1659127 16 14388305 LCORL A 0.024 0.35 1.09 1.14 
rs8052560 16 87304743 TBX2 A 0.0392 0.79 1.07 1.24 
rs4640244 17 21284223 CCDC3 A 0.0279 0.59 1.24 1.16 
rs3110496 17 24941897 PDIA4 C 0.0229 0.36 1.01 1.13 
rs3764419 17 29164023 GSDMC C 0.0374 0.39 1.18 1.22 
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Rsid Chr Pos Closest gene Effect allele Effect size Freq Observed OR Expected OR 
rs17780086 17 30343282 SLC22A5 A 0.0346 0.16 1.16 1.21 
rs1043515 17 36922196 CLIC4 C 0.0219 0.46 1.14 1.13 
rs4986172 17 43216281 FOLH1 C 0.0283 0.39 0.97 1.16 
rs4605213 17 46599746 QSOX2 C 0.0234 0.32 1.21 1.13 
rs2072153 17 47390014 GFPT2 C 0.0264 0.30 0.99 1.15 
rs227724 17 52133816 SUPT3H/RUNX2 A 0.0272 0.61 1.07 1.16 
rs2079795 17 59496649 BMP6 T 0.0395 0.30 1.58 1.24 
rs11867479 17 68090207 C2orf34 T 0.024 0.34 0.97 1.14 
rs9967417 18 46959500 SYN3 C 0.0381 0.62 0.98 1.23 
rs17782313 18 57851097 PITX1 G 0.0249 0.80 1.15 1.14 
rs12982744 19 2177193 HDAC11 C 0.0325 0.61 1.36 1.19 
rs891088 19 7184762 DOT1L G 0.0251 0.70 0.96 1.14 
rs4072910 19 8644031 C9orf64 G 0.0289 0.48 1.18 1.17 
rs2279008 19 17283303 SENP6 T 0.0308 0.68 1.45 1.18 
rs1741344 20 4101800 MEF2C C 0.0263 0.64 0.94 1.15 
rs2145272 20 6626218 ID4 C 0.0386 0.69 1.42 1.23 
rs7274811 20 32333181 TLE3 A 0.0402 0.24 1.29 1.24 
rs143384 20 33489170 ZBTB38 G 0.0639 0.55 1.68 1.41 
rs237743 20 47903019 VGLL2 A 0.0338 0.21 1.30 1.20 
rs2834442 21 35690786 IGF2BP3 A 0.0269 0.67 1.16 1.16 
rs4821083 22 31386341 KCNQ1 T 0.0332 0.84 1.09 1.20 
 
The table shows the results for the SNPs used in the individual association analysis in the 
FINRISK cohort. 
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Table 2.3: Meta-analysis of individual SNPs for HUNT and FINRISK cohort 
 
Rsid Chr Pos Closest gene Effect 
allele 
Freq Effect Size Observed 
OR 
P-value Expected 
OR 
rs425277 1 2069172 PRKCZ t 0.28 0.02 1.19 0.0932 1.14 
rs2284746 1 17306675 MFAP2 t 0.50 0.03 1.30 0.0045 1.19 
rs1738475 1 23536891 HTR1D t 0.59 0.02 1.15 0.1364 1.12 
rs4601530 1 24916698 CLIC4 c 0.74 0.02 1.10 0.3495 1.14 
rs2154319 1 41745770 SCMH1 g 0.23 0.03 1.27 0.0355 1.19 
rs17391694 1 78623626 GIPC2 t 0.11 0.04 1.56 0.0008 1.24 
rs6699417 1 89123443 PKN2 t 0.62 0.02 0.97 0.7864 1.12 
rs10874746 1 93323971 RPL5 c 0.63 0.02 1.06 0.5108 1.12 
rs9428104 1 118855587 SPAG17 c 0.76 0.04 1.19 0.1106 1.22 
rs11205277 1 149892872 SF3B4 g 0.42 0.05 1.56 0.0000 1.27 
rs17346452 1 172053287 DNM3 g 0.27 0.04 1.07 0.5121 1.21 
rs1325598 1 175058872 PAPPA2 a 0.57 0.03 1.17 0.0992 1.14 
rs1046934 1 184023529 TSEN15 c 0.36 0.05 1.32 0.0050 1.28 
rs10863936 1 212237798 DTL g 0.46 0.02 1.12 0.2176 1.12 
rs6684205 1 218609702 TGFB2 g 0.29 0.03 1.15 0.1579 1.19 
rs11118346 1 219743719 LYPLAL1 c 0.54 0.03 1.19 0.0702 1.15 
rs4665736 2 25187599 DNAJC27 a 0.53 0.03 1.35 0.0017 1.19 
rs6714546 2 33361425 LTBP1 g 0.72 0.02 1.36 0.0033 1.14 
rs2341459 2 44768202 C2orf34 t 0.27 0.03 1.34 0.0040 1.16 
rs3791675 2 56111309 EFEMP1 c 0.77 0.05 1.49 0.0002 1.30 
rs11684404 2 88924622 EIF2AK3 c 0.33 0.03 1.11 0.2966 1.15 
rs7567288 2 134151294 NCKAP5 c 0.20 0.03 1.08 0.4521 1.18 
rs12470505 2 219908369 CCDC108/IHH t 0.90 0.05 1.05 0.7572 1.29 
rs2629046 2 225047744 SERPINE2 t 0.55 0.02 1.21 0.0364 1.14 
rs12694997 2 241911659 SEPT2 g 0.76 0.03 1.00 0.9930 1.16 
rs2597513 3 13555836 HDAC11 c 0.11 0.04 1.28 0.1184 1.23 
rs13088462 3 51071713 DOCK3 c 0.06 0.05 1.32 0.1658 1.34 
rs2336725 3 53093779 RTF1 c 0.46 0.03 1.14 0.1695 1.15 
rs9835332 3 56642722 C3orf63 a 0.54 0.02 1.16 0.1039 1.12 
rs9863706 3 72437413 RYBP a 0.79 0.03 1.15 0.2250 1.18 
rs9844666 3 135974216 PCCB g 0.74 0.03 1.21 0.0929 1.16 
rs724016 3 142588510 ZBTB38 g 0.43 0.07 1.55 0.0000 1.43 
rs572169 3 172165727 GHSR t 0.31 0.04 1.21 0.0543 1.21 
rs720390 3 185548683 IGF2BP2 a 0.39 0.03 1.21 0.0528 1.18 
rs2247341 4 1671115 SLBP/FGFR3 a 0.36 0.03 1.13 0.2082 1.14 
rs6449353 4 18033488 LCORL t 0.85 0.07 1.48 0.0111 1.46 
rs17081935 4 57823476 POLR2B t 0.19 0.03 1.01 0.9645 1.18 
rs7697556 4 73515313 ADAMTS3 t 0.48 0.02 1.31 0.0036 1.12 
rs10010325 4 106106353 TET2 a 0.49 0.02 1.17 0.0885 1.12 
rs7689420 4 145568352 HHIP c 0.84 0.07 1.45 0.0043 1.44 
rs955748 4 184215675 WWC2 g 0.75 0.02 1.08 0.4925 1.14 
rs1173727 5 32830521 NPR3 t 0.39 0.04 1.26 0.0176 1.21 
rs11958779 5 55001899 SLC38A9 t 0.30 0.03 1.10 0.3480 1.16 
rs10037512 5 88354675 MEF2C t 0.56 0.03 1.29 0.0086 1.15 
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Rsid Chr Pos Closest gene Effect 
allele 
Freq Effect Size Observed 
OR 
P-value Expected 
OR 
rs274546 5 131727766 SLC22A5 g 0.61 0.03 1.39 0.0005 1.16 
rs526896 5 134384604 PITX1 t 0.73 0.03 1.18 0.1189 1.18 
rs4282339 5 168256240 SLIT3 g 0.80 0.04 1.01 0.9540 1.21 
rs12153391 5 171203438 FBXW11 c 0.75 0.03 1.25 0.0350 1.19 
rs889014 5 172984114 BOD1 c 0.64 0.03 1.16 0.1339 1.17 
rs422421 5 176517326 FGFR4/NSD1 c 0.78 0.03 1.15 0.2751 1.19 
rs6879260 5 179731014 GFPT2 c 0.61 0.03 1.29 0.0067 1.16 
rs3812163 6 7670759 BMP6 a 0.47 0.04 1.22 0.0320 1.21 
rs806794 6 26200677 Histone a 0.71 0.05 1.08 0.4548 1.33 
rs3129109 6 29084232 OR2J3 c 0.60 0.03 0.89 0.2318 1.15 
rs2256183 6 31380529 MICA g 0.45 0.03 1.35 0.0016 1.20 
rs2780226 6 34199092 HMGA1 c 0.08 0.08 1.32 0.1486 1.52 
rs9472414 6 44946506 SUPT3H/RUNX2 g 0.79 0.03 1.26 0.0438 1.18 
rs310405 6 81800362 FAM46A a 0.53 0.03 1.20 0.0566 1.17 
rs7759938 6 105378954 LIN28B c 0.32 0.04 1.17 0.1087 1.25 
rs1046943 6 109783941 ZBTB24 c 0.58 0.02 0.93 0.4634 1.12 
rs961764 6 117522156 VGLL2 c 0.59 0.02 1.26 0.0156 1.12 
rs1490384 6 126851160 C6orf173 t 0.50 0.04 1.15 0.1290 1.22 
rs6569648 6 130349119 L3MBTL3 c 0.24 0.04 1.26 0.0383 1.21 
rs7763064 6 142797289 GPR126 g 0.71 0.04 1.50 0.0002 1.27 
rs543650 6 152110943 ESR1 g 0.60 0.03 1.28 0.0075 1.18 
rs9456307 6 158929442 TULP4 g 0.94 0.05 1.01 0.9579 1.30 
rs798489 7 2801803 GNA12 c 0.71 0.05 1.29 0.0106 1.32 
rs1708299 7 28189946 JAZF1 a 0.31 0.04 1.22 0.0498 1.25 
rs6959212 7 38128326 STARD3NL c 0.68 0.02 1.12 0.2541 1.13 
rs42235 7 92248076 CDK6 t 0.31 0.05 1.28 0.0188 1.34 
rs822552 7 148650634 PDIA4 g 0.25 0.03 1.21 0.0714 1.17 
rs6473015 8 78178485 PEX2 c 0.29 0.03 1.29 0.0147 1.19 
rs6470764 8 130725665 GSDMC c 0.79 0.05 1.01 0.9297 1.28 
rs12680655 8 135637337 ZFAT a 0.60 0.03 1.18 0.0854 1.17 
rs7864648 9 16358732 BNC2 t 0.32 0.02 1.04 0.6868 1.14 
rs11144688 9 78542286 PCSK5 g 0.89 0.05 1.05 0.7566 1.34 
rs7853377 9 86552205 C9orf64 g 0.23 0.03 1.30 0.0289 1.14 
rs2778031 9 90835726 SPIN1 t 0.24 0.03 1.29 0.0167 1.15 
rs1257763 9 96893945 PTPDC1 a 0.04 0.07 1.27 0.2484 1.44 
rs473902 9 98256235 PTCH1/FANCC t 0.92 0.07 1.04 0.8135 1.48 
rs7027110 9 108638867 ZNF462 a 0.23 0.03 0.87 0.2405 1.20 
rs751543 9 119122342 PAPPA t 0.71 0.03 1.17 0.1351 1.17 
rs7466269 9 133464084 FUBP3 a 0.64 0.04 1.24 0.0246 1.21 
rs7849585 9 138251691 QSOX2 c 0.33 0.03 0.99 0.9361 1.18 
rs7909670 10 12918764 CCDC3 c 0.57 0.02 1.07 0.4500 1.12 
rs2145998 10 81121696 PPIF g 0.52 0.03 1.16 0.1120 1.14 
rs11599750 10 101805442 CPN1 c 0.61 0.02 1.14 0.1950 1.13 
rs2237886 11 2810731 KCNQ1 t 0.11 0.04 1.28 0.1129 1.26 
rs7926971 11 12698040 TEAD1 g 0.46 0.02 0.99 0.9516 1.14 
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Rsid Chr Pos Closest gene Effect 
allele 
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OR 
P-value Expected 
OR 
rs1330 11 17316029 NUCB2 t 0.35 0.02 1.13 0.2302 1.14 
rs1814175 11 49559172 FOLH1 t 0.34 0.02 1.21 0.0438 1.13 
rs3782089 11 65336819 SSSCA1 c 0.94 0.06 1.01 0.9532 1.36 
rs7112925 11 66826160 RHOD c 0.64 0.02 1.14 0.1905 1.13 
rs634552 11 75282052 SERPINH1 a 0.14 0.04 1.26 0.0734 1.24 
rs494459 11 118574675 TREH t 0.40 0.02 1.04 0.6646 1.12 
rs654723 11 128586155 FLI1 a 0.61 0.02 1.17 0.1041 1.13 
rs2856321 12 11855773 ETV6 t 0.36 0.03 1.15 0.1499 1.17 
rs10770705 12 20857467 SLCO1C1 a 0.33 0.03 1.19 0.0721 1.18 
rs2638953 12 28534415 CCDC91 c 0.68 0.04 1.28 0.0133 1.21 
rs2066807 12 56740682 STAT2 g 0.08 0.05 1.49 0.0334 1.32 
rs1351394 12 66351826 HMGA2 t 0.49 0.05 1.36 0.0009 1.33 
rs11107116 12 93978504 SOCS2 t 0.22 0.05 1.34 0.0106 1.32 
rs11830103 12 122389499 SBNO1 g 0.22 0.04 0.95 0.6298 1.21 
rs1809889 12 124801226 FAM101A t 0.29 0.03 1.28 0.0150 1.18 
rs7332115 13 33147548 PDS5B/BRCA2 g 0.38 0.03 1.03 0.7892 1.14 
rs3118905 13 51105334 DLEU7 g 0.71 0.05 1.27 0.0230 1.32 
rs7319045 13 92024574 GPC5 g 0.39 0.03 1.24 0.0188 1.16 
rs1950500 14 24830850 NFATC4 t 0.30 0.03 1.33 0.0075 1.19 
rs1570106 14 68813115 RAD51L1 c 0.79 0.03 1.15 0.2214 1.14 
rs7155279 14 91555634 TRIP11 t 0.62 0.03 1.01 0.9025 1.15 
rs16964211 15 49317787 CYP19A1 g 0.95 0.05 1.35 0.1532 1.31 
rs7178424 15 62380259 C2CD4A c 0.54 0.02 1.19 0.0699 1.13 
rs12902421 15 72161403 MYO9A a 0.03 0.06 0.94 0.8741 1.34 
rs5742915 15 74336633 PML c 0.47 0.03 0.94 0.4832 1.18 
rs11259936 15 84580582 ADAMTSL3 c 0.52 0.04 1.49 0.0000 1.25 
rs16942341 15 89388905 ACAN c 0.97 0.13 1.43 0.2533 2.04 
rs4965598 15 98577137 ADAMTS17 c 0.32 0.04 1.19 0.0952 1.21 
rs1659127 16 14388305 MKL2 a 0.34 0.02 1.07 0.5156 1.14 
rs4640244 17 21284223 KCNJ12 a 0.61 0.03 1.09 0.3451 1.16 
rs3110496 17 24941897 ANKRD13B g 0.67 0.02 0.89 0.2488 1.13 
rs3764419 17 29164023 ATAD5/RNF135 c 0.61 0.04 1.14 0.1612 1.22 
rs17780086 17 30343282 LRRC37B a 0.15 0.03 1.06 0.6451 1.20 
rs1043515 17 36922196 PIP4K2B g 0.54 0.02 1.28 0.0067 1.12 
rs4986172 17 43216281 ACBD4 c 0.65 0.03 1.00 0.9611 1.16 
rs2072153 17 47390014 ZNF652 g 0.31 0.03 0.98 0.8110 1.15 
rs227724 17 52133816 NOG t 0.32 0.03 1.10 0.2980 1.16 
rs2079795 17 59496649 TBX2 t 0.33 0.04 1.34 0.0032 1.23 
rs11867479 17 68090207 KCNJ16/KCNJ2 t 0.35 0.02 1.14 0.1713 1.14 
rs9967417 18 46959500 DYM a 0.42 0.04 1.12 0.2481 1.22 
rs17782313 18 57851097 MC4R c 0.24 0.02 1.15 0.2121 1.14 
rs12982744 19 2177193 DOT1L g 0.41 0.03 1.32 0.0043 1.19 
rs891088 19 7184762 INSR g 0.26 0.03 0.93 0.5104 1.14 
rs4072910 19 8644031 ADAMTS10 t 0.56 0.03 1.12 0.2580 1.18 
rs2279008 19 17283303 MYO9B t 0.75 0.03 1.20 0.0657 1.18 
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Rsid Chr Pos Closest gene Effect 
allele 
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OR 
P-value Expected 
OR 
rs1741344 20 4101800 SMOX c 0.37 0.03 1.07 0.4895 1.15 
rs2145272 20 6626218 BMP2 g 0.35 0.04 1.31 0.0099 1.23 
rs7274811 20 32333181 ZNF341 g 0.77 0.04 1.40 0.0018 1.24 
rs143384 20 33489170 GDF5 g 0.42 0.06 1.52 0.0000 1.41 
rs237743 20 47903019 ZNFX1 t 0.21 0.03 1.20 0.0900 1.20 
rs2834442 21 35690786 KCNE2 a 0.62 0.02 1.20 0.0613 1.14 
rs4821083 22 31386341 SYN3 t 0.83 0.03 1.13 0.3619 1.19 
 
The table shows the results for the SNPs used in the meta-analysis of the HUNT and FINRISK 
cohorts. 
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specific allele frequencies (see Materials and Methods). Overall, the number of SNPs with 
observed odds ratio greater than expected odds ratios was no different than expectation under the 
model of equal effect sizes in extremes and the general population (HUNT 79/160 SNPs, p=0.94; 
FINRISK 75/155 SNPs, p=0.48 and combined 75/141, p=0.45); (Table 2.1; Table 2.2 and Table 
2.3). Next, for each SNP we tested for a difference between the expected and observed odds ratio 
in the individual studies and in the meta-analysis. Overall there were no more or fewer 
significant associations than would be expected under the equal effect size model (Figure 2.1). 
This result demonstrates that the individual SNPs have similar effects at the extremes as in the 
general population. 
 
Weighted Allele Score (WAS) analysis: The additive effect of the common variants differs 
significantly from expected in the short extremes 
 After determining that the individual SNPs have similar effects at the extremes of the 
height distribution as in the general population, we then performed additional analyses on the 
combined set of height-associated variants. We asked whether extremely short and extremely tall 
individuals show overall enrichment of height-decreasing and height-increasing alleles, 
respectively, to the extent expected under a purely polygenic additive model. If the enrichment is 
less than expected, this result would suggest that the common variants are not explaining as 
much of the phenotypic variation in the extremes as in the general population. To test this 
possibility, we first calculated the weighted allele score (WAS) for each individual using the 
height-associated SNPs previously described. The WAS is the cumulative effect of all of the 
SNPs on height weighted by each SNP's estimated effect size (β). In Figure 2.2, we show a plot 
of each individual’s WAS based on the 143 loci genotyped in both cohorts versus the individual  
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Figure 2.1: QQ Plot of p-values for individual SNPs based on the meta-analysis of HUNT 
and FINRISK. The figure shows a Q-Q plot of the p-values of the difference between the 
observed odd-ratios and the expected odd-ratios. 
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Figure 2.2: Plot of weighted allele scores (WAS) against Height Z-scores for HUNT and 
FINRISK Cohorts. The plot shows the WAS, a measure of the genetic prediction of height by 
known common variants, against the height Z-scores. The tall individuals (Z-score > 2.14) have 
generally larger WAS than the short individuals (Z-score < -2.14). Individuals from the HUNT 
study are labeled blue and individuals from the FINRISK study are labeled red. 
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height Z-scores. As expected, the WAS are significantly different between the tall extremes and 
the short extremes (p<3x10
-86
), with individuals in the tall extreme having higher WAS on 
average than individuals in the short extremes.  
We then tested whether the WAS in the short and tall groups are within expectations based 
on the population specific allele frequencies and previously estimated effect sizes of these SNPs, 
assuming a purely polygenic model. To generate the distribution of WAS under these 
expectations, we simulated populations that mimicked our ascertainment of extreme samples 
from the HUNT and FINRISK populations (see Materials and Methods). For each cohort, we 
compared the observed mean WAS with the distribution of mean WAS under the simulated model 
(Figure 2.3 and Figure 2.4). For the HUNT study the sample of 1224 individuals from the middle 
of the distribution suggest our modeling is behaving as expected (Figure 2.3). Finally, we 
analyzed the data by combining both studies using the 143 SNPs present in both data-sets 
(Figure 2.5). In each study separately and in the combined analysis, the mean observed WAS for 
the tall individuals was within expectation, but we observed a significant upward deviation of the 
mean observed WAS in the short extremes (p=0.006 for the combined-analysis). These results 
suggest that the collective effect of the common variants in the short extremes do not account for 
as much of the phenotypic variation in height as predicted from the effects seen in the general 
population. 
 
The reduced effect of common variants is limited to the most extreme short individuals 
Having established that the common variants do not explain as much phenotypic 
variation in the short extremes, we then sought to determine if this finding was accentuated in  
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Figure 2.3: Comparison of the observed versus simulated mean weighted allele score (WAS) 
in the HUNT study. The plot shows the result of comparing the mean WAS of the short and tall 
individuals observed in the HUNT cohort against that obtained from simulation. Each row 
represents a different stratification of the extremes identical to those defined in Figure 2.5. The 
plot also show the mean WAS of 1224 non-extreme individuals taken from the middle of the 
height distribution. There is no difference between the mean WAS of the non-extreme individuals 
from that obtained from simulation (p=0.56). 
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Figure 2.4: Comparison of the observed versus simulated mean weighted allele score (WAS) 
in the FINRISK study. The plot shows the result of comparing the mean WAS of the short and 
tall individuals observed in the FINRISK cohort against that obtained from simulation. Each row 
represents a different stratification of the extremes identical to those defined in Figure 2.5. 
  
62 
 
 
Figure 2.5: Comparison of the observed versus simulated mean weighted allele score (WAS) 
in the combined cohort. The plot shows the result of comparing the mean WAS of the short and 
tall individuals observed from both the HUNT and FINRISK cohorts against that obtained from 
simulation. Each row represents a different stratification of the extremes. The percentiles and 
numbers of individuals in the short and tall extreme respectively are listed for each stratum. The 
p-values represent the comparison between the observed and simulated mean WAS. The observed 
mean WAS for the tall individuals were not different from the simulation in any of the strata. The 
observed mean WAS for the short individuals was not different from the simulation in the first 
stratum. As a progressively more extreme sample is used, the short individuals’ mean WAS 
becomes progressively more significantly different than the simulation.  
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individuals with the most extreme short stature. We stratified our analysis in several ways 
(Figure 2.5; Figure 2.3; Figure 2.4). First, we removed the most extreme individuals: those below 
the 0.25 percentile and above the 99.75 percentile. In the combined cohorts, the mean observed 
WAS in the short extremes was no longer significantly different than expected (p=0.526), 
indicating that the shift in WAS is driven by the most extremely short individuals. To further 
explore this hypothesis, we then selected more extreme individuals at two thresholds, including 
only the top and bottom 0.5% or 0.25% of the population (see Materials and Methods). For both 
strata, there was a more pronounced deviation of the mean observed WAS in the short extremes 
(p=7.12 x 10
-6
 and p=9.88 x 10
-7 
for the 0.5% and 0.25% extremes respectively), but again no 
deviation in the tall extremes. Similar observations occurred when we analyzed the cohorts 
separately using the same stratification procedure (Figure 2.3; Figure 2.4). We repeated the 
analysis using Z-scores based on inverse normal transformation, and with the three -6 SD 
outliers removed, and the results were essentially unchanged. The difference observed in the 
WAS analysis is also supported by the individual SNP analysis: when we performed the 
combined analysis described above for the 0.25% extremes rather than the entire cohort, 60% 
(84/139) of the SNPS have an observed effect size smaller than expected (p=0.02) (data not 
shown). This analyses clearly suggest that the initial marginally significant shift of the mean 
observed WAS in the short extremes is primarily driven by the most extreme short individuals. 
Therefore, in general, as one selects individuals with more extreme short stature, in particular 
those with heights below the 0.25 percentile, the common variants play a much smaller role in 
explaining stature, indicating that there must be other factors contributing to the phenotypic 
variation in these extremely short individuals. 
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Low frequency or rare variants with larger effect sizes could explain the phenotypic 
variation in the short extremes 
We hypothesized that lower frequency and rare genetic variants with larger effect sizes 
than the common variants may explain the phenotypic variation in the short extremes. To test this 
hypothesis, we performed population simulations with rare-variants of various allele frequencies 
and effect sizes, and asked if our observed data were consistent with these simulated scenarios 
(Figure 2.6). As a negative control, we first modeled an additional 180 SNPs, each with allele 
frequency of 0.3 and average effect sizes of -0.05 SD, which is similar to the allele frequency 
and effect size for previously discovered common variants associated with height. In this 
simulation, the mean WAS distribution did not change, indicating that adding additional common 
variants of similar effect sizes cannot explain the phenotypic variation in the short extremes. We 
then modeled a single rare variant of very large effect: frequency 0.005 and effect size of -4 SD.  
In this model, the mean WAS distribution in the extremely short individuals shifts more than we 
observed in our population. This simulation essentially excludes the possibility of a 0.5% variant 
of very large effect within our cohort. Such a variant would also be likely to be discovered in 
linkage studies of several thousand sib-pairs [6]. 
However, there are several rare variant models that would likely not have been detected 
in previous linkage analyses of height and generate a shift in the mean WAS consistent with our 
observed data (Figure 2.6). One such possibility is a single low frequency variant (allele 
frequency = 0.005) with an effect size of -2 SD; another model consistent with our data includes 
10 variants each with an allele frequency of 0.005 and a moderate effect size of -1 SD.  These 
simulations suggest that individuals with very short stature may harbor small numbers of low 
frequency variants of moderately large effect or a greater number of low  
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Figure 2.6: Comparison of the observed versus simulated mean WAS with models 
incorporating additional variants. The plot shows the result of comparing the mean WAS of the 
short and tall individuals observed from both the HUNT and FINRISK cohorts against that 
obtained from simulation with different scenarios of additional variants. All rows use the 
approximate 1.5% tails of the height distribution as extremes, resulting in 566 short and 648 tall 
individuals. The 1
st
 row shows the result where the model has no additional variants affecting 
height and thus is identical to that from the 2
nd
 row of Figure 2.5. The 2
nd
 row shows a model 
where there are 180 additional common variants that slightly decreases height (allele frequency = 
0.3 and effect size (β) = -0.05). This model does not result in any significant change to the 
simulated WAS of the short individuals and the observed WAS is still significantly different 
(p=0.00756). The 3
rd
 row shows a model where there is 1 additional low frequency variant with a 
large height decreasing effect (allele frequency = 0.005 and effect size (β) = -4). This model 
results in a large shift in the simulated WAS of the short individuals to the right. The observed 
WAS is still significantly different (p=4.54 x 10
-8
) than the simulation but in the opposite 
direction and thus is not consistent with our data. The 4
th
 row shows a model where there is 1 
additional low frequency variant that decreases height significantly (allele frequency = 0.005 and 
effect size (β) = -2). This model results in a shift in the simulated WAS of the short individuals to 
the right such that the observed WAS is no longer different from the simulation (p=0.544). The 5
th
 
row shows a model where there are 10 additional low frequency variants that moderately 
decreases height (allele frequency = 0.005 and effect size (β) = -1). This model also results in a 
shift in the simulated WAS of the short individuals to the right such that the observed WAS is no 
longer different from the simulation (p=0.39). The final two models are consistent with our 
observed data. 
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Figure 2.6 (Continued)   
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frequency variants of moderate effects contributing to their short stature. This result stands in 
contrast to the remainder of the height distribution in which a polygenic effect of common and 
rare variants with small effects could explain the majority of the heritability of height, even 
though only a small percentage of height-associated common variants have been identified. 
 
Sibling analysis provides support for a different genetic architecture in extreme short 
individuals  
To provide further support for a different genetic architecture in individuals in the 
extreme short tails we performed an analysis in siblings from the HUNT study. We queried the 
entire HUNT database (N=106,455) and identified 21,365 siblings pairs. The correlation of age 
and gender adjusted height between siblings was high (r = 0.466). We then identified 98 
individuals (aged between 20-70yrs) with a Z-score < -2.81 (~0.25% tails) and 80 with a Z-score 
> 2.81 who also had at least one sibling in the database (the results are similar if we use inverse 
normal transformation). The average height Z-score for the siblings of the extreme short group 
was -0.97 (95% CI: -0.80, -1.15); the average Z-score for the full siblings of the extreme tall 
group was 1.29 (95% CI: 1.14, 1.45) which are significantly different (t-test, p=0.007 after 
reversing signs for the short group). We then performed this same analysis for the 0.25% to 1.5% 
tails individuals and there was no significant difference in z-scores of siblings between the short 
(-1.05 95% CI: -1.13, -0.97) and tall (1.11 95% CI: 1.03, 1.18) groups (t-test, p=0.28). So the 
differential regression to the mean appears to be limited to the shortest ~0.25% of individuals 
with this group regressing more quickly than the tall extreme group. This is consistent with the 
results we observe with the weighted allele score (WAS) approach. We do not have the twin data 
that would allow us to separate out the environmental and genetic effects in this group and our 
68 
 
data is consistent with both. If the effect were due to genetics, then a model with de novo 
mutations and/or multiple recessive rare variants could cause an increased regression to the mean 
in extremely short individuals, although there are other plausible explanations. 
 
DISCUSSION 
We have assessed whether common variants robustly associated with height in the 
general population also associate with height at the extreme tails of the height distribution. We 
further tested whether this association is to the extent expected under a purely polygenic model. 
By genotyping ~160 height SNPs identified from the GIANT study [2] (that explain ~10% of the 
population variation in height) in individuals from the ~1% tails of height from two large 
population based cohorts, we have shown that the polygenic model can explain the associations 
in the ~1% tails of height. However, our data indicate that the polygenic model starts to break 
down in extreme short individuals near the 0.25 percentile cut off. This conclusion is supported 
by our sibling analysis, which demonstrated that siblings in the 0.25% short tail regress to the 
mean more than those in the 0.25% tall group. Interestingly, the overall height distribution also 
shows a slight asymmetric deviation from normality, with an excess of individuals with 
extremely short stature but not for extremely tall stature. 
While in general the individuals in the ~1% tails carry as many height increasing alleles 
as would be predicted based on their height, there was a clear deviation for individuals in the 
shortest 0.25% tail. On average, these individuals carry significantly more “tall” alleles at the 
160 SNPs than would be expected if common alleles were explaining their short stature. This 
suggests that the heights of these individuals are explained by factors other than common 
variants. Our simulations suggest that rare variants could explain this difference in the 0.25% 
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shortest tail. For example, 10 rare variants with modest effects on height (1SD) are consistent 
with our observed data, as is a single variant with a 2SD effect. The sibling analysis also suggests 
a role for de novo or multiple recessive variants in the extreme short individuals. While rare 
height-decreasing variants of large effect are a plausible explanation, there are many other 
genetic models consistent with our data, including a mixture of height-decreasing with a smaller 
number of height-increasing rare variants, or variants having non-additive effects. While non-
additive genetic effects could explain the data, no evidence was found for dominance or gene-
gene interaction effects for the SNPs used in this study in the original GIANT publication [2]. It 
is also possible that these individuals are short for non-genetic reasons. One could suggest that 
these individuals are short because of differences in ancestry, but we have taken steps to remove 
any possible ethnic outliers from our extremes (see Materials and Methods). Measurement or 
recording error is another possibility, although the fact that the tall group does not show this 
effect (which presumably is equally likely to contain measurement error as the short group) 
suggests this is an unlikely explanation. Non-genetic factors could also be a possibility, for 
example, poor early-life nutrition, severe infection, or other chronic childhood diseases could 
have prevented these individuals from reaching their genetic height potential.  
This result also suggests that these families would be good candidates to investigate in 
sequencing studies, as they may be enriched for rare or de novo, higher penetrance alleles. More 
generally, the weighted allele score (WAS) method developed here could be used to select 
individuals to sequence in the search for these types of rarer variants, not only for height but also 
for other polygenic traits and diseases. Specifically, individuals in the extreme tails of a trait 
distribution who have an unexpectedly high or low weighted allele score may be particularly 
useful to sequence, especially if multiple relatives with these characteristics were present in the 
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extreme tails. 
Our study also demonstrates empirically that selecting individuals from the extreme tails 
of a complex trait distribution is an efficient approach for genetic studies, as was proposed both 
for linkage studies [7,8] and association studies [9,10]. Despite a quite modest sample size 
(N<1000), we replicated a large fraction of the individual SNPs identified in the GIANT study in 
our extreme height analysis.  Ninety-one percent of the SNPs had odds ratios that were 
directionally consistent with the direction in the published GIANT study (p<0.0001), and 35% 
(49/141) of SNPS had p<0.05 in the consistent direction. Our analyses also demonstrate that, 
outside of the 0.25% tails, this level of association is entirely consistent with that expected given 
the extreme tail ascertainment of our samples and the individual SNP continuous distribution 
effect sizes. Given this result, the ascertainment of our 923 samples from the ~1% to 0.25% tails 
provides equivalent power to approximately 6000 samples randomly selected from the general 
population for a variant explaining approximately 0.1% of the variation in height. Indeed, the 
ability to detect associations in samples ascertained for extreme phenotypes has been recently 
demonstrated in studies of bone mineral density [11], body mass index [12], triglyceride levels 
[13], and type 2 diabetes (using a liability threshold model [14]). Also, our results suggest that 
the statistical power of detecting these small effect variants would be reduced if we were to 
include the most extreme tails of the phenotypic distribution (in our case, the shortest 0.25% of 
individuals), consistent with predictions made based on simulation studies of mixtures of 
common and rare variants [15]. Nonetheless, our findings suggest that the use of individuals with 
the most extreme phenotypes could be particularly valuable to detect rarer variants with larger 
effect sizes more efficiently. 
In conclusion, we have shown that common genetic variants associated with height in the 
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general population are also associated with height at the ~1% tails of the height distribution. Our 
data suggest that common variants play less of a role, and the effect of rarer larger-effect alleles 
and/or strong environmental factors start to predominate around the 0.25% extreme. This finding 
may also have broader implications for studies of disease, in that the polygenic model may apply 
well to those diseases that represent the tails of an underlying normal distribution, but perhaps 
less well to diseases that correspond to more extreme phenotypes. 
 
MATERIALS AND METHODS 
Ethics statement 
Both studies were conducted according to the principles expressed in the Declaration of 
Helsinki.  Attendance was voluntary, and each participant signed a written informed consent 
including information on genetic analyses.  Local institutional review boards approved study 
protocols. 
 
Subjects 
The HUNT study 
The Nord-Trøndelag Health Study (HUNT) is a comprehensive population based health 
study (www.ntnu.edu/hunt) with personal and family medical histories on approximately 
120,000 people from Nord-Trøndelag County, Norway, collected during three intensive studies 
(HUNT 1, 2, and 3).  Inviting all citizens aged 20 and over, information was collected from self-
reported questionnaires consisting of >200 health-related questions, standardized clinical 
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examinations, urine and non-fasting venous blood sample.  The population in Nord-Trøndelag 
County is ethnically homogeneous, <3% of non-Caucasian ethnicity, making it especially 
suitable for epidemiological genetic research.  Height was measured by trained personnel to the 
nearest 1.0 cm with the participants wearing light clothes without shoes according to 
standardized methods [16].  
For this study we sourced data from HUNT 2 (1995-97) in which 65,258 individuals 
participated (71.2% of invited). We generated age and gender standardized height for the whole 
population, and selected the shortest 1000 individuals and the tallest 1000 individuals from the 
54,909 participants aged between 18 and 70yrs. We removed known 1st degree relatives based 
on information from the Medical Birth Registry of Norway, those reporting to be living outside 
of Norway their first year of life, and those with low DNA concentrations. We then genotyped 
the remaining shortest 471 individuals (<-2.14 SDs) and the tallest 479 individuals (>2.14 SDs) 
from the cohort. We also genotyped 1,458 individuals of all ages with a Z-score between +/- 2 
SDs as our middle group. 
 
The FINRISK Study 
FINRISK is a Finnish national survey on risk factors of chronic and non-communicable 
diseases. It is carried out every five years since 1972 using independent, random and 
representative population samples from different parts of Finland [17]. For this study, we 
selected individuals from 4 different sub-populations divided by geography (East vs. West 
Finland) and gender (Table 2.4). Individuals aged 25 to 74 years were included. We then took 
approximately the tallest and shortest 50 individuals (Table 2.4) from each tail of the distribution  
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Table 2.4: The FINRISK cohort divided into 4 sub-populations 
 
Cohort No. of 
Individuals 
No. of short 
extremes 
No. of tall 
extremes 
men/west 4271 53 51 
men/east 6582 52 52 
women/west 5025 52 52 
women/east 7610 52 52 
Total 23488 209 207 
Total successfully 
genotyped 
 186 192 
Total with genotypes used  181 192 
 
The table shows the number of individuals used for each of the FINRISK sub-populations. The 
FINRISK cohort is sub-divided between male and female as well as individuals from east and 
west Finland. 
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from each sub-population (extremes) and performed genotyping. 
 
Genotyping and Quality Control 
HUNT study 
Blood sampling was done whenever subjects attended HUNT 2.  DNA was extracted 
from peripheral blood leukocytes from whole blood or blood clots stored in the HUNT Biobank, 
using the Puregene kit (Gentra Systems, Minneapolis, MN) manually or with an Autopure LS 
(Gentra Systems).  Laboratory technicians were blinded to the results of the height 
measurements.  Details on the DNA extraction and the HUNT Biobank are described elsewhere 
[16].   
Genotyping of short and tall individuals were done at the Norwegian University of 
Science and Techonology, Norway using the iSelect Metabochip (Illumina, San Diego, CA) and 
the Infinium HD ultra protocol.  Each 96-well plate included both tall and short individuals and 
one sample of identical reference DNA.  Genotype calling was done using GenTrain version 2.0 
in GenomeStudio V2010.3 (Illumina, San Diego, CA).  Genotyping of the middle group was 
done on the Metabochip at the Center for Inherited Disease Research (CIDR, MD) and called 
with BeadStudio 3.3.7 with Gentrain version 1.0 (Illumina, San Diego, CA).   
Samples that did not meet a 99% completion threshold were excluded from further analysis 
(N=19; 0.7%).  Additional post-genotyping exclusions based on gender discrepancy (N=11) and 
first-degree relatedness (pi-hat >0.2; N=152, 6.3%) were done using PLINK [18]. Ethnic outliers 
(N=174, 7.2%) were excluded using the EIGENSTRAT software package [19].  After quality 
assessment 2,063 individuals (85.7%) remained for further analysis, 385 (81.2%) short, 456 
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(95.2%) tall and 1,224 (83.9%) individuals in the middle group. 
106 SNPs of the 180 GIANT height hits were directly typed on the Metabochip.  In 
addition, we used the SNP Annotation and Proxy Search to map 54 of the remaining 74 SNPs 
with a HapMap r2 > 0.8 linkage disequilibrium proxy result [20]. These 160 SNPs (i.e. 106 
directly typed and 54 proxies) were used in subsequent analyses. All SNPs showed a genotyping 
success rate >98% and were in Hardy Weinberg equilibrium. 
 
FINRISK study 
We directly genotyped the samples for the 180 previously identified height SNPs. The 
genotyping was done at Children’s Hospital Boston using Sequenom iPLEX genotyping 
(Sequenom, Inc, San Diego, CA, USA). In total, 186 short individuals and 192 tall individuals 
were successfully genotyped for 158 SNPs. All 158 SNPs had a genotyping success rate ≥ 90% 
and the overall genotyping rate was 97.85%. One of these SNPs (rs1809889) is not part of the 
180 GIANT SNPs, but data were available for this SNP from the GIANT meta-analysis so it was 
included in our analysis. 
We genotyped an additional 49 ancestry informative markers (AIMs) to identify ethnic 
outliers [21]. We inputted genotype data from our subjects as well as the reference HAPMAP 
samples (CEU, YRI, CHB+JPT) for the 49 AIMs together with 130 height SNPs into Structure 
2.3.3 [22]. We detected 5 ethnic outliers with >10% Asian ancestry who were excluded from 
further analysis leaving a total of 181 short and 192 tall individuals as our FINRISK study group. 
 
Statistical Analysis 
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Individual SNP analysis 
For FINRISK, we calculated the observed odds ratio for each of our 158 SNPs using the 
Cochran-Manzel-Hansel test, which is a stratified chi-square test. We stratified the individuals 
into 4 sub-cohorts based on geography and gender (Table 2.4) and performed the test using 
PLINK [18]. The observed odds-ratio for each SNP was recorded, along with the 95% 
confidence interval.  For HUNT the observed odds-ratio and 95% confidence intervals and the 
single association analysis was performed using logistic regression in PLINK. 
For both cohorts, we calculated the expected odds ratio for each SNP by estimating the 
odds of the height-increasing versus the height-decreasing allele in both the tall extremes (cases) 
and the short extremes (controls) assuming a standard normal distribution for standardized 
height, i.e. height ~ Normal(0,1). For a given SNP, we defined the height-increasing effect size as 
β and the height-increasing allele frequency as p. The mean height for the height-increasing 
allele would be Mi = β (1 - p) and the mean height for the height-decreasing allele would be Md = 
- β p. The variance of height for the both alleles would be V = 1 – β2 p (1-p). We then calculated 
the odds of observing the height-increasing allele versus the height-decreasing allele for both the 
tall extremes (cases) and the short extremes (controls) by taking the ratio of the probabilities of 
each allele being seen in the cases and the controls respectively. These are calculated as: 
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where N(x|M,V) denotes the density function at x of a Normal distribution with mean M and 
variance V. We use a cut-off of +/-2.326 to denote the approximate 1% tails. We then calculated 
the expected odds-ratio by taking the ratio between Oddscases over Oddscontrols, i.e. 
                    
         
            
 
To assess whether individual SNPs had odds ratios significantly different from expectation, we 
generated upper and lower 95% confidence limits for the expected distribution based on the 
GIANT beta and standard errors estimates as above, and used the natural log of these confidence 
limits to estimate an approximate standard error for the expected odds ratio, i.e. 
              
                     
      
 
We then assessed significance by a Z-test of the difference between observed odds ratio and 
expected odds ratio to obtain the Zscore, i.e. 
        
                               
              
               
 
 
Meta-analysis  
The HUNT and FINRISK studies genotyped different sets of SNPS, with only 98 of the 
SNPs matching exactly across the studies. We therefore used forty-three of the HUNT SNPs that 
had r
2
 > 0.8 HapMap proxies with a genotyped FINRISK SNPs. We used the inverse variance 
method to meta-analyze the odds ratios for these 141 SNPs from the two studies. As opposed to 
the individual studies, where study specific allele frequencies were used, we used the GIANT 
allele frequency information to generate the expected odds ratios for the meta-analysis. This did 
78 
 
not appreciably affect the results for individual SNP analysis within the individual studies, and 
the meta-analyzed results were consistent to those in the two individual studies. 
 
Modeling the Weighted Allele Score (WAS) 
To calculate the Weighted Allele Score (WAS) for each individual, we took the sum of the 
effective allele dosages of the height SNPs multiplied by their respective estimated effect sizes 
(βs) using the Stage 1 betas from the GIANT study, as shown in the formula below. 
              
 
   
 
β and SNP are the effect size and effective allele dosage (0, 1 or 2) of the height SNPs and WAS 
is the weighted allele score. N is the total number of SNPs available to calculate the weighted 
allele score. α is the mean of the sum such that the expected WAS is 0 as shown by the formula 
below. 
                  
 
   
 
Frequency is the allele frequency of the effect allele obtained from the Finnish or HUNT 
estimates.  
We calculated the statistical difference between the WAS of the short versus the tall 
individuals by performing a 2-tailed 2-sample t-test to obtain the respective p-value. All the 
calculations were done using the R statistical software package. 
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Obtaining Finnish allele frequency estimates 
The allele frequency estimate for each SNP was obtained by taking only the Finnish 
individuals from the GIANT height study and calculating the expected allele frequency. The 
cohorts used were the FUSION NIDDM Case control study from Finland, the GenMets Case 
control study from Finland and the FINRISK component of the MIGen cohort. The total number 
of individuals used for obtaining the estimates is 3618. 
 
Simulating the distribution of WAS under the null model 
The null model assumes that the only factors determining height (Z-score) are the 
cumulative additive effects of the GIANT height SNPs and noise. We modeled the Z-score with 
the formula below. 
                            
Zscore is the height Z-score, N(0, σ2remaining) is a normally distributed random variable with mean 
0 and variance σ2remaining. σ
2
remaining is calculated such that the variance of Zscore is 1, i.e. 
σ2remaining  is 1 – var(WAS). The variance of WAS can be calculated with the formula below, 
              
                           
 
   
 
On the other hand, a simulated individual's effective allele dosage is obtained by sampling from a 
set of binomial distributions with N=2 and p being the allele frequencies of each SNP. The 
simulated effective allele dosages can then be used to calculate each individual's WAS. The 
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simulation approach for each cohort was modeled to mirror the methods of subject selection. 
 
Simulating FINRISK 
For the FINRISK study, the simulations were performed using the following steps. We 
first generated the effective allele dosages for each SNP for 200,000 individuals by random 
sampling. We then randomly sampled 4271, 6582, 5025 and 7610 individuals to represent the 4 
sub-populations and obtained their Z-scores using the previously described modeling. For each 
subgroup, we picked the appropriate number of the most extreme individuals to mimic the actual 
sample selection. We then pooled the short and tall extremes together and randomly dropped 
individuals to obtain exactly 181 short extremes and 192 tall extremes. We then randomly drop 
SNPs from the simulated individuals to mimic the missing genotype rate in FINRISK and then 
calculate the Weighted Allele Score (WAS) for each simulated individual. This simulation process 
was repeated 10,000 times. For the stratified analyses of various height cut-offs, we adjusted the 
numbers of selected individuals in each strata by taking the floor of the expected number of 
individuals in that strata. In our cohort, the top 0.5% extremes included 21, 32, 25 and 38 
individuals from each tail of the 4 sub-populations respectively, and for the top 0.25% extremes 
included 10, 16, 12 and 19 individuals from each tail of the 4 sub-populations. For the top ~1% 
to 0.25% extremes, we included all our extremes but excluded the top 10, 16, 12 and 19 
individuals from each tail of the 4 sub-populations. 
 
Simulating HUNT 
The simulations for HUNT were performed as follows. We generated the effective allele 
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dosages for each SNP for 400,000 individuals by random sampling. We then randomly selected 
50,000 individuals and obtained their Z-scores. 
We then selected all short and tall extremes with a Z-score cut-off of -2.14 and +2.14 
respectively. Next, we randomly selected 385 short extremes and 456 tall extremes and 
calculated the WAS. This process was repeated 10,000 times. As in the FINRISK simulation, the 
number of individuals varies for each stratified analysis. Because we performed stratified 
analyses for varying levels of height cut-offs, our definition for the top 0.5% extremes is a Z-
score cut-off below -2.57 and above +2.57 and for the top 0.25% extremes is a Z-score cut-off 
below -2.81 and above +2.81. For the top ~1.5% to 0.25% extremes, we used only extremes that 
had Z-scores between -2.14 and -2.81 for the short extremes and between 2.14 and 2.81 for the 
tall extremes. 
 
Determining if the mean observed WAS is significantly different from the simulated 
expectation  
We evaluated the significance of the mean observed WAS by determining the p-value of the 
mean observed WAS from the null distribution of the mean WAS obtained from the simulations. 
The two-tailed p-value is calculated by evaluating the mean observed WAS from 
Normal(μsimulation , σ
2
simulation) where μsimulation is the mean of the mean WAS and σ
2
simulation is the 
variance of the mean WAS from the simulations. 
 
Modeling Rare-variants with moderate to large effect sizes 
Modeling the rare-variant effect into the simulation is accomplished by adding an additional 
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rare-variant term into the calculation of the height Z-score without changing the definition of 
WAS as shown in the equation below. 
                  
 
   
           
 
           
where n is the number of independent rare-variants, B represents the effect size of the rare-
variants, and  V is the allele dosage of the rare-variant. αrv is the mean of the rare-variants score 
such that the rare-variants do not change the expected Z-score, i.e. the expected Z-score is still 0. 
Similarly, αrv can be calculated by the following formula, 
            
 
   
 
σ2remaining in this case will have to be adjusted for the rare-variants such that the variance of the Z-
score remains at 1, i.e. σ2remaining is 1 – var(WAS) – var(Σ B V). F is the allele frequency of the 
rare-variants. Simulations done with modeling rare-variants are identical to the prior simulations 
of FINRISK or HUNT except that the new terms are used for calculating the Z-score. 
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ABSTRACT 
In most complex diseases, much of the heritability remains unaccounted for by common 
variants. It has been postulated that lower frequency variants contribute to the remaining 
heritability. Here, we describe a method to test for polygenic inheritance from lower frequency 
variants using GWAS summary association statistics. We explored scenarios with many causal 
low frequency variants and showed that there is more power to detect risk variants than 
protective variants, resulting in an increase in the ratio of detected risk to protective variants (R/P 
ratio). Such an excess can also occur if risk variants are present and kept at lower frequencies 
because of negative selection. The R/P ratio can be falsely elevated because of reasons unrelated 
to polygenic inheritance, such as uneven sample sizes or asymmetric population stratification, so 
precautions to correct for these confounders are essential. We tested our method on published 
GWAS results and observed a strong signal in some diseases (schizophrenia and type 2 diabetes) 
but not others. We also explored the shared genetic component in overlapping phenotypes related 
to inflammatory bowel disease (Crohn’s disease [CD] and ulcerative colitis [UC]) and diabetic 
nephropathy (macroalbuminuria and end stage renal disease [ESRD]). While the signal was still 
present when both CD and UC were jointly analyzed, the signal was lost when 
macroalbuminuria and ESRD were jointly analyzed, suggesting that these phenotypes should 
best be studied separately. Thus, our method may also help guide the design of future genetic 
studies of various traits and diseases. 
 
INTRODUCTION 
Most common diseases involve a mix of both genetic and environmental factors and do 
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not follow simple patterns of Mendelian inheritance. In such diseases, the genetic component is 
usually polygenic: genetic variation in many genes individually contribute a small or a moderate 
component of disease risk [1]. Genome-wide association studies (GWAS) have identified 
numerous genomic loci in which common variants (≥5% frequency) are associated with complex 
diseases [2]. Even in some of the largest and most successful GWAS to date, much of the genetic 
contribution to phenotype remains unexplained (sometimes called “missing heritability”) [3,4], 
suggesting that lower frequency variants, not well surveyed by GWAS, may also contribute to 
the missing heritability. Indeed, in some diseases such as autism spectrum disorders (ASD [MIM 
209850]), inherited rare (<1% frequency) and low frequency (<5% frequency) variants have 
been recently shown to play an important role in the genetic architecture of the disorder [5,6], 
suggesting that more loci with low frequency variants could be identified if appropriate 
additional studies were performed. In other diseases, there is as yet little evidence of a substantial 
role for low frequency variation, leaving open the question of whether studies of low frequency 
variation will be fruitful for those diseases. 
The relative success of different approaches in identifying more contributing loci will 
depend on what type of variation accounts for the missing heritability. Low frequency variants 
may remain undetected because they may not be well-represented or well-tagged by markers on 
genotyping arrays and therefore would not be well-imputed [7]. Along these lines, the statistical 
power to detect low frequency variants in GWAS is much lower than common variants if their 
underlying effect sizes are similar[8]. Knowing whether low frequency variants contribute to the 
missing heritability of a disease is important because approaches better-suited to identify 
additional common variants differ from those aimed at identifying rarer variants (genotyping 
arrays with common variants compared to arrays with lower frequency variants or sequencing). 
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Methods for detecting a contribution from common variants to the missing heritability 
have been described previously. In a GWAS of schizophrenia (SCZ [MIM 181500]) [9], Purcell 
and colleagues developed the concept of a polygenic score by combining the effects of multiple 
common variants that are modestly associated with schizophrenia. They showed that the score is 
predictive of schizophrenia in an independent cohort, thus indicating that there is a polygenic 
signal from many yet-to-be-detected common variants in schizophrenia. Yang and colleagues 
adopted a different approach by assessing the narrow-sense heritability of human height with a 
linear-model analysis using hundreds of thousands of common variants [10]. They found that at 
least 45% of the variance of height can be accounted for by common variants, indicating that 
there are many common variants associated with height that have yet to be discovered. Although 
both methods can be used to detect a signal of polygenic inheritance from common variants in 
complex diseases, these tests were not designed to specifically test for low frequency variants, 
and also require individual-level genotype data. 
In this chapter, we describe an approach that can be applied directly to GWAS summary 
statistics to ascertain the presence of polygenic inheritance from low frequency variants. We 
observed that, if low frequency variants contribute to disease susceptibility, there can be an 
excess of associated risk variants compared to protective variants at a given significance level. 
Here, risk variants are defined as variants for which the minor allele is associated with increased 
risk of disease and protective variants are defined as variants for which the minor allele is 
associated with decreased risk of disease. Under the null model, there should be no excess of 
associated risk variants compared to protective variants. We calculated the risk to protective ratio 
(R/P ratio): the ratio of the number of detected risk variants over the number of detected 
protective variants, to test for such an excess of risk variants. We explored various scenarios that 
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could give rise to an increased in the R/P ratio. First, we showed empirically and analytically that 
when low allele frequency variants contribute to polygenic inheritance of a disease with low 
prevalence, there is an elevated R/P ratio because of greater power to detect risk variants than 
protective variants. Next, we showed through simulations that under a scenario of polygenic 
inheritance that includes negative selection, risk variants can have lower average frequencies 
than protective variants leading to an elevated R/P ratio within the lower frequency range. 
However, we also showed that such an elevated R/P ratio can occur because of reasons unrelated 
to polygenic inheritance. First, we showed that an uneven sample size of having substantially 
more controls than cases can produce an apparent increase in the R/P ratio and therefore, where 
the sample size is not balanced between cases and controls, one should compare the observed 
R/P ratio against that obtained through simulations with the same number of cases and controls. 
Next, we showed that particular scenarios of asymmetric population stratification can  produce a 
similar excess of low frequency risk variants and recommend that precautions for detecting and 
correcting for such stratification should be performed before one can confidently interpret an 
excess of risk variants as being a signal of polygenic inheritance. 
We then applied our method to results from published GWAS for several diseases, 
including schizophrenia [11], bipolar disorder (BIP [MIM 125480]) [12], major depressive 
disorder (MDD [MIM 608516]) [13], type 2 diabetes (T2D [MIM 125853]) [14] and various 
classes of obesity (OB [MIM 601665]) [15]. We observed strong signals of increased risk 
variants in several of the diseases but little or no signal in others, suggesting that efforts to 
discover low frequency and rare variants will be more fruitful for the diseases with such a signal. 
We further used our method to test whether apparently related phenotypes share low frequency 
or rare genetic contributors and hence should be analyzed together or separately. By applying the 
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method to phenotypes related to diabetic nephropathy (DN [MIM 603933] [16] and 
inflammatory bowel disease (IBD [MIM 266600]) [17], we found that the polygenic signal was 
eliminated when individuals with macroalbuminuria and individuals with end stage renal disease 
were analyzed together, whereas we still observed a significant signal when individuals with 
Crohn’s disease and ulcerative colitis were analyzed together. Thus, our method has the potential 
to guide the strategy in searching for additional genetic loci as well as in prioritizing the choice 
of phenotype for future studies of rare genetic variation in polygenic traits and diseases.  
 
MATERIALS AND METHODS 
Testing for an excess of risk variants from GWAS summary statistics 
Calculating the R/P ratio statistic from observed GWAS summary statistics 
The four input fields we used for R/P ratio calculations for each SNP are: an identifier 
(rsID), the minor allele frequency, the association P-value, and a field to determine the direction 
of effect, i.e. either an odds-ratio (OR) or an effect size (β). The ORs or βs were adjusted to 
reflect the effect of the minor allele by inverting the ORs or changing the sign of the βs if they 
were reported for the major allele. Each variant was assigned as risk if the OR > 1 or β > 0 and 
protective if the OR < 1 or β < 0. Neutral variants, i.e. OR = 1 or β = 0 were discarded from the 
analysis. We removed SNPs not present in the Hapmap CEU population (phase 2 release 28) 
[18,19],not in the 1,000 Genomes EUR population [20] as well as SNPs with minor allele 
frequency less than 1%. We sorted the remaining variants in order from most significant to least 
and performed LD-pruning by systematically going through the variants and removing variants 
that have an r
2
 > 0.1 with any of the more significantly associated variants. We used PLINK [21] 
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to calculate r
2
 correlations of variant-pairs within a 1 mega-base window from 379 EUR 
individuals of the 1,000 Genomes. To measure the excess of risk variants in the lower frequency 
range, we separated the low frequency variants into 3 distinct bins, i.e. 1%-5%, 5%-10% and 
10%-15%. We also included the 30%-50% bin as a negative-control, where we should not 
observe any excess of risk variants. For each bin, we counted the number of detected risk 
variants and the number of detected protective variants that meet significance cutoffs of P < 
0.001 and P < 0.01. We calculated the R/P ratio as, 
          
                            
                                  
 
 
Assessing the significance of the observed Risk/Protective (R/P) ratio 
To assess the significance of an elevation in R/P ratio, we simulated individuals using 
HAPGEN  [22] by using parameters from the Hapmap CEU population (phase 3, r2) to obtain 
the null distribution of the log2 R/P ratio statistic. We first simulated 100,000 individuals to form 
a pool of individuals that we can subsequently sample from. Next, we randomly sampled the 
same number of individuals in cases and controls as were used in the actual GWAS, performed 
the association test using PLINK, with LD-pruning and R/P ratio calculations identical to the 
procedure described above. We repeated this process 1000 times to obtain accurate estimates of 
the sample mean ( ) and standard deviation ( ) of the log2 R/P ratio under the null for each of 
our frequency bins and P-value cutoffs. We calculated the significance of the observed log2 R/P 
ratio by performing a one-tailed Z-test to obtain the Zscore and P-value (P), i.e. 
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We defined P < 0.01 as our significance threshold for calling a significant excess of risk variants. 
 
Calculating non-centrality parameter (NCP) for comparing power between risk and 
protective variants 
Power calculation 
The power of a variant is expressed by calculating the expected non-centrality parameter 
(NCP) of the χ2 distribution for the alternative distribution. The greater the NCP, the more power 
there is to detect the effective variant. The algorithm for calculating NCP is identical to the 
genetic power calculator[8] for case-control threshold-selected quantitative traits, assuming an 
additive model of the QTL effect, i.e. the dominance to additive QTL effect parameter is set to 0. 
The variance explained for a SNP with allele frequency as p and effect size as β is β22p(1-p). For 
risk variants, we calculated the NCP (NCPrisk) for multiple values of effect sizes (β), ranging 
from 0 to 0.5 with intervals of 0.01. Similarly, for protective variants, we calculated the NCP 
(NCPprotective) for multiple values of β, ranging from 0 to -0.5 with intervals of 0.01. The relative 
difference in power between risk and protective variants is measured by the NCP ratio. The NCP 
ratio is calculated as, 
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Base Model 
We define the base model as a set of parameters used for calculating NCP. 10,000 cases, 
10,000 controls, effective and marker variant frequency set to 1%. The prevalence is set as 1%, 
i.e. the trait threshold’s lower and upper limit is 2.33 and 9 respectively for cases and -9 and 2.33 
for controls. We have used 9 and -9 as surrogates for infinity (+∞ and -∞ respectively) but any 
sufficiently large number will not change the conclusions of the downstream analyses. Complete 
linkage disequilibrium (LD) between the causal variant and marker variant is assumed, i.e. D’ = 
1. 
Simulating R/P ratios for negative selection 
Obtaining frequencies and effect sizes 
If the variants that have an effect on the phenotype are under negative selection, it can 
lead to scenarios where there are more risk variants than protective variants to begin with, 
especially for low frequency variants. To illustrate this, we simulated neutral variants and causal 
variants under negative selection using previously published models and parameters that result in 
an allele spectrum similar to that observed in European population [23,24]. We used the forward 
simulation package ForSim [25] to simulate coding sequence variation in the European 
population in 1000 genes. The average gene coding length was set as 1500bp. We used a 
mutation rate per site of 2x10
-8 
and a uniform locus-wide recombination rate of 2Mb/cM. We 
modeled the distribution of selection coefficients (s) for de novo missense mutations by a gamma 
distribution [26]. We used the conventional 4-parameter model of the history of the European 
population with long-term constant size (N=8100 for 45,000 generations) followed by a 
bottleneck (N=2000) and then by exponential growth (1.5% increase per generation for 370 
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generations) to achieve a final population size of approximately 500,000 individuals [23,24]. We 
obtained 823 non-neutral variants that have minor allele frequencies ≥ 1% and assigned them as 
effective variants and assuming that the allele under negative selection confers risk, i.e. positive 
effect (Figure 3.1). By considering only additive genetic effects, we assigned effect sizes as: 
β=sτ(1+ε) as suggested in Eyre-Walker [27]. Here, β is the variant’s additive effect on the 
quantitative trait; s is the absolute value of the variant’s selection coefficient and ε is a normally 
distributed random noise parameter which was set to having mean 0 and standard deviation 0.05. 
τ is the degree of coupling between β and s and was set at 0.5 for our analyses. The effect sizes 
are scaled so that these 823 variants explain 60% of the phenotypic variance. 
95 
 
 
 
Figure 3.1: The frequency and effect sizes for the 823 SNPs under selection. The plot shows 
the minor allele frequency (x-axis) and effect size in standard deviation units (y-axis) for the 823 
SNPs that were obtained through simulating a trait under negative selection. 
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Obtaining phenotypes and calculating R/P ratio for the selection model 
We use the 100,000 HAPGEN simulated individuals and selected 823 matched SNPs 
such that the frequency matches the variants generated by ForSim. We then assigned these 
matched SNPs with effect sizes determined earlier. We calculated the phenotypic Zscore for each 
of our 100,000 individuals in the same way that we did in a previous study [28], i.e. by 
calculating the weighted allele score (WAS) and adding it to a randomly generated variable 
sampled from a normal distribution of mean 0 and variance 0.4 such that the total variance 
explained is 1. We then sampled 2,000 individuals with phenotypic Zscores > 1.645 (5% 
prevalence) as cases and another 2,000 individuals with phenotypic Zscores ≤ 1.645 as controls. 
We used PLINK to perform the association test on all the variants and calculated the R/P ratio 
within the same frequency bins as well as P-value cutoffs as described above. This process was 
repeated 1,000 times to obtain the distribution of the R/P ratio. For the control model, we 
randomly sampled 2,000 individuals as cases and 2,000 individuals as controls and calculated the 
R/P ratio as described above. 
 
Simulating R/P ratios for population stratification 
We use HAPGEN to simulate 4,000 distinct individuals from the Hapmap CEU 
population (phase 3, r2) as well as another 4000 distinct individuals from the Hapmap TSI 
population (phase 3, r2). For complete stratification, we randomly sampled 1,000 individuals 
from the CEU pool as controls and 1,000 individuals the TSI pool as cases. We simulated 
asymmetric mixtures of 1, 5 and 10 percent by randomly sampling 1000 individuals from the 
CEU pool as controls and sampled 10, 50 and 100 individuals from the TSI pool as cases, 
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respectively, and made up the remainder of the cases from the CEU pool. We used PLINK to 
perform the association test on all the variants and calculated the R/P ratio within the same 
frequency bins as well as P-value cutoffs as described above. Each process was repeated 1,000 
times to obtain the distribution of the R/P ratio. All PCA analysis was performed using smartpca 
from the EIGENSOFT 3.0 package [29]. All meta-analysis of GWAS summary statistics were 
performed using METAL[30]. Inflation of the GWAS test statistic due to population stratification 
was assessed by genomic control inflation factor (λGC) [31]. 
 
Calculating R/P ratio from published GWAS summary statistics 
Schizophrenia, major depressive disorder and bipolar disorder 
GWAS summary statistics were provided from published results of schizophrenia [11], 
bipolar disorder [12] and major depressive disorder [13]. SNPs that failed imputation (INFO < 
0.6) were discarded. The number of cases and controls used for simulating the null distribution 
are as follows: Schizophrenia (SCZ), 9,394 cases and 12,462 controls; major depressive disorder 
(MDD), 9,240 cases and 9,519 controls; bipolar disorder (BIP), 7,481 cases and 9,250 controls. 
 
Type 2 diabetes 
GWAS summary statistics were provided from published results of type 2 diabetes [14]. 
SNPs that passed imputation for less than 15,000 individuals (Ncases < 15,000) were discarded. 
The number of cases and controls used for simulating the null distribution are 15,000 cases and 
50,337 controls. 
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Obesity 
GWAS summary statistics were provided from published results of various classes of 
obesity[15]. SNPs that passed imputation for less than 50,000 individuals (Ncases < 50,000), 
10,000 individuals (Ncases < 10,000), 2,000 individuals (Ncases < 2,000) and 1,000 individuals 
(Ncases < 1,000) were discarded for the overweight (BMI > 25), class1 (BMI > 30), class2 (BMI > 
35) and class3 (BMI > 40) datasets respectively. The number of cases and controls used for 
simulating the null distribution are as follows: overweight, 50,000 cases and 35,715 controls; 
class1, 10,000 cases and 20325 controls; class2, 2,000 cases and 12,466 controls; Class3, 1,000 
cases and 18,346 controls. 
 
Inflammatory bowel disease 
GWAS summary statistics were provided from published results of Crohn’s disease (CD) 
[32], ulcerative colitis (UC) [33] and the combined case cohort of both Crohn’s disease and 
ulcerative colitis (CD+UC) [17]. SNPs that failed imputation (INFO < 0.6) were discarded. The 
number of cases and controls used for simulating the null distribution are as follows: CD, 5,956 
cases and 14,927 controls; UC, 6,968 cases and 20,464 controls; CD+UC, 12,882 cases and 
21,770 controls. 
 
Diabetic nephropathy 
GWAS summary statistics were provided from published results of phenotypes related to 
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diabetic nephropathy [16] which are Macroalbuminuria (MACRO) and End stage renal disease 
(ESRD). SNPs that failed imputation in at least 1 cohort were discarded. The number of cases 
and controls used for simulating the null distribution are as follows: macroalbuminuria versus 
control (MACROctrl), 1,478 cases and 3,315 controls; end stage renal disease versus control 
(ESRDctrl), 1,399 cases and 3,315 controls; ESRD versus controls that include MACRO 
(ESRDctrl+macro), 1,399 cases and 5,253 controls; combined MACRO and ESRD versus control 
([MACRO + ESRD]ctrl), 2,916 cases and 3,315 controls. 
 
RESULTS 
We developed a method to detect and assess the significance of an excess of risk variants, 
measured by the ratio of risk variants to protective variants (R/P ratio) within a series of 
frequency bins and P-value cutoffs (see Materials and Methods). We proceeded to show that 
under an assumption of polygenic inheritance from low frequency variants, there is more 
statistical power to detect risk variants than protective variants, which can result in an increased 
R/P ratio. We also showed that such an excess can also occur if risk variants are kept at lower 
frequencies because of negative selection. However, such an excess can also occur because of 
reasons unrelated to a contribution of rare variants to disease risk: uneven sample sizes or 
asymmetric population stratification. Therefore, steps have to be taken to account for these latter 
possibilities before one can confidently interpret the excess of risk variants as a true signal of 
polygenic inheritance. Finally, we applied the method to GWAS summary statistics from several 
published studies. 
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Significantly higher power to detect low frequency risk variants of moderate to large effect 
The liability threshold model for disease [34] has been shown to be consistent with 
results from GWAS for multiple diseases [35]. This model assumes that there is an underlying 
unmeasured trait related to disease risk, and that individuals are affected with disease only when 
the value of the trait exceeds a particular threshold. Under such a model, we discovered that the 
statistical power to detect risk variants is higher than the power to detect protective variants, even 
when they have the same effect size with respect to the underlying unmeasured trait. For 
example, we calculated power using a pre-defined set of parameters defined as the ‘base model’ 
(see Materials and Methods). From our calculations, we observed that, as effect size increases, 
there is significantly more power to detect risk than protective variants as indicated by the 
increase in the NCP ratio (Figure 3.2). This result shows that for this scenario, where the number 
of risk and protective variants are equal and have similar absolute effect sizes, the difference in 
power can create an excess of detected risk variants over protective variants which can result in 
an increased R/P ratio. 
 
The difference in power is larger under certain scenarios 
We explored how the difference in power to detect risk and protective variants would be 
affected when we varied the parameters in the model under which we calculated power. First, we 
calculated power using the base model but varied the minor allele frequency from 1% to 15%. 
The difference in power for risk and protective variants decreases as the variant frequency 
increases (Figure 3.3A). Second, we varied the disease prevalence from 1% (trait Z-score > 2.33) 
to 15% (trait Z-score > 1.03). Here, the difference in power decreases with increasing disease  
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Figure 3.2: Comparing the power to detect risk and protective variants with the same 
underlying effect size. The plot shows the power as the non-centrality parameter (NCP) for 
detecting minor alleles that confer risk (risk variants) and minor alleles that confer protection 
(protective variants) with varying absolute effect sizes (0 < β < 0.5 in standard deviation units) 
using parameters from the base model (see Materials and Methods). It also shows the NCP Ratio, 
which is the NCP of risk variants divided by the NCP of protective variants with the same 
absolute effect size (right vertical axis). The equivalent odds-ratio (OR) for the risk variants is 
also shown on the horizontal axis. 
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Figure 3.3: Effects of varying various parameters on the NCP Ratio. The plots show the 
difference in power for detecting risk versus protective variants through the NCP Ratio under 
varying parameters. Unless otherwise specified, the parameters used for calculating NCP are 
from the base model (see Materials and Methods). (A) Minor allele frequency of the associated 
variant varying from 1% to 15%. (B) Disease prevalence (threshold of liability) varying from 1% 
to 15%. (C) Linkage disequilibrium (LD) between the causal variant and the marker variant as a 
function of D’ (varying from 0.5 to 0.8). (D) The marker variant frequency is set at 5% with the 
causal variant frequency ranging from 1% to 4%. 
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prevalence (Figure 3.3B), and there is no difference in power at any effect size when the disease 
prevalence is exactly 50%. Third, we varied the linkage disequilibrium (LD) between the 
associated variant and the causal variant from moderate LD (D’ = 0.5) to strong LD (D’ = 0.8). 
While there is a general loss of power with decreasing LD, the difference in power between risk 
and protective variants increases with decreasing LD (Figure 3.3C). Along similar lines, when 
we assumed that low frequency causal variants are being tagged by variants of higher 
frequencies (fixing the frequency of the tagged variant at 5% and varying the frequency of the 
causal variant from 4% to 1%), we also observed a greater difference in power as the causal 
variant frequency decreased (Figure 3.3D). These results show that the difference in power 
between risk and protective variants should be more obvious when testing variants within the 
low frequency range (< 5% frequency), in polygenic diseases with lower prevalence, and when 
the markers being tested are proxies for lower frequency causal variants. The driving force 
behind this result is that cases are ascertained from individuals with an extreme distribution of 
liability scores whereas controls have a much broader distribution of liability scores. 
Consequently, given an equal number of cases and controls, the increase in minor allele count of 
a risk variant in the cases is greater than the increase in minor allele count of an equally strong 
protective variant in the controls, leading to higher power for detecting the risk variant (see 
Appendix for derived formulae that confirm the increase in power). Thus, if rare or low 
frequency variants play a substantial role in certain diseases with polygenic architecture, these 
results predict that we could observe an increased R/P ratio for low frequency variants in the 
GWAS summary statistics for these diseases. 
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Excess of risk variants can be caused by negative selection 
Beyond the differences in power, an excess of risk compared to protective variants can 
also occur if there is negative selection against the disease, leading risk variants to be kept at 
lower frequencies than protective variants. To illustrate this scenario, we simulated negative 
selection by coupling effects on evolutionary fitness and on a quantitative trait for a set of 
variants (frequency ≥ 1%), and then assigning case-control status based on the trait values (see 
Materials and Methods). We observed an increase in the R/P ratio for the frequency bins within 
1% to 15% but not for the 30-50% frequency bin (Figure 3.4). These results show that under a 
model where rare variants contribute to disease and are under negative selection, we could also 
observe an increase in the R/P ratio for low frequency variants in the GWAS summary statistics 
for these diseases. 
 
Excess of risk variants arise from having more controls than cases 
The previous results show that polygenic inheritance from lower frequency variants can 
lead to an increase in the R/P ratio, but such an increase can also occur in other settings. Under 
the null hypothesis, one would expect that on average, the number of detected risk variants to be 
equal to the number of detected protective variants resulting in an expected R/P ratio of 1. 
However, in our simulations, we observed that the expected R/P ratio can deviate from 1 because 
of an imbalance between the number of cases and controls. Specifically, if there are substantially 
more controls than cases, a feature present in some GWAS of dichotomous traits, it would result 
in the increase of the expected R/P ratio (R/P ratio > 1). To illustrate this, we randomly simulated 
1,000 cases and 3,000 controls (1k/3k) and measured the distribution of the R/P ratio under a null  
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Figure 3.4: The distribution of the R/P ratio from simulating variants under negative 
selection. The figure shows the distribution of the log2 R/P ratio for various frequency bins and 
P-value cutoffs from simulating variants under negative selection. The selection model (red) uses 
the 823 effective variants while the control (black) model assumes no variants affect the 
phenotype. 
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Figure 3.5: The null distribution of the R/P ratio with larger number of controls than cases. 
The figure shows the distribution of the log2 R/P ratio for various frequency bins and P-value 
cutoffs from simulating larger number of controls than cases. The 1k/3k (red) model simulates 
the null distribution of the log2 R/P ratio for 1,000 cases and 3,000 controls. The 10k/30k 
(orange) model simulates the null distribution of the log2 R/P ratio for 10,000 cases and 30,000 
controls. The control (black) model simulates the null distribution of the log2 R/P ratio for 1,000 
cases and 1,000 controls. 
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model of no association (see Materials and Methods). We observed that there is an increase in the 
R/P ratio distribution for 1k/3k for the low frequency bins (Figure 3.5). This increase is not seen 
with common variants (30-50% frequency bin), nor if the number of cases and controls are equal 
(Figure 3.5). Of note, with larger sample sizes (10,000 cases and 30,000 controls; 10k/30k, we 
observed that the increase in R/P ratio is substantially attenuated (Figure 3.5). These results show 
that an excess of controls can increase the expected R/P ratio, and should be accounted for by 
comparing the observed R/P ratio against those obtained through simulations under a null model. 
These results also show that with sufficiently large number of cases (e.g. > 10,000 cases), the 
increase in the expected R/P ratio due to this imbalance will be minimal. 
 
Excess of risk variants can be due to asymmetric population stratification 
We also considered whether an excess of risk variants could be seen in GWAS that are 
confounded by population stratification. As a first test, we randomly simulated 1,000 individuals 
of either northern European ancestry (CEU, based on allele frequencies in the CEU HapMap 
sample) or southern European ancestry (TSI, based on allele frequencies in the TSI HapMap 
sample). In one experiment, we simulated 1,000 CEU individuals as controls and 1,000 TSI 
individuals as cases (see Materials and Methods), and as a stratification-free experiment, we 
simulated 1,000 CEU controls and 1,000 CEU cases. We found that while there was a large 
excess of apparent associations for both risk and protective variants, leading to enormous 
inflation of the genomic control test statistic (λGC ~ 22.9), the resulting R/P ratio did not deviate 
substantially from expectations under the null (Figure 3.6). Therefore, even extreme scenarios 
with the usual forms of population stratification should not cause substantial deviations of the  
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Figure 3.6: The distribution of the R/P ratio from simulating population stratification. The 
figure shows the distribution of the log2 R/P ratio for various frequency bins and P-value cutoffs 
from simulating population stratification. The stratification model (red) simulates the association 
perform with cases only from the TSI population and controls only from the CEU population. 
The control model (black) simulates both cases and controls from the CEU population. 
  
109 
 
 
Figure 3.7: The distribution of the R/P ratio from simulating asymmetric population 
stratification. The figure shows the distribution of the log2 R/P ratio for various frequency bins 
and P-value cutoffs from simulating asymmetric population stratification. The models for 
asymmetric population stratification are as follows. Mixed 10%, 5% and 1% indicates 10%, 5% 
and 1% of the cases are TSI individuals respective while the rest of the individuals used are of 
CEU ancestry. The control model comprises of only CEUs without any population stratification. 
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R/P ratio. However, we reasoned that a special case of asymmetric population stratification could 
potentially cause the R/P ratio to depart from expectations under the null. Specifically, if there 
were a mixture of different populations only in cases but not in controls, or vice-versa, it could 
lead to an increase or decrease of the R/P ratio. To test this, we randomly simulated a series of 
models where controls are homogenous (CEU), while cases are a mixture of CEU and TSI (see 
Materials and Methods). At a 1% mixture in cases (λGC ~ 1.01), we did not observe any 
significant excess of risk variants, but at 5% mixture (λGC ~ 1.06), we observed an excess of risk 
variants within the low frequency ranges (Figure 3.7). This excess is even larger with a 10% 
mixture (λGC ~ 1.24) (Figure 3.7). Variants within the common frequency range do not show an 
excess of risk variants (Figure 3.7). These results show that such asymmetric population 
stratification can increase the R/P ratio, with only moderate increases in the genomic control 
statistics. As a corollary, if the mixture were to exist in controls but not cases, we would expect 
the R/P ratio to decrease. 
Finally, we meta-analyzed the results from the asymmetrically stratified GWAS with 
results from non-stratified GWAS (see Materials and Methods) to determine the effect on the R/P 
ratio if only a subset of the studies had asymmetric population stratification. We found that the 
increase in the R/P ratio is attenuated after meta-analysis (Figure 3.8). These results indicate that 
while asymmetric population stratification can give rise to an excess of risk variants, combining 
such results with non-stratified results can reduce the magnitude of the signal. Because this 
particular type of stratification is unlikely to be present in most of the cohorts prior to meta-
analysis, it may be useful to examine the summary statistics of each study individually to 
determine if the increased R/P ratio is derived from a subset of studies in the GWAS  
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Figure 3.8: The distribution of the R/P ratio from simulating asymmetric population 
stratification after meta-analysis. The figure shows the distribution of the log2 R/P ratio for 
various frequency bins and P-value cutoffs from simulating asymmetric population stratification 
after meta-analysis with non-stratified data. The model “mixed 10%” and “metaanalyzed” refers 
to asymmetric population stratification of 10% mixture of TSI individuals of the cases before and 
after being meta-analyzed with 4 other datasets without such stratification respectively. The 
control model indicates no asymmetric population stratification. 
meta-analysis. 
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Ideally, if an increased R/P ratio is observed, principal component analysis or other methods 
should also be applied to the primary data to search for outliers present exclusively in cases, to 
further rule out asymmetric population stratification as a cause of an increased R/P ratio. 
 
Using the R/P ratio in actual GWAS results to search for signals of low frequency variants 
contributing to disease risk 
Schizophrenia, major depressive disorder and bipolar disorder 
We applied our method to data from several psychiatric disorders: schizophrenia [11], bipolar 
disorder [12] and major depressive disorder [13]. We observed a significant increase in the R/P 
ratio only for schizophrenia in the 1-5% frequency bin, at a cutoff of P < 0.01 (P = 2.42 x 10
-7
) 
(Table 3.1). We did not observe any significant differences in the other frequency bins nor for 
any of the other psychiatric disorders (Table 3.1). These results are indicative of polygenic 
inheritance from low frequency variants in schizophrenia but do not provide similar support for a 
role of low frequency variants in major depressive disorder or bipolar disorder. 
 
Type 2 diabetes 
Next, we applied our method to GWAS results of type 2 diabetes [14]. The R/P ratio for 
type 2 diabetes was significantly increased in the low frequency bins (Table 3.2). The most 
significant difference was observed in the 1-5% bin with cutoff of P < 0.01 (P = 3.08 x 10
-15
).  
113 
 
Table 3.1: Schizophrenia, Major depressive disorder and Bipolar disorder 
  SCZ MDD BIP 
Freq 
(%) 
Pvalue 
cutoff 
O(R/P) E(R/P) P O(R/P) E(R/P) P O(R/P) E(R/P) P 
1-5 0.001 1.864 1.127 0.0298 1.210 1.058 0.269 0.884 1.110 0.748 
 0.01 1.623 1.032 2.42e-7 1.169 1.006 0.048 0.953 1.028 0.778 
5-10 0.001 1.348 1.057 0.1279 0.933 1.039 0.623 1.038 1.077 0.509 
 0.01 1.230 1.019 0.0111 0.914 1.005 0.865 0.973 1.013 0.678 
10-15 0.001 1.050 1.082 0.4926 1.348 1.035 0.126 1.038 1.055 0.473 
 0.01 1.054 1.019 0.3335 1.193 1.005 0.027 1.046 1.015 0.349 
30-50 0.001 1.063 1.022 0.3736 1.098 1.003 0.264 1.122 1.039 0.291 
 0.01 1.001 1.003 0.5010 0.944 1.001 0.836 1.070 1.009 0.165 
 
The observed, expected R/P ratios and P-values obtained from analyzing GWAS summary 
statistics of psychiatric disorders: Schizophrenia (SCZ), major depressive disorder (MDD) and 
bipolar disorder (BIP). O(R/P) refers to the observed R/P ratio while E(R/P) refers to the 
expected R/P ratio obtained through simulations. P refers to the p-value obtained from a 1-tailed 
Z-test (In bold: P < 0.01). 
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Table 3.2: Type 2 diabetes 
  T2D 
Freq 
(%) 
Pvalue 
cutoff 
O(R/P) E(R/P) P 
1-5 0.001 3.833 1.205 5.89e-6 
 0.01 2.009 1.069 3.08e-15 
5-10 0.001 1.636 1.131 0.043 
 0.01 1.439 1.051 2.28e-5 
10-15 0.001 1.660 1.081 0.031 
 0.01 1.400 1.033 8.36e-4 
30-50 0.001 1.041 1.038 0.459 
 0.01 1.035 1.008 0.308 
 
The observed, expected R/P ratios and P-values obtained from analyzing GWAS summary 
statistics of type 2 diabetes (T2D). O(R/P) refers to the observed R/P ratio while E(R/P) refers to 
the expected R/P ratio obtained through simulations. P refers to the p-value obtained from a 1-
tailed Z-test (In bold: P < 0.01).  
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We also observed a significant excess of risk variants in the 10-15% bin (P < 0.01, P = 2.28 x 10
-
5
). As the difference in power between risk and protective variants becomes minimal as the 
variant frequency increases, this observed excess of risk variants is more likely due to negative 
selection on diabetes risk alleles, tagging of low frequency variants by the more common SNPs 
in this frequency range, and/or possibly asymmetric population stratification. Nonetheless, these 
results are indicative of polygenic inheritance from low frequency variants in type 2 diabetes. 
 
Obesity 
We also applied our method to GWAS results for various classes of obesity [15]: overweight 
(BMI > 25), class 1 (BMI > 30), class 2 (BMI > 35) and class 3 (BMI > 40). The controls used 
for each class of obesity were individuals with BMI < 25. We observed a significant increase in 
the 1-5% frequency bin with a cutoff of P < 0.01 for only the class 1 dataset (P = 8.8 x 10
-6
) 
(Table 3.3). Also, while we generally observed a gradual increase in the R/P ratio with increasing 
BMI definitions of obesity, which could be consistent with a role of lower frequency variants, the 
increase in R/P ratio could also be explained by having more controls than cases. We did not 
observe any significant excess of risk variants for the low frequency bins in the class 2 or class 3 
datasets, likely because of the severely reduced sample sizes for the more extreme BMI 
definitions of obesity. 
 
Testing whether related phenotypes are likely to share low frequency causal variants 
To increase the power of GWAS, some studies have pooled apparently related phenotypes  
116 
 
Table 3.3: Obesity 
  Overweight Class1 
Freq 
(%) 
Pvalue 
cutoff 
O(R/P) E(R/P) P O(R/P) E(R/P) P 
1-5 0.001 1.188 0.997 0.228 0.917 1.164 0.758 
 0.01 1.120 0.986 0.078 1.536 1.050 8.8e-6 
5-10 0.001 1.026 0.998 0.408 1.139 1.098 0.393 
 0.01 1.023 0.991 0.328 0.937 1.023 0.838 
10-15 0.001 0.784 0.999 0.826 0.971 1.087 0.610 
 0.01 1.109 1.003 0.113 1.013 1.028 0.544 
30-50 0.001 1.121 0.991 0.194 1.059 1.020 0.380 
 0.01 1.022 0.999 0.340 1.045 1.004 0.225 
  Class2 Class3 
Freq 
(%) 
Pvalue 
cutoff 
O(R/P) E(R/P) P E(R/P) O(R/P) P 
1-5 0.001 2.462 2.410 0.410 3.700 3.454 0.354 
 0.01 1.533 1.376 0.114 1.814 1.617 0.111 
5-10 0.001 0.697 1.640 0.999 1.857 2.067 0.607 
 0.01 1.108 1.222 0.871 1.227 1.346 0.845 
10-15 0.001 1.276 1.567 0.713 1.385 1.766 0.779 
 0.01 1.066 1.208 0.883 1.269 1.267 0.479 
30-50 0.001 0.949 1.094 0.763 1.019 1.112 0.696 
 0.01 0.985 1.035 0.816 0.955 1.044 0.946 
 
The observed, expected R/P ratios and P-values obtained from analyzing GWAS summary statistics of 
clinical classes of obesity: Overweight (BMI > 25), Class1 (BMI > 30), Class2 (BMI > 35) and Class3 
(BMI > 40). O(R/P) refers to the observed R/P ratio while E(R/P) refers to the expected R/P ratio 
obtained through simulations. P refers to the p-value obtained from a 1-tailed Z-test (In bold: P < 
0.01).
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into a single case group [16,17]. We applied our method to measure the R/P ratio on published 
GWAS results of these related phenotypes. We reasoned that our method could also be used to 
test if pooling related phenotypes would increase power to detect low frequency variants, using 
only the GWAS summary statistics. We applied our method to GWAS results from two different 
pairs of related phenotypes, one pair for inflammatory bowel disease and one pair for diabetic 
nephropathy. 
 
Inflammatory bowel disease 
The two major types of inflammatory bowel disease are Crohn’s disease (CD) and ulcerative 
colitis (UC)[36]. We examined the R/P ratio in GWAS results for Crohn’s disease [32], ulcerative 
colitis[33] and the combined case cohort of both Crohn’s disease and ulcerative colitis [17]. We 
observed significant increases in the R/P ratio for both Crohn’s disease and ulcerative colitis 
within the low frequency bins (Table 3.4). The most significant increases were found in the 1-5% 
bin with cutoff of P < 0.01 (CD: P = 1.55 x 10
-10
, UC: P = 2.25 x 10
-9
), consistent with a 
polygenic role of low frequency variants in both diseases. However, when Crohn’s disease and 
ulcerative colitis were combined as a single case group (CD + UC), the increase in R/P ratio is 
less significant than in the individual GWAS results (Table 3.4). These results suggest that there 
are some low frequency genetic contributors to Crohn’s disease and ulcerative colitis that are not 
shared by both diseases. However, because the signal is still present (albeit attenuated) when 
both diseases were studied together, it also suggests that the two diseases do share some 
overlapping low frequency genetic contributors, although the attenuated signal could reflect  
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Table 3.4: Inflammatory bowel disease: Crohn’s disease and Ulcerative Colitis 
  CD UC CD+UC 
Freq 
(%) 
Pvalue 
cutoff 
O(R/P) E(R/P) P O(R/P) E(R/P) P O(R/P) E(R/P) P 
1-5 0.001 2.545 1.347 0.017 1.958 1.358 0.075 1.385 1.159 0.222 
 0.01 1.994 1.111 1.55e-10 1.866 1.106 2.25e-9 1.457 1.048 1.6e-4 
5-10 0.001 1.148 1.162 0.477 1.490 1.192 0.153 1.099 1.107 0.463 
 0.01 1.314 1.069 1.4e-3 1.460 1.066 8.59e-5 1.239 1.027 0.012 
10-15 0.001 1.200 1.181 0.424 1.279 1.186 0.337 1.583 1.076 0.059 
 0.01 1.043 1.059 0.551 1.213 1.066 0.075 1.104 1.026 0.205 
30-50 0.001 0.925 1.035 0.743 1.163 1.037 0.217 1.036 1.026 0.445 
 0.01 1.052 1.018 0.266 1.004 1.009 0.524 1.043 1.005 0.251 
 
The observed, expected R/P ratios and P-values obtained from analyzing GWAS summary 
statistics of inflammatory bowel diseases: Crohn’s disease (CD), Ulcerative colitis (UC) and the 
combined CD and UC as a single case group (CD+UC). O(R/P) refers to the observed R/P ratio 
while E(R/P) refers to the expected R/P ratio obtained through simulations. P refers to the p-
value obtained from a 1-tailed Z-test (In bold: P < 0.01).   
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Table 3.5: Diabetic Nephropathy: Macroalbuminuria and End stage renal disease 
  MACROctrl ESRDctrl 
Freq 
(%) 
Pvalue 
cutoff 
O(R/P) E(R/P) P O(R/P) E(R/P) P 
1-5 0.001 2.000 1.655 0.205 1.944 1.706 0.283 
 0.01 1.560 1.198 1.4e-3 1.705 1.207 6.4e-5 
5-10 0.001 1.563 1.359 0.253 1.278 1.404 0.585 
 0.01 1.200 1.116 0.175 1.240 1.143 0.147 
10-15 0.001 0.893 1.275 0.892 1.343 1.304 0.403 
 0.01 1.208 1.104 0.150 1.190 1.128 0.258 
30-50 0.001 1.122 1.066 0.343 1.198 1.051 0.197 
 0.01 0.990 1.023 0.690 1.152 1.014 0.017 
  ESRDctrl+macro [MACRO + ESRD]ctrl 
Freq 
(%) 
Pvalue 
cutoff 
O(R/P) E(R/P) P E(R/P) O(R/P) P 
1-5 0.001 2.667 2.008 0.146 1.087 1.133 0.504 
 0.01 2.270 1.285 9e-11 1.026 1.042 0.550 
5-10 0.001 1.533 1.584 0.496 0.875 1.071 0.754 
 0.01 1.552 1.187 2.9e-4 1.045 1.017 0.352 
10-15 0.001 1.462 1.397 0.380 0.912 1.038 0.640 
 0.01 1.310 1.160 0.078 1.053 1.009 0.290 
30-50 0.001 0.968 1.076 0.719 1.037 1.001 0.382 
 0.01 1.038 1.032 0.449 0.981 1.003 0.652 
 
The observed, expected R/P ratios and P-values obtained from analyzing GWAS summary 
statistics of diabetic nephropathy: macroalbuminuria (MACROctrls), end stage renal disease 
(ESRDctrls), ESRD versus controls that include MACRO (ESRDctrls+macro) and the combined 
MACRO and ESRD as a single case group ([MACRO + ESRD]ctrls). O(R/P) refers to the 
observed R/P ratio while E(R/P) refers to the expected R/P ratio obtained through simulations. P 
refers to the p-value obtained from a 1-tailed Z-test (In bold: P < 0.01). 
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persistence of two separate individual signals that are diluted after combination of the two sets of 
cases. 
 
Diabetic nephropathy 
We performed a similar analysis on two phenotypes used to characterize diabetic 
nephropathy[16]: macroalbuminuria (MACRO) and end stage renal disease (ESRD). Unlike 
inflammatory bowel disease, MACRO and ESRD are not necessarily distinct; MACRO is a 
milder form of diabetic nephropathy and some of those individuals progress to develop ESRD. 
The controls used for that study were diabetic individuals that did not develop nephropathy. We 
analyzed the GWAS results performed for individuals with macroalbuminuria versus controls 
(MACROctrl), individuals with end stage renal disease versus controls (ESRDctrl), individuals 
with end stage renal disease versus controls that also include individuals with macroalbuminuria 
(ESRDctrl+macro) and a combined case cohort that includes both individuals with 
macroalbuminuria and end stage renal disease versus controls ([MACRO + ESRD]ctrl). For the 
analyses of MACROctrl and of ESRDctrl, we observed significant increases to the R/P ratio in the 
1-5% bin with cutoff of P < 0.01 (MACROctrl: P = 0.001, ESRDctrl: P = 6.4 x 10
-5
) (Table 3.5). 
For the ESRDctrl+macro analysis, where individuals with macroalbuminuria are included within the 
controls, there is an even larger increase of the R/P ratio (ESRDctrl+macro: P = 9 x 10
-11
) (Table 
3.5). However, when MACROctrl and ESRDctrl were combined into a single case group 
([MACRO + ESRD]ctrl), none of the frequency bins showed significant increases in the R/P ratio 
(Table 3.5). These results suggest that while there are low frequency contributors to both 
macroalbuminuria and end stage renal disease, these contributors do not substantially overlap. 
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There is no detectable increase in the R/P ratio when both phenotypes are combined, unlike our 
observations for inflammatory bowel disease. Thus, these results indicate that studies of low 
frequency variation for diabetic nephropathy would be more fruitful if MACRO and ESRD are 
tested separately. 
 
DISCUSSION 
We have shown that our method for measuring the R/P ratio can be used as a test for the 
presence of multiple low frequency or rare genetic contributors to disease risk. This method can 
be applied to GWAS summary statistics, even if there are few or no genome-wide significant 
associations. We analyzed results from multiple published GWAS studies, and found significant 
signals in some but not all diseases. These results support the hypotheses that the diseases where 
the R/P ratio is increased have a polygenic contribution from as-yet undetected low frequency or 
rare variants.  
Some existing methods for detecting polygenic inheritance [9,10,37] use variants that 
achieve nominal significance in GWAS to determine if they are informative as predictors of 
phenotype. Because our method assesses the direction of effect of these variants against the null 
model, our method represents a rather different, independent approach for assessing polygenic 
inheritance of low frequency variants. Furthermore, our method does not require having 
identified associated loci or the availability of individual level data. For example, in 
schizophrenia, it has been shown that a substantial proportion of schizophrenia disease risk is the 
result of variants with frequency > 1% [38]. Our finding suggests that some of disease risk is 
accounted for by variants within the low frequency range (frequency < 5%). In a recent exome 
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sequencing study of 2,536 schizophrenia cases and 2,543 controls[39], Purcell and colleagues 
showed a polygenic burden of rare disruptive mutations, which is consistent with our 
observation. Similarly, for type 2 diabetes, our results suggest the presence of low frequency or 
rare variants contributing to disease risk, even though most of the variants known to be 
associated with disease risk are common (frequency ≥ 5%) [14]. 
We also showed that negative selection under polygenic inheritance can increase the R/P 
ratio for low frequency variants, because risk variants would be kept at lower frequencies while 
the protective variants could drift to higher frequencies. Indeed, in a previous study [40], Park 
and colleagues showed that across most qualitative traits, minor alleles conferred risk more often 
than protection which they concluded to be evidence for purifying selection. While this can be 
the case for some diseases, we also showed that this increase in the R/P ratio can also arise 
because there is more power to detect risk variants than protective variants. Furthermore, we 
have established that if there are substantially more controls than cases, a feature present in many 
GWAS, this imbalance can distort the null distribution such that there would appear to be more 
risk than protective variants. However, this imbalance can be accounted for through simulations, 
as we have demonstrated. 
Our method also provides a simple and early way of assessing the utility of different 
phenotype definitions for genetic studies of low frequency variation simply from GWAS 
summary statistics. Our results for inflammatory bowel disease are consistent with the idea that 
Crohn’s disease and ulcerative colitis have some overlapping genetic contributors. Indeed, a 
previous study exploring the effect of common Crohn’s disease variants on ulcerative colitis 
identified significant overlaps between the two diseases, but also loci specific to Crohn’s disease 
[41]. For diabetic nephropathy, where there are few established loci from which to draw 
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conclusions from, we observed signals for both macroalbuminuria and particularly for end stage 
renal disease when analyzed separately, but no significant signal when both diseases were 
combined as a single case group. This suggests that macroalbuminuria and end-stage renal 
disease are distinct in their genetic architecture and would be more productive if they were to be 
studied separately. Interestingly, the same GWAS on diabetic nephropathy discovered a single 
genome-wide significant locus only when end stage renal disease was treated separately from 
macroalbuminuria [16], consistent with our observation. 
Finally, asymmetric population stratification between cases and controls can lead to both 
false positive associations (as evidenced by an increased genomic control inflation factor) [42], 
and also an increase in the R/P ratio. Thus, while our observations of higher than expected R/P 
ratios in some of the published GWAS datasets are suggestive of a role of low frequency 
variants, we cannot completely rule out that some of these signals could be in part explained by 
asymmetric population stratification. Of note, none of the R/P ratios showed a deficit of risk 
variants (which would be expected under some models of asymmetric population stratification), 
suggesting that asymmetric population stratification is not widespread. Furthermore, these 
GWAS have used methods to detect and correct for population stratification. 
In conclusion, our method can be used to screen for polygenic inheritance from low 
frequency or rare variants in diseases where GWAS have been performed. Our method can also 
be extended to other summary statistics, e.g. studies from sequencing or exome-chip genotyping, 
to assess low frequency variants that were directly genotyped rather than imputed. This method 
can serve as a simple approach to guide researchers in prioritizing strategies in searching for as 
yet unexplained heritability for specific diseases. For example, in a study of epilepsy [43], 
Heinzen and colleagues failed to identify any rare variants of large effect through exome 
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sequencing; analysis of GWAS data for epilepsy can in theory help guide decisions about 
embarking on additional studies of low frequency or rare variants with larger sample sizes. 
Although a lack of a signal from our method does not rule out a role for low frequency variants, 
and may reflect a combination of small sample sizes, and a set of effect sizes and frequencies 
that do not significantly alter the R/P ratio, a positive signal can provide greater confidence about 
the likelihood that low frequency or rare variants contribute to disease risk. 
 
APPENDIX 
Calculating NCP from various given parameters 
We define the following parameters required to calculate the non-centrality parameter 
(NCP) as a function of effect size of minor allele (β), minor allele frequency (p), liability 
threshold (t), number of case individuals (Nd) and number of control individuals (Nc). We denote 
the minor allele (effect allele) as a1 and the major allele (non-effect allele) as a2. As such, the 
liability distribution of a1 is N(x, μ1, σ
2
) and the liability distribution of a2 is N(x, μ2, σ
2
) such that 
N(x, μ,σ2) is the probability density function of a normal distribution with mean μ and variance 
σ2. 
The mean liabilities for a1 and a2 are as follows: 
Mean liability for a1 = μ1 = β - β p = β q 
Mean liability for a2 = μ2 = - β p 
where q is the major allele frequency such that p + q = 1. The variance remaining σ2 is: 
Variance remaining = σ2 =1 – β 2 p q 
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Next, we calculate a series of conditional probabilities as follows:  
                   
 
 
       
                   
 
 
       
                       
 
  
       
                       
 
  
       
With these conditional probabilities, we proceed to calculate the expected allele frequencies of 
both the minor allele and major allele in both cases and controls using Bayes’ theorem. These are 
calculated as: 
                
            
           
 
 
 
                       
                     
               
           
 
  
 
                          
We then calculate the NCP by the χ2 statistic from a 2 by 2 contingency table for the expectation 
of the observed number of a1 and a2 in both cases and controls. 
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 Case Control Total 
a1 2 Nd Pd1 2 Nc Pc1 2 A 
a2 2 Nd (1- Pd1) 2 Nc (1- Pc1) 2 B 
Total 2 Nd 2 Nc 2 T 
 
where, 
A = Nd Pd1 + Nc Pc1 
B = Nd (1- Pd1) + Nc (1- Pc1) 
T = A + B = Nd + Nc 
The expected number for each cell is the row total times the column total divided by the grand 
total. 
Thus, the NCP is calculated as: 
     
                    
        
         
 
 
    
         
    
   
 
    
  
  
         
    
   
 
    
  
 
         
    
   
 
    
  
 
         
    
   
 
    
  
 
     
       
 
 
 
    
 
         
       
 
 
 
    
 
        
           
 
 
 
    
 
            
           
 
 
 
    
 
             
127 
 
     
       
 
 
  
       
 
 
 
           
 
 
 
           
 
 
    
After some algebra and simplification, 
 
     
  
  
             
  
Therefore, 
                   
   
     
                          
) 
We verified that these formulae were correct by comparing to simulated results. 
 
Determining NCP ratio between risk and protective variants with the same magnitude of 
effect 
We formulated the various probabilities between risk and protective variants. Assuming β 
to be positive, the risk variant would have the following probabilities, 
    
         
 
 
       
       
 
 
    
 
      
          
 
  
     
       
 
  
    
 
and the protective variant with the same magnitude of effect would have the following 
probabilities, 
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Assuming that there are equal number of cases and controls (N1 = N2), then 
       
        
 
 
      
       
 
 
    
 
        
 
  
     
       
 
  
    
 
 
 
The ratio between risk and protective variants with the similar magnitude of β is therefore 
          
 
        
 
 
      
       
 
 
    
 
         
 
  
     
       
 
  
    
  
 
         
 
 
      
       
 
 
    
 
          
 
  
     
       
 
  
    
  
 
 
We can transform the distributions such that, 
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When prevalence is 50% (t=0),  
       
 
   
 
             
   
 
 
     
and therefore 
            
This shows that when prevalence is 50% (t=0) and there are equal sample numbers in cases and 
controls (N1 = N2), the NCP between risk and protective variants with identical magnitudes of 
effect (β) would be the same regardless of any other parameters. 
For the case where t > 0, if 
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then the NCP for risk variants will be greater than the NCP for protective variants and the NCP 
ratio will be greater than 1.  When t > βq, this will be true because the normal distribution is 
monotonic decreasing above z=0 (y=0).  
To extend this to the more general case of t>0, we first examine the individual components, 
       
 
    
 
            
 
  
            
    
 
  
     
 
 
 
       
 
  
   
 
 
       
    
   
   
 
 
 
     
 
  
      
    
   
   
where eft is the error function. Similarly, 
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Taking the first 2 terms of the Taylor-series expansion of the error function and approximating σ 
to 1 (σ ≈ 1), 
    
 
  
   
 
 
     
    
   
  
 
 
     
    
   
  
  
 
  
 
 
  
 
  
   
   
 
 
 
 
  
  
    
  
 
       
   
  
 
 
 
 
  
  
    
  
 
       
   
  
 
 
  
 
   
   
 
   
   
 
      
   
 
       
   
 
      
   
 
       
   
  
 
 
  
 
                    
   
  
 
 
  
 
                                                   
   
  
 
 
  
 
      
  
  
As such, if t >0, 
 
  
 
      
  
    
Therefore, if t > 0, 
       
 
    
 
             
    
 
 
     
            
Therefore, for diseases with low prevalence (t > 0), there is more power to detect risk variants 
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compared with the protective variant.  
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ABSTRACT 
 Body proportion is a phenotype that is determined by the ratio of different components of 
the human anatomy. While there are many genetic studies that have been performed for height, 
little is known about the genetics underlying our body proportion and the genes regulating our 
proportion might play a more important role for growth and development. Here we report our 
findings of our analysis on sitting height ratio (SHR), the ratio of sitting height to overall height. 
We show that genetics contribute in a major way to explain the difference in SHR between 
African Americans and European Americans. After adjusting for height, age, sex, body mass 
index and the relevant principal components, the genome-wide association study (GWAS) in 
African and Europeans Americans uncover 3 loci associated with SHR. One of the loci 
(rs5959358) resides on the X-chromosome and was reported to be also associated with height. 
Comparing the known loci associated with height with the results of SHR reveal that most of the 
loci are associated with alterations of SHR too. While these confirm that SHR is largely 
genetically determined, nonetheless more samples are required to reveal the full genetic 
architecture in SHR determination. 
 
INTRODUCTION 
 Human height is a commonly used trait to illustrate a highly heritable that is polygenic. 
Our height however, is in reality a summation of many different components, e.g. head length, 
trunk length, leg length, etc. One of the first reports on how these individual lengths should 
correlate with each other was given by Leonardo da Vinci in his illustration of Vitruvian Man 
circa 1490. In it, he recorded the expected proportions of these measurements in relation with 
each other for the human body. Further research have postulated that some of these 
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measurements may be predictors of diseases [1]. For example, there is evidence that leg length 
can be a predictor of metabolic disorders underlying type 2 diabetes [2]. 
 One such measurement is sitting height. Sitting height is defined as total stature that is 
comprised by head and trunk and is usually measured by having the individual sit on a table and 
measuring the length from the table surface to the top of the person’s head. Since sitting height is 
a component of an individual’s total height, the sitting height ratio (SHR), defined as the sitting 
height divided by total height is an indicator of an individual’s body proportion. The SHR of an 
individual changes as we grow. Unlike height which increases as we age, SHR rapidly decreases 
as we progress from being a baby to being a teenager an increases slightly as we become adults 
[3,4]. In the extreme case, individuals affected with skeletal dysplasias not only have short 
stature, but also have disproportionate SHR [5]. Depending on the type of skeletal dysplasia, the 
SHR can be severely increased. For example, individuals with Achondroplasia have average 
SHR of 0.66 (normal range: 0.52-0.53) [6]. On the other hand, individuals with 
spondyloepiphyseal and spondylometaepiphyseal dysplasias may have normal SHR values [7]. 
The SHR is also slightly different between people from different ancestries. Individuals 
of Asian ancestry have higher SHR than individuals of European ancestry and individuals of 
European ancestry have higher SHR than individuals of African ancestry [8]. This difference is 
assumed to be due to genetic factors, although it remains unclear whether the difference is due to 
many variants with small effect sizes or a few variants with large effect sizes. 
 In this chapter, we described our approach to determine if there is a strong genetic 
influence on the SHR difference between individuals of different ancestry. We found that SHR is 
highly correlated with the degree to which African Americans have admixed of European 
ancestry. The more European ancestry an African American has, the higher his or her SHR, 
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consistant with the reported observations. We performed genome wide association study of SHR 
with both European Americans as well as African Americans and reported 3 loci associated with 
SHR. We then examine several variants that were known to be associated with height and 
observed that many of these variants were also marginally associated with SHR. These results 
suggest that variants associated with height that are also associated with SHR might be in genes 
that regulate development of the growth plate. 
 
RESULTS 
European Americans have higher sitting height ratios (SHR) than African Americans 
 We used the ARIC [9] and CARDIA [10] cohorts as they include both European and 
African Americans with both sitting height and height measurements. After removing individuals 
that failed our quality control (see Materials and Methods), we have 7,257 European American 
individuals and 2,354 African American individuals from ARIC. For CARDIA, we have 1,047 
European American individuals and 715 African American individuals. Comparing the sitting 
height ratio (SHR) between European and African American individuals, we find that European 
Americans have higher SHR values than their African Americans (Figure 4.1). In both ARIC and 
CARDIA, the mean SHR for European Americans is 0.53 while the mean SHR for African 
Americans is 0.51. After correcting SHR for covariates like height, age, sex, BMI and expressed 
SHR in terms of a Zscore (see Materials and Methods), we observed that there is more than a 1 
standard deviation difference (ARIC = 1.16, CARDIA = 1.06) between European Americans and 
African Americans. This result is consistent with earlier findings that European Americans have 
higher SHR than African Americans [8]. 
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Figure 4.1: Sitting height, height and sitting height ratio (SHR) distribution. We examined 
the sitting height, heights and sitting height ratios (SHRs) for individuals in both the ARIC and 
CARDIA cohorts. European Americans (EA) are colored in blue while African Americans (AA) 
are colored in red. (A) The top panel plots the sitting heights versus total height for the 
individuals in the ARIC cohort (N=9,611). The bottom panel represents the histogram of SHR of 
European American and African Americans where there is about a 1.18 standard deviation 
difference between the 2 populations. (B) The CARDIA cohort (N=1,762). The bottom panel 
shows the histogram of SHR of EA and AA where there is about a 1.06 standard deviation 
difference between the 2 populations. 
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Degree of European admixture is predictive of sitting height ratio (SHR) in African 
Americans 
 To determine if the SHR difference between European and African Americans has a 
genetic component, we reasoned that we could test this by exploring the genetic landscape of 
African Americans. As it is common for African Americans to high levels (>10%) of European 
ancestry [11], the level of European ancestry in any given African American should be correlated 
with SHR, if there is a genetic component to this difference. Given that European Americans 
have higher SHR than African Americans, we expect this correlation to be positive. To test this, 
we used principal component analysis to determine the degree of European admixture for the 
African Americans in both the ARIC and CARDIA (see Materials and Methods). We observed 
that there is a gradient of percentage European admixture in the African Americans (Figure 4.2A-
B) with some African Americans having as much as 60% European ancestry. There are 
significance positive correlations between the percentage European admixture and normalized 
sitting height ratios (SHR) (Figure 4.2C-D). This result shows that the SHR difference between 
European and African Americans has a significant genetic component. 
 
Analysis of African American individuals identifies variant associated with sitting height 
ratio (SHR) 
 Given evidence for a genetic component, we proceeded to test for genetic markers that 
are associated with sitting height ratio (SHR). We performed genome wide association on the 
using the genotypes of the African American individuals from both the ARIC and CARDIA 
cohorts and performed the meta-analysis by combining the results from both cohorts (see 
Materials and Methods). We observed a genome-wide significant signal at the chromosome   
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Figure 4.2: Association of global European ancestry with sitting height ratio (SHR). The 
plots show the degree of European admixture for each African American individual and how it 
correlates with SHR. A and C show the degree of European admixture in the 2 cohorts by 
principal component analysis. Individuals closer to CEU (blue) have more European ancestry 
than individuals close to YRI (red). B and D show the association of European ancestry with 
SHR using linear regression. (A) Global European ancestry for ARIC. (B) Correlating global 
European ancestry with SHR for ARIC. (C) Global European ancestry for CARDIA. (D) 
Correlating global European ancestry with SHR for CARDIA. 
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Figure 4.3: Genome wide association study (GWAS) of African American individuals. The 
Manhattan plot of the GWAS performed for the African American individuals from the ARIC 
and CARDIA cohorts. Only 1 locus (rs201786365) reached genome wide significance. 
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3p21.33 locus of which the lead variant (rs201786365) has an association statistic of P=1.252 x 
10
-8
 with the minor allele (MAF = 0.14) associated with increased SHR (β = 0.21) (Figure 4.3). 
This variant is present only in African Americans and is fixed as the major allele in European 
Americans. As such, this variant does not explain for the SHR difference between African and 
European Americans. The closest gene in the locus to the lead SNP is ABHD5 of which 
mutations in the gene has been associated with Chanarin-Dorfman syndrome [12]. 
 
Analysis of European American individuals identifies 2 loci associated with sitting height 
ratio (SHR) 
 We continued to explore for genetic associations for SHR by performing the test on our 
European American individuals. We performed the test on the European American individuals in 
the ARIC, CARDIA, CHS, FHS cohorts (see Materials and Methods). We observed a genome-
wide significant signal at the chromosome 18p11.23 locus of which the lead variant 
(rs140449984) has an association statistic of P=3.70 x 10
-9 
with the minor allele (MAF = 0.07) 
associated with decreased SHR (β = -0.149) (Figure 4.4). This variant lies within an intron of the 
PTPRM gene, which the protein encoded is a member of protein tyrosine phosphatase (PTP) 
family. 
 Additionally, we observed a significant signal on the X-chromosome (rs5959358) that the 
minor allele (MAF = 0.37) is associated with decrease SHR (β = -0.097, P = 9.71 x 10-8) only in 
women (Figure 4.5). Interestingly, the locus, which is in the vicinity of ITM2A, has been shown 
to be associated with height and also reported to escape dosage compensation [13]. That reported 
variant (rs1751138) is also associated with decrease SHR (β = -0.0945, P = 3.18 x 10-7) and is in 
strong linkage disequilibrium (LD) with rs5959358. 
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Figure 4.4: Genome wide association study (GWAS) of European American individuals. 
The Manhattan plot of the GWAS performed for the European American individuals from the 
ARIC, CARDIA, CHS and FHS cohorts. Only 1 locus reached genome wide significance. The 
lead variant (rs140449984) is in the PTPRM gene. 
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Figure 4.5: Genome wide association study (GWAS) of the X-chromosome in European 
American women. The plot of the X-chromosome association performed for the European 
American women from the ARIC, CARDIA, CHS and FHS cohorts. The strongest association 
signal (rs5959358) has the closest gene (ITM2A) that was previously reported to harbor variants 
that escape dosage compensation. 
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Variants associated with height are also associated with sitting height ratio (SHR) 
 As sitting height is one of the components of height, we reasoned that variants that alter 
our height may be enriched for variants that also alter our SHR. To test this, we obtained a set of 
421 LD-independent variants that have been shown to be robustly associated with height (Wood 
et. al., unpublished) and determine if they are also associated with SHR. Although none of these 
421 variants reached genome-wide significance, we observed that as a whole, the 421 height 
associated variants are also significantly associated with SHR (Figure 4.6). We observed 49 of 
the 421 variants to have SHR P-values less than 0.05, which is significant (Expected=21.05/421; 
P=2x10
-8
). The strongest associated variant (rs2079795) has an association with SHR with a P-
value of approximately 3 x 10
-6
. Also, the variant associated with height in GDF5, which was 
previously suggested to also have some association with sitting height [14] had some marginal 
association with SHR (P=0.01) (Table 4.1). These results are indicative that SHR is polygenic 
and a substantial number of height associated alleles do alter the SHR as well. 
 
DISCUSSION 
 We have shown that body proportion as determined by our sitting height ratio (SHR) is 
mainly genetically driven. SHR also appears to be more constraint than height as while a 
standard deviation (SD) of height is 6.08 cm (ARIC), an SD of sitting height adjusted for height 
is just 1.95 centimeters (ARIC). Also, in general, men and women can differ in heights as much 
as 12cm [15], the sitting height adjusted for height difference between men and women is just 
approximately 0.47cm (ARIC). This is suggestive that the genes underlying the variability of 
SHR might just be more relevant than height to development as there is more selective pressure 
to keep our SHR within an acceptable range. However, we and others have shown that there is a 
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Figure 4.6: QQ-plot of the 421 LD-independent SNPs known to be associated with height. 
The plot shows the 421 height SNPs are as a group, also associated with sitting height ratio 
(SHR) even if none of them reached genome wide significance. The x-axis is the expected -log10 
of the P-values while the y-axis is the observed -log10 of the P-values obtained from the 
association with SHR from the European American individuals. The gray points represent 5 
different random samplings of 421 different variants from the GWAS of SHR from the European 
American individuals. 
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Table 4.1: The effect sizes, P-values of the 421 height associated SNPs with sitting height 
ratio (SHR). 
      Height Sitting height ratio  
Rsid Chr Position Ref Alt Reffreq Effect Size P-value Effect Size P-value Closest 
Gene 
rs2079795 17 56851431 t c 0.33 0.045 8.60E-48 -0.067 2.99E-06 C17orf82 
rs310421 6 81848782 t g 0.54 0.028 1.40E-21 0.0508 0.0001647 FAM46A 
rs4369779 18 18989406 c t 0.79 0.056 1.40E-54 -0.0557 0.0006526 CABLES1 
rs1614303 10 123386796 t g 0.83 0.023 1.50E-09 -0.0579 0.0009193 FGFR2 
rs42039 7 92082358 t c 0.27 0.051 4.10E-39 -0.0518 0.0009542 CDK6 
rs217181 16 70671503 t c 0.2 0.024 2.20E-10 -0.055 0.0009664 HPR 
rs3790086 16 68445208 c g 0.56 0.023 9.80E-16 0.0417 0.001443 WWP2 
rs4803468 19 46614192 a g 0.42 0.029 1.20E-20 0.0421 0.001541 BCKDHA 
rs3807931 7 20348199 a g 0.45 0.027 4.00E-21 -0.0425 0.001648 ITGB8 
rs3825199 12 92501085 g a 0.23 0.054 1.90E-53 0.0504 0.001875 SOCS2 
rs3791679 2 55950396 a g 0.77 0.084 1.30E-96 -0.0467 0.002166 EFEMP1 
rs2224538 20 37985492 t c 0.65 0.018 4.90E-09 0.0404 0.002936 MAFB 
rs3760318 17 26271841 g a 0.63 0.054 2.30E-59 -0.0399 0.00306 CENTA2 
rs8006657 14 54314899 g a 0.59 0.024 3.70E-15 0.0396 0.003301 SAMD4A 
rs1966913 16 65941727 a t 0.96 0.042 1.00E-08 -0.092 0.004018 LRRC36 
rs7733195 5 172927230 g a 0.64 0.028 3.40E-20 0.0404 0.004234 FAM44B 
rs6485978 11 12634991 c t 0.46 0.022 2.10E-14 -0.036 0.006102 TEAD1 
rs12323101 13 32041406 a g 0.37 0.021 2.40E-12 0.0374 0.007877 PDS5B 
rs11642612 16 29937696 c a 0.4 0.017 3.20E-08 -0.0351 0.008347 FLJ25404 
rs17081935 4 57518233 t c 0.2 0.03 5.00E-16 -0.0444 0.009117 C4orf14 
rs9428104 1 118657110 g a 0.75 0.044 1.10E-37 -0.0386 0.01043 SPAG17 
rs16968242 15 74527274 g c 0.07 0.034 6.20E-09 -0.0634 0.01065 SCAPER 
rs143384 20 33489170 g a 0.42 0.063 1.30E-71 0.0343 0.01146 GDF5 
rs314263 6 105499438 c t 0.32 0.043 3.10E-43 -0.0365 0.01148 LIN28B 
rs2888893 12 105862761 c t 0.51 0.017 7.30E-09 -0.0334 0.01289 C12orf23 
rs11659752 18 75323850 t g 0.7 0.025 2.10E-13 -0.0361 0.0133 NFATC1 
rs212524 1 21455898 c t 0.6 0.021 4.70E-12 0.0326 0.01502 ECE1 
rs10877030 12 56542981 t g 0.68 0.023 2.80E-13 0.0347 0.01597 CTDSP2 
rs2871865 15 97012419 c g 0.88 0.059 8.10E-32 0.0499 0.01789 IGF1R 
rs3116168 2 232698075 c t 0.73 0.022 2.40E-09 -0.0337 0.01866 DIS3L2 
rs10770705 12 20748734 a c 0.34 0.03 4.80E-22 -0.0338 0.01879 SLCO1C1 
rs1797625 3 114309105 t a 0.36 0.018 1.00E-09 -0.0318 0.01912 C3orf17 
rs1884897 20 6560832 a g 0.36 0.038 4.70E-33 -0.0313 0.02021 BMP2 
rs1658351 3 57988613 c t 0.35 0.023 3.00E-13 0.0318 0.021 FLNB 
rs2597513 3 13530836 c t 0.11 0.042 1.10E-18 -0.0476 0.02557 HDAC11 
rs953199 9 99522797 c a 0.76 0.02 6.10E-09 0.0331 0.0278 XPA 
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Table 4.1 (Continued) 
      Height Sitting height ratio  
Rsid Chr Position Ref Alt Reffreq Effect Size P-value Effect Size P-value Closest 
Gene 
rs7517682 1 103292177 g a 0.44 0.022 9.20E-14 0.0282 0.03245 COL11A1 
rs7544462 1 37735343 a c 0.91 0.032 1.10E-09 -0.0517 0.03251 C1orf149 
rs1326023 20 54275785 a g 0.3 0.024 9.80E-14 0.0299 0.03458 MC3R 
rs17349981 15 80018975 a t 0.85 0.028 2.40E-11 0.0399 0.03573 MEX3B 
rs9825951 3 100752611 t a 0.35 0.02 4.20E-10 -0.0287 0.03733 COL8A1 
rs7701414 5 131613857 g a 0.44 0.041 4.90E-42 -0.0276 0.0396 PDLIM4 
rs12519505 5 77541632 c t 0.78 0.023 3.20E-10 0.0327 0.04161 AP3B1 
rs3814333 1 182273742 t c 0.32 0.049 1.90E-53 -0.0288 0.04288 GLT25D2 
rs2763273 6 168577472 c t 0.76 0.022 1.80E-10 -0.0325 0.04334 SMOC2 
rs1171615 10 61139096 c t 0.22 0.022 4.50E-09 -0.0371 0.04364 SLC16A9 
rs11640018 16 73885809 c t 0.37 0.019 2.10E-09 -0.0275 0.04409 CFDP1 
rs12779328 10 12983979 c t 0.72 0.028 1.50E-17 -0.0298 0.0446 CCDC3 
rs4953951 2 135903815 c t 0.9 0.035 4.30E-11 -0.0433 0.04661 ZRANB3 
rs12120956 1 113004094 g a 0.77 0.025 9.90E-13 -0.0313 0.05032 CAPZA1 
rs7033487 9 118169078 t c 0.79 0.041 3.50E-29 0.0316 0.05056 PAPPA 
rs10948222 6 45352393 c t 0.58 0.032 8.70E-22 0.0266 0.05165 SUPT3H 
rs1055144 7 25837634 t c 0.19 0.022 1.80E-09 -0.0327 0.05777 NFE2L3 
rs2272566 11 234552 a g 0.48 0.016 2.40E-08 -0.0246 0.05786 PSMD13 
rs606452 11 74953826 a c 0.14 0.043 6.40E-23 -0.0352 0.05948 SERPINH1 
rs936339 3 144018195 t c 0.19 0.022 2.00E-08 -0.031 0.06448 PCOLCE2 
rs4802134 19 43038525 a g 0.21 0.027 2.90E-11 0.0279 0.06557 SIPA1L3 
rs1546391 3 116180147 g c 0.07 0.042 2.50E-12 -0.0446 0.06734 ZBTB20 
rs7534365 1 148142748 c t 0.19 0.045 3.50E-20 -0.0336 0.06785 SV2A 
rs7985356 13 114045564 t a 0.77 0.023 2.50E-11 0.0285 0.07016 CDC16 
rs26868 16 2189377 a t 0.47 0.025 2.70E-13 0.0264 0.07022 CASKIN1 
rs12186664 5 95655981 t a 0.32 0.021 6.00E-12 -0.0255 0.07265 PCSK1 
rs9650315 8 57318152 g t 0.87 0.057 2.50E-34 0.0352 0.07642 CHCHD7 
rs798497 7 2762483 a g 0.7 0.057 2.70E-71 0.0262 0.07826 GNA12 
rs1405212 6 117597357 c t 0.59 0.023 4.60E-14 0.0242 0.08067 VGLL2 
rs2166898 2 121329129 g a 0.84 0.027 8.70E-11 -0.0305 0.08378 GLI2 
rs6446315 4 5086488 g a 0.17 0.025 3.60E-09 -0.0309 0.08545 CYTL1 
rs2034172 3 55386803 g a 0.68 0.018 2.50E-08 0.0247 0.08616 WNT5A 
rs4686904 3 188921216 c t 0.35 0.022 1.00E-12 -0.0232 0.08732 BCL6 
rs8103992 19 19526643 a c 0.2 0.024 3.60E-10 0.0274 0.08779 PBX4 
rs2338115 17 34183104 t c 0.54 0.024 1.10E-16 0.0222 0.08954 PIP4K2B 
rs1461503 11 122350285 c a 0.57 0.018 3.70E-10 -0.0222 0.09167 BSX 
rs2093210 14 60027032 c t 0.42 0.039 7.50E-36 0.022 0.09649 C14orf39 
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Gene 
rs9967417 18 45213498 g c 0.43 0.037 1.20E-32 0.0218 0.101 DYM 
rs2275325 1 202067358 c g 0.28 0.019 5.00E-09 -0.0241 0.1031 ZC3H11A 
rs3885668 2 10095930 c t 0.43 0.022 6.90E-14 0.022 0.1049 KLF11 
rs6955948 7 150139653 t c 0.28 0.031 8.80E-20 0.0242 0.1052 TMEM176A 
rs4868126 5 171216074 g t 0.6 0.025 2.70E-11 -0.025 0.108 FBXW11 
rs2633761 3 4703104 a g 0.5 0.017 3.70E-09 0.021 0.1086 ITPR1 
rs820848 5 74000416 g a 0.29 0.021 3.60E-09 0.0239 0.1169 HEXB 
rs1681630 11 47925728 t c 0.34 0.031 1.10E-23 -0.0214 0.1218 PTPRJ 
rs422421 5 176449932 c t 0.78 0.034 1.70E-20 -0.0243 0.1277 FGFR4 
rs17574650 5 42472673 c a 0.11 0.036 1.50E-11 -0.0353 0.1278 GHR 
rs3802758 11 45892611 a g 0.94 0.041 5.10E-10 -0.0349 0.1346 PEX16 
rs1562975 4 109628057 a g 0.3 0.025 4.00E-15 -0.0217 0.1376 RPL34 
rs7659107 4 114961698 g a 0.23 0.024 6.60E-12 -0.024 0.1385 CAMK2D 
rs10997979 10 69607198 g a 0.5 0.018 3.50E-10 0.0196 0.1405 MYPN 
rs862034 14 74060499 g a 0.64 0.03 2.60E-23 -0.0199 0.1408 LTBP2 
rs6441170 3 159289654 c t 0.38 0.022 8.60E-14 -0.0198 0.1409 SHOX2 
rs6694089 1 170350504 a g 0.28 0.027 2.00E-13 0.0211 0.141 DNM3 
rs6061231 20 60390312 c a 0.72 0.02 1.70E-10 -0.0212 0.1436 RPS21 
rs11144688 9 77732106 g a 0.89 0.064 5.90E-24 -0.03 0.1437 PCSK5 
rs10767838 11 30304503 a g 0.72 0.025 1.80E-14 0.0212 0.1457 C11orf46 
rs17792664 14 20960523 g c 0.14 0.033 2.70E-14 -0.0275 0.1459 CHD8 
rs12209223 6 76221309 a c 0.12 0.046 1.90E-20 -0.0321 0.1466 FILIP1 
rs2326458 16 83545180 c a 0.25 0.022 4.50E-10 -0.0218 0.1478 ZDHHC7 
rs6584575 10 105567399 a g 0.1 0.032 1.20E-09 -0.0323 0.1492 SH3PXD2A 
rs291979 10 121119787 a g 0.23 0.03 5.50E-18 -0.023 0.1492 GRK5 
rs17410035 5 31576899 t g 0.33 0.017 1.70E-08 -0.0205 0.1524 C5orf22 
rs1935157 1 219383881 g c 0.3 0.024 3.10E-14 -0.0206 0.1525 HLX 
rs9816693 3 38022958 c g 0.17 0.031 3.60E-15 0.0248 0.1548 VILL 
rs8052560 16 87304743 a c 0.79 0.037 8.40E-17 -0.0235 0.1634 C16orf84 
rs17511102 2 37814117 t a 0.09 0.049 2.80E-17 -0.0334 0.1665 CDC42EP3 
rs17264185 15 64784141 g a 0.27 0.021 1.30E-10 -0.0203 0.1679 SMAD6 
rs7971536 12 100897919 t a 0.54 0.028 5.00E-18 0.0185 0.1685 CCDC53 
rs181338 9 88297981 t c 0.51 0.029 5.70E-24 -0.0178 0.1697 ZCCHC6 
rs4735677 8 78310746 t a 0.28 0.036 1.20E-29 -0.0203 0.1706 PXMP3 
rs552707 7 28171828 t c 0.31 0.047 7.40E-49 -0.02 0.1752 JAZF1 
rs2956605 8 76045609 a c 0.38 0.027 1.70E-17 -0.0186 0.1891 CRISPLD1 
rs13177718 5 108141243 c t 0.92 0.054 5.40E-19 -0.0337 0.1902 FER 
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rs2834442 21 34612656 a t 0.64 0.024 5.70E-15 -0.0179 0.1907 KCNE2 
rs3809790 17 24979666 c t 0.53 0.022 1.50E-13 0.0173 0.1914 SSH2 
rs6894139 5 88363538 t g 0.56 0.031 4.50E-25 -0.0175 0.1918 MEF2C 
rs11612228 12 447245 t c 0.38 0.02 3.70E-10 -0.0192 0.1925 B4GALNT3 
rs2164747 12 102868966 g a 0.1 0.028 9.10E-09 -0.0278 0.1969 HSP90B1 
rs301901 5 37082383 a g 0.57 0.026 4.50E-19 0.0172 0.1997 NIPBL 
rs12228415 12 14411968 g a 0.45 0.017 2.70E-08 -0.0173 0.2032 ATF7IP 
rs7727731 5 64710202 t c 0.11 0.033 2.10E-11 -0.0259 0.2171 ADAMTS6 
rs9858528 3 184838099 a g 0.74 0.021 8.50E-11 -0.0179 0.2196 KLHL24 
rs9766 17 38106367 a g 0.54 0.021 2.40E-13 -0.0161 0.2203 EZH1 
rs12214804 6 34296844 c t 0.08 0.087 1.60E-52 0.0302 0.2221 HMGA1 
rs8756 12 64646019 c a 0.49 0.054 1.30E-71 -0.0163 0.2235 HMGA2 
rs17450430 20 47205671 t a 0.24 0.034 6.20E-24 -0.0188 0.2251 STAU1 
rs8180991 8 126569532 c g 0.77 0.029 2.80E-16 -0.0193 0.2274 TRIB1 
rs891088 19 7135762 g a 0.26 0.027 1.30E-15 -0.0177 0.229 INSR 
rs273945 7 137262106 c a 0.58 0.018 2.90E-09 0.0164 0.2322 CREB3L2 
rs17806888 3 67499012 t c 0.88 0.033 4.30E-12 0.0236 0.2343 SUCLG2 
rs2211866 21 38609977 a g 0.41 0.022 1.90E-13 -0.0157 0.2349 KCNJ15 
rs9977276 21 46260755 g t 0.78 0.023 1.30E-10 0.0185 0.2354 COL6A1 
rs12855 1 51212681 t c 0.09 0.036 1.00E-12 0.0266 0.2363 CDKN2C 
rs584828 17 35852756 c t 0.6 0.028 3.30E-20 0.0159 0.2396 IGFBP4 
rs7043114 9 94427804 c t 0.44 0.028 1.30E-22 -0.0154 0.2401 IPPK 
rs1812175 4 145794294 g a 0.84 0.052 8.40E-30 -0.0211 0.2404 HHIP 
rs11867479 17 65601802 t c 0.35 0.025 2.00E-15 -0.0164 0.243 KCNJ16 
rs11616380 13 79603316 t g 0.28 0.02 1.20E-09 -0.0176 0.2431 SPRY2 
rs955748 4 184452669 g a 0.76 0.028 4.80E-16 0.0184 0.2436 WWC2 
rs2117563 17 70880580 g a 0.83 0.025 2.10E-10 -0.0196 0.2467 GRB2 
rs4548838 15 98578713 t c 0.46 0.034 9.10E-30 -0.0152 0.2487 ADAMTS17 
rs12190423 6 72259432 g c 0.62 0.016 4.30E-08 0.016 0.2497 OGFRL1 
rs11152213 18 56003928 c a 0.25 0.025 9.20E-13 -0.0176 0.2518 MC4R 
rs9880211 3 137590239 g a 0.75 0.032 1.30E-20 -0.0173 0.2531 STAG1 
rs4974480 3 135661252 t a 0.68 0.037 5.70E-23 -0.0158 0.2552 ANAPC13 
rs12470505 2 219616613 t g 0.9 0.046 4.00E-20 -0.0246 0.256 CCDC108 
rs4875421 8 4814740 t a 0.46 0.019 1.10E-10 0.0153 0.2567 CSMD1 
rs4725061 7 8053164 g a 0.44 0.02 1.50E-10 0.016 0.2569 GLCCI1 
rs7181724 15 92352611 g a 0.45 0.02 2.40E-10 0.0155 0.2573 MCTP2 
rs7259684 19 12047611 g a 0.07 0.039 1.70E-09 0.0271 0.2587 LOC729747 
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rs7567851 2 178392966 c g 0.08 0.039 2.20E-12 0.0268 0.2604 PDE11A 
rs10083886 17 67434950 t c 0.26 0.02 3.40E-09 -0.0163 0.2621 SOX9 
rs11047239 12 24099047 g c 0.3 0.022 4.10E-12 0.0166 0.2622 SOX5 
rs7319045 13 90822575 a g 0.39 0.024 3.70E-15 0.0156 0.2668 GPC5 
rs1113765 7 55856828 g a 0.82 0.025 1.00E-10 0.019 0.2709 SEPT14 
rs6949739 7 46383928 t a 0.91 0.037 4.80E-12 0.0285 0.2725 IGFBP3 
rs10131337 14 36214267 t c 0.24 0.027 5.60E-13 0.0173 0.2743 PAX9 
rs16834765 1 32144029 t c 0.06 0.045 1.40E-12 -0.0305 0.2747 PTP4A2 
rs11750568 5 178468319 a g 0.33 0.019 4.20E-10 -0.0153 0.2805 ADAMTS2 
rs12513181 4 124055106 c a 0.26 0.019 2.10E-08 0.0161 0.285 NUDT6 
rs6879260 5 179663620 c t 0.61 0.027 1.10E-17 -0.0146 0.286 GFPT2 
rs13088462 3 51046753 c t 0.06 0.053 1.10E-14 0.0322 0.2916 DOCK3 
rs4239020 17 77769930 c t 0.33 0.021 1.50E-11 0.0146 0.2968 CCDC57 
rs17113369 1 95559811 t c 0.97 0.07 2.40E-08 0.0374 0.2995 RWDD3 
rs4656220 1 168915901 t c 0.39 0.022 7.50E-12 0.0146 0.2998 PRRX1 
rs6794009 3 61488535 g a 0.44 0.016 2.80E-08 -0.0134 0.3011 PTPRG 
rs2306694 12 54966903 g a 0.07 0.047 1.20E-16 0.0277 0.3015 CS 
rs6920372 6 109830632 g a 0.59 0.026 5.70E-19 0.0138 0.3081 PPIL6 
rs2662027 5 56290242 g t 0.9 0.032 1.40E-11 0.022 0.3082 MIER3 
rs10880969 12 45113290 c t 0.7 0.023 1.10E-12 0.0146 0.3117 SLC38A2 
rs14062 18 17704301 g a 0.67 0.018 1.60E-08 0.014 0.3175 MIB1 
rs7834383 8 13317848 t g 0.36 0.021 1.90E-11 -0.0144 0.3186 DLC1 
rs2581830 3 53109138 t c 0.4 0.025 7.60E-16 0.013 0.328 RFT1 
rs2748483 6 146377253 a t 0.55 0.018 2.40E-09 -0.0132 0.3281 GRM1 
rs3782089 11 65093395 c t 0.94 0.053 1.00E-15 -0.0258 0.3288 SSSCA1 
rs199515 17 42211804 c g 0.8 0.023 1.60E-09 0.0163 0.3297 WNT3 
rs6696239 1 225816691 g a 0.81 0.038 2.80E-25 -0.0164 0.3299 ZNF678 
rs6420435 16 80741702 a c 0.21 0.025 1.80E-11 -0.0151 0.3308 MPHOSPH6 
rs2306596 4 39020335 a c 0.52 0.02 1.80E-11 0.0132 0.3354 RFC1 
rs316618 15 39583790 t a 0.78 0.026 9.80E-13 -0.0155 0.3393 LTK 
rs724016 3 142588260 g a 0.44 0.078 1.10E-156 0.0123 0.3484 ZBTB38 
rs12621643 2 223626227 g t 0.7 0.019 1.70E-08 -0.0133 0.3489 KCNE4 
rs7692995 4 17545732 t c 0.85 0.101 5.20E-100 -0.0169 0.3516 LCORL 
rs1265097 6 31214438 c a 0.89 0.04 6.50E-15 0.02 0.3538 PSORS1C1 
rs7033940 9 6430419 g c 0.87 0.024 3.80E-08 0.0182 0.354 UHRF2 
rs692964 18 13084132 g a 0.4 0.019 2.30E-10 -0.0123 0.3556 CEP192 
rs1036821 8 135719665 g a 0.7 0.047 2.80E-38 -0.0137 0.3563 ZFAT 
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rs780094 2 27594741 c t 0.61 0.021 7.50E-12 0.0122 0.3564 GCKR 
rs7466269 9 132453905 a g 0.64 0.033 1.70E-26 -0.0126 0.3606 FUBP3 
rs989393 9 100783157 t c 0.71 0.023 5.80E-13 -0.013 0.3611 COL15A1 
rs26024 5 127723921 c a 0.35 0.023 3.90E-13 -0.0128 0.3654 FBN2 
rs4640244 17 21224816 a g 0.61 0.025 6.60E-14 -0.0136 0.3668 KCNJ12 
rs11221442 11 128082834 g c 0.75 0.027 3.00E-14 -0.0137 0.3672 FLI1 
rs11683207 2 97699722 t c 0.8 0.024 5.70E-09 -0.0183 0.3723 ZAP70 
rs12987566 2 171860892 t c 0.27 0.023 1.30E-12 0.013 0.377 METTL8 
rs1832871 6 158642022 a g 0.34 0.021 9.20E-12 -0.0124 0.3786 TULP4 
rs3739707 9 112832527 c a 0.75 0.024 1.60E-11 -0.0133 0.3793 LPAR1 
rs870183 17 546561 g a 0.53 0.017 3.80E-09 0.0114 0.381 VPS53 
rs4812586 20 34978087 a g 0.84 0.033 1.70E-16 -0.0163 0.3847 SAMHD1 
rs2961830 5 50490489 a t 0.35 0.019 1.10E-09 0.0121 0.3886 ISL1 
rs1036477 15 46702218 a g 0.9 0.032 2.80E-11 -0.0179 0.39 FBN1 
rs354196 2 54819911 g a 0.53 0.021 1.90E-12 -0.0112 0.3937 SPTBN1 
rs17038954 2 1624680 t c 0.06 0.04 1.10E-10 -0.0241 0.3959 PXDN 
rs2510396 11 68174228 c g 0.86 0.029 2.60E-12 0.0158 0.3969 GAL 
rs5742915 15 72123686 c t 0.47 0.038 1.20E-34 0.0115 0.4033 PML 
rs34651 5 72179761 c t 0.08 0.042 4.20E-13 -0.0207 0.4079 TNPO1 
rs13416119 2 42316434 a g 0.9 0.029 4.90E-09 0.0197 0.409 EML4 
rs7273787 20 4046567 g a 0.35 0.022 3.00E-12 -0.0113 0.411 SMOX 
rs6974574 7 38076598 t a 0.69 0.031 2.30E-19 -0.0116 0.4115 STARD3NL 
rs10779751 1 11206923 a g 0.28 0.02 5.80E-10 0.0118 0.4139 FRAP1 
rs6952113 7 120564855 g a 0.62 0.018 1.10E-09 -0.0112 0.4145 C7orf58 
rs738288 22 38237607 g a 0.47 0.019 1.50E-10 0.0106 0.4151 SMCR7L 
rs1047014 6 19949472 c t 0.25 0.033 7.50E-20 0.0135 0.4209 ID4 
rs17807185 7 77146231 g a 0.38 0.022 3.30E-13 0.0107 0.4358 RSBN1L 
rs12904334 15 70629759 a g 0.02 0.094 1.50E-13 0.0417 0.4384 ARIH1 
rs3132297 9 136441687 g a 0.83 0.024 6.40E-09 0.0136 0.4409 RXRA 
rs2815379 1 67283062 g a 0.71 0.018 2.50E-08 -0.011 0.4445 SLC35D1 
rs1923367 10 80802835 g c 0.52 0.029 3.20E-22 0.0104 0.4457 ZCCHC24 
rs7177711 15 60167263 a g 0.54 0.021 1.60E-13 0.0101 0.4471 FAM148A 
rs6988484 8 49576333 c t 0.25 0.023 4.20E-12 -0.0116 0.4482 EFCAB1 
rs2057291 20 56905438 a g 0.34 0.02 4.80E-10 0.0104 0.4508 GNAS 
rs12137162 1 19635983 a c 0.28 0.019 4.90E-09 0.0109 0.4535 CAPZB 
rs1550162 8 117632713 g a 0.29 0.024 2.90E-14 0.011 0.4641 EIF3H 
rs6813055 4 88849055 a t 0.49 0.017 5.50E-09 0.0098 0.4663 DMP1 
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rs4072910 19 8550031 g c 0.56 0.031 9.90E-18 -0.0101 0.4685 ADAMTS10 
rs7551732 1 88911629 a t 0.61 0.027 2.50E-19 -0.0096 0.471 PKN2 
rs1401795 17 52194651 a g 0.51 0.03 5.00E-25 -0.0093 0.4711 C17orf67 
rs4425077 2 216118761 g c 0.41 0.02 1.40E-11 -0.0095 0.4726 FN1 
rs9841435 3 192593854 g a 0.32 0.019 6.10E-10 0.0099 0.4745 CCDC50 
rs4350272 10 25096124 a g 0.28 0.02 2.00E-09 0.0108 0.4747 ARHGAP21 
rs7980687 12 122388664 a g 0.2 0.036 1.30E-21 0.0118 0.4763 SBNO1 
rs888403 18 2756938 g a 0.36 0.019 1.00E-08 -0.0104 0.4772 SMCHD1 
rs564914 1 47687820 t a 0.39 0.025 4.10E-17 0.0096 0.4773 FOXD2 
rs17122659 12 58243190 g a 0.12 0.032 6.80E-11 -0.0154 0.4782 SLC16A7 
rs749234 2 144947819 a g 0.32 0.018 1.30E-08 0.0099 0.4809 ZEB2 
rs4605213 17 46599746 c g 0.34 0.019 2.00E-09 -0.0098 0.482 NME1-
NME2 
rs567401 1 85760746 t c 0.17 0.028 3.10E-11 -0.0132 0.4906 DDAH1 
rs7743622 6 132772065 g c 0.58 0.018 4.60E-08 -0.0094 0.4917 MOXD1 
rs9292468 5 32854830 t c 0.4 0.053 4.80E-46 -0.0092 0.4987 C5orf23 
rs9434723 1 9214869 a g 0.16 0.028 8.60E-12 -0.0122 0.5023 H6PD 
rs3812040 5 39461777 t c 0.72 0.024 3.50E-13 0.0102 0.5048 DAB2 
rs757081 11 17308259 g c 0.34 0.024 3.20E-14 -0.0092 0.5057 NUCB2 
rs9309101 2 43483116 g a 0.33 0.02 3.20E-10 0.0092 0.5068 THADA 
rs11687941 2 241840083 c g 0.75 0.025 4.00E-13 -0.01 0.5077 HDLBP 
rs7112925 11 66582736 c t 0.64 0.023 2.60E-14 -0.0089 0.5116 RHOD 
rs11835818 12 120979192 c t 0.49 0.017 4.30E-09 0.0088 0.5121 BCL7A 
rs11090631 22 44225035 t c 0.2 0.022 1.50E-08 -0.011 0.5143 RIBC2 
rs17783015 12 88755517 c t 0.84 0.025 5.20E-10 0.0122 0.5169 ATP2B1 
rs318095 17 44329733 t c 0.46 0.023 3.30E-15 0.0083 0.5228 ATP5G1 
rs7849585 9 138251691 t g 0.33 0.036 9.80E-29 0.0091 0.5248 QSOX2 
rs16964211 15 49317787 g a 0.95 0.044 4.80E-09 0.0188 0.5248 CYP19A1 
rs817300 9 97420043 g a 0.93 0.07 2.20E-23 -0.0177 0.5274 PTCH1 
rs7567288 2 134151294 c t 0.2 0.028 3.80E-13 -0.0107 0.529 NAP5 
rs486359 6 160694431 c g 0.49 0.017 1.60E-08 0.0085 0.5299 SLC22A3 
rs17250196 7 99655132 t g 0.07 0.044 8.70E-10 0.0205 0.5335 GATS/ 
rs2023693 16 20787541 g a 0.6 0.017 1.40E-08 0.0081 0.5388 DCUN1D3 
rs2682587 19 48774269 a c 0.2 0.024 4.30E-10 -0.0103 0.5442 XRCC1 
rs429433 8 8785304 a g 0.05 0.046 6.70E-11 -0.0228 0.5449 MFHAS1 
rs1659127 16 14295806 a g 0.34 0.03 1.20E-19 -0.0087 0.546 MKL2 
rs2145357 6 116558135 g a 0.27 0.022 1.70E-11 0.0091 0.5461 NT5DC1 
rs763318 4 12572672 g a 0.53 0.025 4.40E-17 -0.008 0.5476 RAB28 
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rs32855 5 79871948 a g 0.78 0.024 4.50E-11 0.0098 0.5518 FAM151B 
rs2631676 10 93027389 g a 0.19 0.028 1.50E-12 0.0103 0.5539 PCGF5 
rs2974438 5 168183481 g a 0.8 0.038 3.90E-26 -0.0098 0.5541 SLIT3 
rs4883972 13 73956482 c g 0.55 0.019 1.70E-10 0.008 0.5565 KLF12 
rs2806561 1 23377382 a g 0.57 0.027 2.70E-21 0.0076 0.5588 LUZP1 
rs2856321 12 11747040 g a 0.36 0.031 1.00E-25 -0.0081 0.5603 ETV6 
rs12871822 13 48099041 g t 0.34 0.018 2.70E-09 -0.0082 0.5645 CYSLTR2 
rs7162825 15 61226239 t c 0.5 0.016 2.80E-08 0.0073 0.5716 LACTB 
rs6435143 2 202902501 a c 0.44 0.019 2.40E-10 0.0074 0.5737 NOP5 
rs7027110 9 108638867 a g 0.23 0.032 2.30E-20 -0.0087 0.5738 ZNF462 
rs4896582 6 142745570 g a 0.7 0.051 6.90E-58 -0.0082 0.5769 GPR126 
rs497273 12 119689065 c g 0.38 0.019 2.80E-10 -0.0079 0.5774 SPPL3 
rs12882130 14 102948527 c g 0.63 0.024 2.90E-14 -0.0077 0.5819 MARK3 
rs6540834 1 212694042 c t 0.66 0.028 1.70E-17 0.0073 0.5822 PTPN14 
rs6561319 13 46010121 a c 0.64 0.021 1.50E-11 -0.0076 0.5827 LRCH1 
rs11855014 15 83529838 g a 0.71 0.022 1.40E-10 -0.0078 0.5926 PDE8A 
rs2013265 8 24148445 c t 0.75 0.027 9.20E-17 0.008 0.6017 ADAM28 
rs165189 5 139125931 g a 0.15 0.031 2.70E-11 0.0104 0.6018 PSD2 
rs6962887 7 134696326 t g 0.68 0.022 9.60E-11 0.0078 0.6019 CNOT4 
rs10748128 12 68113925 t g 0.35 0.038 4.60E-29 0.0078 0.6033 FRS2 
rs39623 5 129082520 a t 0.08 0.045 7.20E-17 0.0129 0.6075 ADAMTS19 
rs2715094 7 50697946 g a 0.25 0.021 1.20E-09 -0.008 0.6112 GRB10 
rs2289195 2 25316987 a g 0.43 0.042 3.00E-34 -0.0068 0.613 DNMT3A 
rs4986172 17 40571807 c t 0.65 0.038 1.60E-31 0.0069 0.6196 ACBD4 
rs7652177 3 173451771 g c 0.51 0.037 1.00E-36 0.0065 0.6207 FNDC3B 
rs540652 2 169415674 t c 0.46 0.021 6.20E-13 -0.0065 0.6215 NOSTRIN 
rs6688100 1 158666210 t c 0.48 0.016 2.20E-08 -0.0064 0.6225 VANGL2 
rs3818416 13 77372469 c a 0.78 0.021 4.60E-09 0.0078 0.6246 EDNRB 
rs7899004 10 104331425 t c 0.56 0.024 4.30E-17 -0.0066 0.6268 SUFU 
rs9993613 4 73694878 t g 0.47 0.03 7.80E-25 -0.0065 0.6312 ADAMTS3 
rs6761041 2 224738373 t c 0.55 0.024 1.70E-16 -0.0062 0.6318 SERPINE2 
rs16895130 6 42032909 g a 0.28 0.025 2.00E-14 -0.0072 0.6319 CCND3 
rs12474201 2 46774789 a g 0.36 0.029 1.70E-20 -0.0065 0.6333 SOCS5 
rs6971575 7 95877584 c g 0.29 0.022 3.60E-10 -0.007 0.6408 SLC25A13 
rs1996422 4 48382108 g a 0.28 0.022 1.30E-11 -0.0073 0.6428 FRYL 
rs10790381 11 119762705 a g 0.82 0.027 1.20E-12 -0.0081 0.643 ARHGEF12 
rs2123731 19 4880473 a g 0.73 0.025 6.80E-13 -0.0067 0.6462 UHRF1 
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rs6902771 6 152199574 t c 0.46 0.029 1.50E-21 0.0062 0.6485 ESR1 
rs6658763 1 145158997 c t 0.92 0.034 5.10E-10 0.011 0.6504 FMO5 
rs6439168 3 130533633 g a 0.79 0.038 5.20E-26 -0.0071 0.6545 H1FX 
rs2120335 2 68348506 g a 0.59 0.018 8.40E-10 0.0059 0.6546 PPP3R1 
rs6080830 20 17719113 a g 0.56 0.016 1.50E-08 -0.0058 0.6559 BANF2 
rs2149163 9 16445833 c g 0.4 0.02 2.90E-11 0.0059 0.656 BNC2 
rs4843367 16 84975391 c t 0.66 0.02 7.10E-10 -0.006 0.6634 FOXF1 
rs10152739 15 36271158 t a 0.25 0.023 3.00E-11 -0.0064 0.6699 SPRED1 
rs13113518 4 56094405 c t 0.36 0.017 1.60E-08 0.0059 0.6711 CLOCK 
rs17556750 4 82374592 a c 0.31 0.044 2.80E-43 -0.0061 0.6781 PRKG2 
rs10972628 9 35927611 g a 0.74 0.02 1.20E-08 -0.006 0.6846 OR2S2 
rs11156098 6 156629523 t c 0.12 0.029 5.40E-10 -0.0088 0.6867 ARID1B 
rs7007200 8 109854114 g c 0.69 0.017 4.70E-08 0.0059 0.6896 TMEM74 
rs3812423 8 25354627 g c 0.64 0.021 1.00E-12 0.0056 0.6905 KCTD9 
rs11648796 16 732191 g a 0.25 0.034 7.70E-19 -0.0068 0.6928 NARFL 
rs11799609 1 241684940 t g 0.16 0.026 7.00E-10 0.0073 0.6986 SDCCAG8 
rs10794175 10 126348063 t g 0.43 0.021 4.00E-12 0.0052 0.6991 FAM53B 
rs11880992 19 2127403 a g 0.4 0.032 1.10E-26 -0.0051 0.7003 DOT1L 
rs932445 6 2112224 t c 0.59 0.021 1.10E-11 0.0053 0.7006 GMDS 
rs4601530 1 24916698 c t 0.74 0.026 5.90E-15 0.0056 0.704 CLIC4 
rs2072268 17 63814947 g a 0.52 0.021 1.70E-11 -0.0053 0.7058 ARSG 
rs11616067 12 114877557 a g 0.76 0.02 1.00E-08 0.0059 0.709 MED13L 
rs7716219 5 54990828 t c 0.31 0.029 2.50E-21 0.0055 0.7092 SLC38A9 
rs4624820 5 141661972 a g 0.52 0.018 1.80E-10 -0.005 0.7095 SPRY4 
rs12693589 2 191540907 c t 0.25 0.022 5.50E-11 0.0055 0.7114 STAT1 
rs2302580 4 8659534 c t 0.58 0.029 1.20E-15 -0.0052 0.7155 CPZ 
rs992157 2 218863025 a g 0.57 0.018 1.60E-09 -0.0048 0.7166 PNKD 
rs761391 6 85504822 c t 0.46 0.021 6.10E-10 -0.0049 0.7183 TBX18 
rs2811594 1 93115870 g a 0.63 0.023 3.10E-13 0.0048 0.7187 FAM69A 
rs2058092 14 73002719 t c 0.56 0.017 8.40E-09 0.0047 0.7243 NUMB 
rs6714546 2 33214929 g a 0.72 0.035 2.40E-24 0.0051 0.7327 LTBP1 
rs17330192 6 17697354 c t 0.28 0.019 1.20E-08 -0.0052 0.7348 FAM8A1 
rs10883563 10 102674370 a c 0.55 0.023 3.20E-15 0.0045 0.7387 FAM178A 
rs2175513 3 68705056 g a 0.43 0.017 2.00E-08 0.0044 0.7396 FAM19A1 
rs7853235 9 85850602 t c 0.2 0.029 8.80E-15 0.0053 0.7503 RMI1 
rs3923086 17 60979950 c a 0.6 0.025 2.80E-14 -0.0046 0.7511 AXIN2 
rs1980850 14 67716941 g a 0.83 0.029 2.40E-13 -0.0053 0.7554 RAD51L1 
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rs2298265 1 149525667 c t 0.88 0.03 6.90E-11 -0.0061 0.7574 ZNF687 
rs1155939 6 126907826 a c 0.5 0.042 1.30E-47 0.0041 0.7606 C6orf173 
rs7253628 19 35739109 g a 0.16 0.024 6.20E-10 0.0054 0.7612 ZNF536 
rs1325596 1 175060689 a g 0.57 0.025 2.10E-18 0.0039 0.7621 PAPPA2 
rs6746356 2 174524144 a c 0.75 0.019 1.80E-08 0.0045 0.7647 SP3 
rs11618507 13 29070751 t g 0.25 0.023 1.80E-10 0.0049 0.7678 SLC7A1 
rs975210 15 68151406 a g 0.18 0.034 7.90E-17 0.0053 0.7698 TLE3 
rs929637 7 12243047 g t 0.78 0.022 1.90E-10 0.0046 0.7731 TMEM106B 
rs1571892 9 93298657 c a 0.29 0.017 5.00E-08 0.0041 0.7733 NFIL3 
rs12669267 7 72942572 c t 0.87 0.029 2.60E-08 -0.0065 0.7742 WBSCR28 
rs6838153 4 122940449 g a 0.34 0.021 7.90E-12 -0.0039 0.7831 EXOSC9 
rs9835332 3 56642722 g c 0.54 0.028 3.00E-22 -0.0035 0.7845 C3orf63 
rs8058684 16 52072619 a g 0.3 0.021 6.40E-11 0.0038 0.787 RBL2 
rs7261425 20 20016635 c g 0.71 0.021 5.10E-10 0.0039 0.7874 C20orf26 
rs999599 9 116051416 t c 0.37 0.017 9.70E-09 -0.0036 0.7884 COL27A1 
rs8097893 18 73112043 a g 0.95 0.044 1.30E-10 0.0088 0.7893 GALR1 
rs12639764 4 106435654 t c 0.62 0.027 5.00E-20 0.0036 0.7913 TET2 
rs1074683 20 31768314 c g 0.76 0.047 2.40E-42 0.004 0.7939 PXMP4 
rs1420023 12 12767378 c g 0.88 0.028 1.60E-08 0.0056 0.7965 CDKN1B 
rs2284746 1 17179262 g c 0.52 0.04 1.20E-40 0.0033 0.8027 MFAP2 
rs7154721 14 91497101 t c 0.57 0.027 1.30E-20 0.0032 0.8072 TRIP11 
rs2345835 2 18438433 c t 0.54 0.019 3.40E-10 -0.0033 0.809 RDH14 
rs12435366 14 34908140 c t 0.73 0.023 3.60E-11 0.0038 0.8099 NFKBIA 
rs1552173 17 74230437 c t 0.46 0.018 2.00E-10 -0.0031 0.8137 PSCD1 
rs6600365 1 41328840 c t 0.43 0.027 9.90E-21 -0.0031 0.8151 SCMH1 
rs833152 2 182927346 c a 0.42 0.016 4.00E-08 0.003 0.8195 PDE1A 
rs12538407 7 23487841 a g 0.6 0.043 1.00E-35 -0.0031 0.8212 IGF2BP3 
rs11624136 14 58758573 a g 0.5 0.017 3.30E-09 -0.0029 0.8215 DAAM1 
rs2829941 21 26130806 t g 0.61 0.017 3.20E-08 -0.003 0.8222 APP 
rs632124 11 118118445 a t 0.42 0.022 2.20E-14 0.0029 0.8267 DDX6 
rs13006748 2 20015300 c g 0.3 0.023 1.00E-11 0.003 0.8387 WDR35 
rs568610 8 27583914 t c 0.24 0.023 1.20E-11 -0.0031 0.8416 SCARA3 
rs2280470 15 87196630 a g 0.33 0.031 5.50E-21 0.0028 0.8419 ACAN 
rs9217 17 7303812 c t 0.37 0.03 4.40E-23 -0.0026 0.846 ZBTB4 
rs1950500 14 23900690 t c 0.3 0.031 2.70E-22 0.0028 0.8481 NFATC4 
rs4785393 16 48816984 g a 0.16 0.023 1.80E-08 0.0032 0.8497 PAPD5 
rs806794 6 26308656 a g 0.71 0.055 7.80E-59 -0.0028 0.8512 HIST1H2BF 
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rs2059877 19 52880621 t g 0.26 0.019 2.30E-08 -0.0027 0.8556 GLTSCR1 
rs3958122 4 1663729 t c 0.35 0.027 1.20E-17 -0.0025 0.8564 SLBP 
rs7284476 22 36459278 a g 0.43 0.016 4.60E-08 -0.0024 0.8576 TRIOBP 
rs9291926 5 67635412 t g 0.49 0.019 9.30E-10 0.0024 0.8582 PIK3R1 
rs4733724 8 130792910 a g 0.8 0.05 2.60E-42 -0.003 0.8588 MLZE 
rs7740107 6 130416154 t a 0.26 0.034 5.10E-22 0.0027 0.8606 L3MBTL3 
rs11049611 12 28491511 c t 0.7 0.037 6.30E-30 -0.0025 0.8613 CCDC91 
rs991946 6 166249852 c t 0.52 0.022 6.80E-14 -0.0023 0.8628 T 
rs1582931 5 122685098 g a 0.52 0.028 2.70E-20 0.0023 0.8635 CCDC100 
rs8017130 14 22828996 g a 0.69 0.023 6.50E-12 -0.0025 0.8655 HOMEZ 
rs13388725 2 108413622 g a 0.41 0.018 2.40E-09 0.0022 0.8672 GCC2 
rs10863936 1 210304421 g a 0.47 0.021 9.00E-13 -0.0022 0.8677 DTL 
rs6911389 6 144121322 t g 0.35 0.018 1.40E-08 -0.0024 0.8686 PHACTR2 
rs1599473 8 120544539 g t 0.75 0.026 4.10E-14 -0.0024 0.8772 NOV 
rs9395264 6 47582981 g t 0.68 0.02 1.10E-10 -0.0022 0.8805 CD2AP 
rs10995319 10 52432893 t c 0.76 0.019 2.20E-08 0.0022 0.8871 PRKG1 
rs4332428 10 4955434 a g 0.88 0.036 1.10E-15 -0.0028 0.8916 AKR1C1 
rs3915129 3 41218746 g t 0.47 0.016 3.80E-08 0.0017 0.8946 CTNNB1 
rs11783655 8 145109561 t a 0.61 0.019 5.40E-10 0.0018 0.8956 PLEC1 
rs11684404 2 88705737 c t 0.34 0.032 2.30E-25 -0.0018 0.8967 EIF2AK3 
rs1544196 1 222699405 g a 0.77 0.019 2.80E-08 -0.002 0.8991 WDR26 
rs13150868 4 152400121 t g 0.44 0.018 1.20E-09 -0.0016 0.9087 ESSPL 
rs9392918 6 7653630 c t 0.47 0.041 2.40E-43 0.0015 0.9126 BMP6 
rs10780910 9 90039075 t a 0.43 0.028 6.20E-21 0.0014 0.9148 SPIN1 
rs3118905 13 50003335 g a 0.72 0.044 1.60E-33 0.0016 0.9167 DLEU7 
rs8103068 19 17383869 t c 0.86 0.032 5.00E-12 0.0021 0.9176 BST2 
rs2247870 5 90187345 a g 0.55 0.017 1.60E-08 -0.0013 0.9211 GPR98 
rs915506 10 97795064 g a 0.65 0.019 1.50E-10 0.0013 0.9275 CCNJ 
rs7069985 10 27930837 g a 0.25 0.023 1.30E-11 -0.0014 0.9301 RAB18 
rs1945237 11 55986645 c t 0.09 0.03 8.70E-09 -0.0021 0.9312 OR5M9 
rs1576900 9 18619792 g a 0.7 0.019 6.50E-09 -0.0012 0.9342 ADAMTSL1 
rs2781373 14 64637968 g a 0.62 0.021 2.90E-12 0.0011 0.9376 MAX 
rs425277 1 2059032 t c 0.28 0.028 4.80E-17 -0.0011 0.9407 PRKCZ 
rs17391694 1 78396214 t c 0.12 0.04 4.00E-14 -0.0015 0.9437 GIPC2 
rs8102380 19 10662185 g a 0.31 0.021 5.90E-12 0.0008 0.9538 ILF3 
rs11779459 8 124049732 t c 0.35 0.018 3.40E-08 -0.0008 0.9573 ZHX2 
rs822531 7 148260692 t c 0.78 0.035 1.10E-18 0.001 0.9574 EZH2 
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Table 4.1 (Continued) 
      Height Sitting height ratio  
Rsid Chr Position Ref Alt Reffreq Effect Size P-value Effect Size P-value Closest 
Gene 
rs720390 3 187031377 a g 0.38 0.068 8.70E-58 -0.0007 0.9626 IGF2BP2 
rs12330322 3 72538045 c t 0.78 0.034 3.50E-22 0.0007 0.9668 RYBP 
rs991967 1 216682074 c a 0.28 0.038 4.10E-32 0.0006 0.9687 TGFB2 
rs3763631 9 35798334 c g 0.69 0.021 3.40E-11 0.0005 0.9711 NPR2 
rs897080 2 44627706 c t 0.26 0.033 2.60E-21 -0.0004 0.9778 C2orf34 
rs7162542 15 82305294 g c 0.55 0.03 7.70E-16 -0.0003 0.9806 ADAMTSL3 
rs7568069 2 71437993 g a 0.42 0.021 1.40E-13 0.0003 0.9811 ZNF638 
rs6462432 7 32902049 a g 0.39 0.017 1.80E-08 -0.0003 0.9842 KBTBD2 
rs6691924 1 54726833 t c 0.9 0.031 4.70E-10 -0.0004 0.9853 ACOT11 
rs526896 5 134384604 t g 0.73 0.037 2.60E-27 -0.0003 0.9855 PITX1 
rs2854207 17 59300839 g c 0.27 0.04 4.20E-28 0.0001 0.9921 CSH2 
rs2074977 19 3385028 c a 0.36 0.028 4.60E-20 -0.0001 0.9927 NFIC 
rs1199734 13 20468246 g t 0.81 0.021 4.00E-08 0.0001 0.9942 LATS2 
rs2237886 11 2767307 t c 0.11 0.042 1.60E-17 -0.0001 0.9969 KCNQ1 
rs8069300 17 11924957 g c 0.47 0.016 1.70E-08 0 0.9985 MAP2K4 
 
The 421 height associated SNPs and their effect sizes and P-values with sitting height ratio 
(SHR). The reference allele has been aligned such that the effect size for height is always 
positive. The variants are ordered with decreasing significance to SHR. 
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large difference of SHR between people of different ancestral background and there is more than 
1 standard deviation difference between the SHR of European American and African Americans. 
While uncovering the underlying genetic reason for such a difference could improve our 
understanding of developmental biology during growth, differences of other phenotypes between 
European and African Americans could also be studied to determine if genetics is the primary 
cause for the difference. For example, studies of cancer rates have shown that African Americans 
have significantly higher incident rates of cancer [16] and subsequent genetic studies have 
uncovered common variants associated with prostate cancer that could explain for the greater 
incidence in African Americans [17,18]. 
 Interestingly, we managed to observe some loci that reach genome wide significance 
even with our relatively small sample size. The lead variant (rs201786365) discovered in our 
African American samples is not in any genes. The closest gene (120kb upstream) is ABHD5, 
where mutations in ABHD5 (also known as CGI-58) has been associated with Chanarin-Dorfman 
syndrome, a syndrome characterized by the individual’s inability to process triglycerides which 
can lead to having short stature [19]. The variants discovered from our studies in European 
Americans, rs140449984 (PTPRM) and rs5959358 (ITM2A) are also interesting. PTPRM, while 
not known to be associated with height, is associated with a syndrome called deletion 18p 
syndrome which can lead to mental and growth retardation, and craniofacial dysmorphism [20]. 
While the variant (rs5959358) does not lie in any gene, the closest gene, ITM2A (70kb 
upstream), a gene found on the X-chromosome is associated with SHR in women but not in men. 
The locus have also been reported to be strongly associated with height [13]. This result suggests 
that the variant responsible for altering SHR plays a role in escaping dosage compensation in 
women that results in altered SHR [13,21,22]. Finally, we also show that most of the SNPs 
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associated with height do show effects that alter SHR. While variants that increase height have 
slightly higher probability to be associated with decreased SHR (e.g. FGFR2, CDK6), some 
variants that increase height are also associated with increase SHR (e.g. FAM46A, WWP2). 
Other variants while having a strong effect on overall height, they do not seem to be associated 
with SHR (e.g. HMGA2, ZBTB38). These 3 classes of genes might be clustered distinct 
biological pathways that have very different mechanism on how they alter overall height. 
 In conclusion, this study is a large scale whole genome experiment to discover the 
underlying genetic basis for differences in body proportion using the sitting height ratio (SHR) as 
a read out. We uncovered a few loci that are significantly associated with SHR and that there are 
a significant number of loci associated with height that also alters the SHR. These results suggest 
that SHR is also polygenic and further studies of larger sample sizes is required to explain the 
full genetic spectrum of SHR. 
 
MATERIALS AND METHODS 
Quality control (QC) 
The data were downloaded from dbGAP and passed through our quality control pipeline. The 
QC is largely done using PLINK [23] software. Samples that have ambiguous or incorrect gender 
were filtered out (using --check-sex option in PLINK). SNPs that have > 5% missing rate were 
filtered out. Samples that have > 2% missing SNPs were removed. SNPs that have minor allele 
frequencies < 1% were dropped. We then examine samples that have extreme heterozygosity and 
removed samples that were +/- 4 standard deviations (using –het option in PLINK). The SNP 
annotations for chromosome and base-pair positions were set to the coordinates of hg19 
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(GRCh37) using liftover. We then calculated pairwise IBD/IBS (using –genome option in 
PLINK) and remove individuals that have excessive matching with other individuals (PI_HAT > 
0.05). The samples were then superimposed on the HAPMAP [24] version 3 by comparing 
principal components using SMARTPCA [25]. Samples that do not belong to the right PCA 
cluster were removed. SNPs that have excessive plate-effects (P < 1 x 10
-7
) were dropped. For 
samples that are of European ancestry, SNPs that have excessive deviation from Hardy-Weinberg 
equilibrium (P < 1 x 10
-7
) were dropped. 
 
Determining global European ancestry in African American individuals 
For the African American individuals (ARIC and CARDIA cohorts), the global European 
ancestry was calculated by SMARTPCA from the CEU and YRI samples of HAPMAP version 3. 
The CEU individuals are proxies of European ancestry while the YRI individuals are proxies of 
African ancestry. The principal components were calculated using only the CEU and YRI 
individuals while projecting them onto the ARIC and CARDIA African Americans. The first 
principal component is taken to be the axis that represents the degree of global European 
admixture for each of our individuals. 
 
Genotype Imputation 
The genotypes were phased using SHAPEIT2 [26] and imputed using IMPUTE2 [27]. The 
imputation panel used were from the 1000 genomes [28] containing 379 Europeans, 246 Africans 
and African-Americans, 286 Asians and 181 Latin Americans. The imputation panel consists of 
approximately 22 million variants (SNPs and indels). For the X-chromosome, only the non-
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pseudo autosomal region was imputed. The phasing and imputation were done separately for 
males and females. 
 
Genome wide association 
The associations were performed using sitting height ratio (SHR) adjusted for sex, height, age 
and body mass index (BMI). SHR was calculated by taking sitting height divided by total height. 
Individuals that were missing for SHR or any of the above covariate were discarded. Only 
unrelated individuals were used, i.e. no pair of individuals has PI_HAT > 0.05. The SHR were 
inverse-normalized per cohort. The top 10 principal components (PCs) were calculated using 
SMARTPCA and any PCs that had an association with SHR (P < 0.05) were used as a covariate 
as well. For African American individuals, the global percentage European admixture was 
included as an additional covariate. The association for the imputed variants with SHR was 
performed by a linear regression (--linear command with PLINK). The resulting association 
results for each cohort were then meta-analyzed together using METAL [29] with GC correction 
turned on. Variants on the X-chromosome were analyzed separately between males and females. 
 
Atherosclerosis Risk In Communities (ARIC) cohort 
We obtained genotypic and phenotypic data from dbGAP. There were initially 13,113 samples 
(European + African Americans) and after performing the quality control (QC) procedure, there 
were 7,257 (3,551 males and 3,706 females) European Americans and 2,354 African Americans 
(894 males and 1,460 females). The genotypes were typed using the Affymetrix Genome-Wide 
Human SNP Array 6.0 platform. 
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Coronary Artery Risk Development in Young Adults (CARDIA) cohort 
We obtained genotypic and phenotypic data from dbGAP. There were initially 1,675 European 
American samples and after performing the quality control (QC) procedure, there were 1,047 
(494 males and 553 females) samples remaining. For African Americans, there were initially 
1,393 samples and after performing the QC procedure, there were 715 (275 males and 440 
females) samples remaining. The genotypes were typed using the Affymetrix Genome-Wide 
Human SNP Array 6.0 platform. 
 
Cardiovascular Health Study (CHS) cohort 
We obtained genotypic and phenotypic data from dbGAP. There were initially 3,980 European 
American samples and after performing the quality control (QC) procedure, there were 2,926 
(1,163 males and 1,763 females) samples remaining. The genotypes were typed using the 
Illumina HumanCNV370v1-Duo platform. 
 
Framingham Heart Study (FHS) cohort 
We obtained genotypic and phenotypic data from dbGAP. The FHS cohort is largely data with 
family pedigrees. Sitting height measurements were only observed for the original cohort. After 
removing samples that do not have sitting height measurements and that are unrelated, there 
were 713 (269 males and 444 females) samples remaining. The genotypes were typed using the 
Affymetrix 500K platform. 
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OVERVIEW 
 The development of whole genome genotyping technologies (DNA microarrays, whole 
genome sequencing, etc) coupled with computational capabilities for performing genotype-
phenotype associations have allowed genome wide association studies (GWAS) to be  successful 
at identifying genetic variants associated with many complex traits and diseases [1]. This is 
because GWASs are best suited for identifying variants for traits with polygenic architecture 
where many loci have only a small effect on the resulting phenotype [2]. There is now 
compelling evidence that many of these variants result in changes of RNA expression levels 
which could be the reason behind their association with the phenotype [3,4]. While GWASs have 
been largely successful, much of the heritability has not been explained by the currently 
discovered variants although as the sample sizes increase, the better powered GWASs will be in 
detecting variants with smaller effect sizes [5]. Nonetheless, even if GWASs yield no new 
variants associated with phenotypes, the landscape of the genetic association statistics from 
GWASs might still be informative in teaching us about the genetic architecture of the phenotype. 
In this dissertation, we demonstrated how one can leverage the results from GWASs to infer the 
role of rare and common variants to polygenic architecture. 
 
MAJOR FINDINGS AND IMPLICATIONS 
In chapter 2, we discussed experiments that analyze the common variant’s effects on 
height at the tails of the height distribution. The findings are: 
 Single SNP analysis shows that common variants have expected effects at the tails. 
 The short individuals have less than expected number of common short alleles (alleles 
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that are shown to reduce stature). 
 This effect is driven by the shortest individuals. 
 This result is consistent with rare variants having moderate effects on short stature. 
Given that the short individuals have less than expected number of common short alleles, there is 
a fair chance that there are many such rare variants that have moderate effects on short stature in 
the population. Studies have been performed to determine what some of these variants might be 
[6], but might still prove difficult given the lack of power as the allele frequencies of such 
variants are very low. There is also evidence that rare copy number variants (CNVs) in genomic 
regions can explain the short stature in some patients [7,8]. Therefore, one of the implications of 
our results is that if one wants to have a strategy for identifying rare variants that cause short 
stature in the population, the recruitment of individuals with short stature is critical. It would be 
better to first genotype individuals with short stature for their height-associated common variants 
and determine if these individuals have a deficit of height decreasing alleles. As the short stature 
individuals could be short because of rare variants and/or common variants, enriching for 
individuals with a deficit of common height decreasing alleles would enrich for individuals 
harboring rare variants. Our results also implicate the use of ‘extreme’ individuals for genetic 
studies, that such studies can be used to compliment our knowledge about the genetic 
architecture of the trait in question. 
 In chapter 3, we discussed a method to determine polygenic inheritance from low 
frequency variants by examining if there is an excess of risk conferring variants from summary 
statistics of association studies. The findings are, 
 An excess of low frequency risk-increasing variants can be a signal of polygenic 
inheritance as measured by an increase in the risk to protective (R/P) ratio. 
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 This excess can be due to risk-increasing variants being more statistically powered than 
risk-decreasing variants with the same magnitude of effect. 
 This excess can also be due to having more risk variants to begin with because of 
negative selection keeping risk variants at low frequencies. 
 There is a higher probability for false positive associations to be risk variants if there are 
substantially more controls than cases. 
 This excess can also be due to asymmetric population stratification because of badly 
designed GWAS. 
 An analysis of some published GWAS summary statistics reveal significantly increased 
R/P ratios for schizophrenia, type 2 diabetes and obesity. 
 Significant increased R/P ratios were observed for macroalbuminuria and end stage renal 
disease but not if these subtypes of diabetic nephropathy were combined into a single 
case group. 
These findings suggest that one could simply test for an excess of risk conferring variants to 
determine if the low frequency variants contribute as a whole to disease risk. Methods to detect 
for a contribution of low frequency or rare genetic variants to disease risk are crucial as they can 
inform researchers whether pursuing the hypothesis would be a fruitful endeavor. While methods 
like GCTA [9] and polygene score [10] can be adapted to perform such analyses, examining for 
the excess of risk conferring variants provide an independent support for low frequency 
polygenic contributors to disease risk and requires only summary statistics without the need for 
primary genotype data. Besides having such a method, the findings suggest that most GWAS are 
designed to better discover low frequency variants that confer risk to disease. While this is useful 
for explaining disease etiology, it may be suboptimal for discovering genes that might be useful 
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as drug targets for treatment. This is because genes that have low frequency variants that confer 
protection to disease are best suited as drug targets assuming that the variants confer some loss of 
function effect on the gene. For example, low frequency loss of function variants in PCSK9 have 
been found to have a protective effect against coronary heart disease [11] and now has become a 
drug target for lowering LDL cholesterol [12]. Our results suggest that if GWAS were designed 
such that cases are individuals strongly protected against disease and controls are everyone else, 
that design will be better optimized to discover rare protective variants. 
 In chapter 4, we examine the extent of genetic contribution to sitting height ratio (SHR) 
by performing genome wide association studies on African and European Americans. The 
findings are, 
 Degree of European admixed ancestry in African Americans strongly associated with 
sitting height ratio (SHR) suggests strong genetic contribution. 
 GWAS in African Americans discover a locus associated with SHR. 
 GWAS in European Americans discover 2 loci associated with SHR. 
 More than expected height-associated variants show association with SHR as well. 
 Some of these height-increasing allele decreases SHR while other increases SHR. 
These results show that the difference of sitting height ratios (SHRs) between European and 
African Americans is genetic and that GWAS performed can reveal variants that are associated 
with SHR. However, the few variants discovered through GWAS do not explain the difference 
between European and African Americans suggesting that this difference is polygenic. As such, 
to fully uncover the full extent of such a difference, many more samples are required. The excess 
of known height-associated variants associated with SHR is also interesting. While sitting height 
is a component of total height, the sitting height ratio is not. Given that we corrected for total 
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height when performing the linear regression, the association statistic represents the change 
between the upper-body to lower-body ratio. As such, these height-associated SNPs can be 
grouped into 3 categories, i.e. the height-increasing allele does not alter SHR, the height-
increasing allele decreases SHR and the height-increasing allele increases SHR. While we 
perhaps do not have enough height loci to investigate this, there is a strong hypothesis that the 
height-increasing alleles that increases SHR are probably in genes that function to increase spine 
length or that the alternate allele decreases femur or tibia length. On the other hand the height-
increasing alleles that decrease SHR may perhaps be working to increase the length of the femur 
or tibia. The variants that have no effect on SHR may perhaps be regulating hormonal output. 
Perhaps examining these 3-classes of variants will shed more light on the biology of growth and 
the relevant developmental pathways involved. 
 Genome wide association studies (GWAS) can inform us about the genetic architecture of 
traits and diseases. We argue that one should not merely look at only the genome wide significant 
results from GWASs and ignore variants that are insignificant. By performing computational 
modeling on the full range of results, one would be able to infer the genetic architecture of the 
trait or disease and perhaps shed light on the biological mechanism responsible for producing the 
change in the phenotype. 
 
FUTURE DIRECTIONS 
 In this section, we focus on the results from this dissertation to the understanding of 
disease etiology, the broader implications and potential future research directions and goals 
towards the broader aim of improving our understanding of genetic diseases as well as towards 
the discovery therapeutic strategies. It has been suggested that while there is a plethora of effort 
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for performing disease mapping through the use of GWAS, little has been discovered about the 
mechanisms of how these variants influence the disease pathology and even less so in terms of 
therapeutics. This trend might change in the future but there are several issues that might hinder 
the effort for understanding the mechanism of common variants to disease. First, as the effect 
sizes of these common variants are small, studying the variant’s effect either in in-vitro systems 
or animal models may not be feasible as the magnitude of effect may be too small to be observed 
from the readout. Next, given the many number of such variants, it may be impractical to 
simultaneously study most of them. As such, rare-variants with large effects might be better 
suited for such follow up studies. 
  We have observed from the results from studying individuals from the extreme ends of 
the height distribution, individuals with short stature could potentially be short because of rare 
variants of moderate effects. These effect sizes could be large enough to register a read out from 
studying animal models. In fact, it has been shown that human alleles could be introduced into 
zebrafish causing these zebrafish to have similar phenotypes [13]. Therefore, given that rare 
variants with moderate effects are not likely to be discovered from GWAS as the SNP markers 
from GWAS are mainly common, new approaches for rare variant discovery are needed. Some 
have suggested and performed either whole-genome, whole-exome or exome-chip experiments 
as an effort to discover rare variants associated with diseases. Results from our work suggest that 
analyzing the GWAS results may be informative as to how likely such efforts would be fruitful. 
From our studies of individuals with short and tall stature, we found that there is a less than 
expected number of short alleles for the short individuals suggesting that they may have rare 
variants that moderately cause a decrease in height. If one were to sample from short individuals 
where their common variant profile predicts tall stature or above-average stature, these 
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individuals would more likely to harbor such rare-variants. Such rare-variants could lie in genes 
there are known in pathways that regulate growth or could be from genes without much known 
biological function or mechanism. 
 There could be several approaches to studying these genes to elucidate their unknown 
biological function or mechanism. One approach would be to introduce these variants via 
genome-engineering methods into some model organism. Since, if these organisms have 
homologous genes such that the human version of these genes is still functional, it is possible to 
replace the organism’s endogenous gene with a human version harboring these variants. If the 
human allele of the gene causes a similar phenotype in the organism, in this case, short stature, it 
would be evidence that the allele is the causal variant responsible for the human phenotype and 
subsequent studies into the mechanism of action can be studied via the model organism. This 
strategy could be extended to phenotypes of other quantitative traits like body-mass-index 
(BMI), lipid levels and blood pressure. Although not widely done, modeling disease outcome 
using human alleles has been demonstrated to be successful in zebrafish [14]. The key would be 
to identify the rare-variants with large effects and we have shown that studying the phenotypic 
extremes can be more optimal for doing so. 
 While identifying rare variants with relatively larger effect sizes may be useful for 
understanding disease etiology, it may not be as useful for the development of therapeutics, in 
particular, the genes underlying these rare variants do not make good candidate drug targets. This 
is because these variants are usually deleterious variants and therefore targeting these genes is 
predictive of increasing risk to disease. Also, even if the variants are gain of function variants, 
targeting these genes would only work for individuals that have the risk allele, which would still 
be rare in the population. The truth is that most individuals are affected by complex diseases not 
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because of rare variants but by the cumulative effect of common variants in many genes together 
with environmental stimuli. Even when certain traits, like sitting height ratio, are highly 
differentiated between populations, the reason behind that differentiation is usually polygenic. 
Unless it becomes feasible to have drugs that target many genes concurrently where each target 
is only modestly affected, one would perhaps need a better solution for treating a polygenic 
disease. 
 One possibility would be to target genes where there are rare deleterious variants that 
have moderate protective effects. However, we have shown that for case-control association 
studies, there is more power to detect risk than protective variants. Therefore, in order to 
optimize power to detect protective variants, the “case” individuals used in a case-control 
association should be individuals that are protected against the disease. Finding such individuals 
however, is a challenge on its own as individuals who are protected against disease do not show 
up at a clinic. One possibility would be use a quantitative trait measurement that is a proxy for 
the disease. For example, one criterion for having type 2 diabetes is having fasting glucose levels 
above 125 mg/dL. If one were to be able to recruit individuals that have lower than normal 
fasting glucose levels as cases and controls to be anyone else, then that case-control study design 
would be more optimized for detecting such protective variants. Another approach would be to 
use unaffected individuals that have strong environmental exposure to getting the disease. For 
example, the use of healthy middle-aged adults that are obese but do not have type 2 diabetes 
could be used as cases. Since there is a high probability of getting type 2 diabetes if one is obese, 
non-diabetic obese individuals might harbor protective variants against type 2 diabetes. Perhaps, 
such a new paradigm for performing GWAS might be the way forward for optimizing the power 
to detect rare protective variants. 
178 
 
A POSTSCRIPT 
 We are at a point in time when research in human genetics for understanding complex 
diseases is in its critical moment. It was not too long ago where we do not have even a single 
gene or locus associated with any complex disease but now we have many, perhaps too many to 
even comprehend how it is possible to move forward. As genomic techniques improve and 
sequencing cost gets reduced, perhaps having a whole genome sequence for any single individual 
would be easily achieved. In the near future, having a genomic profile for any patient would be 
like measuring blood pressure today. It would be quick, easy and inexpensive. Therefore, the 
challenge of the future would be to determine how one could harness the genome’s sequence of 
every patient to improve our understanding of disease mechanisms as well as to aid in the 
development of new therapeutics. It is incumbent on us scientist to make that a reality and I 
strongly believe that we will succeed. It is only a matter of time. 
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